id	sid	tid	token	lemma	pos
ajlm-1296	1	1	abstract	abstract	ADJ
ajlm-1296	1	2	introduction	introduction	NOUN
ajlm-1296	1	3	methods	method	NOUN
ajlm-1296	1	4	results	result	VERB
ajlm-1296	1	5	discussion	discussion	NOUN
ajlm-1296	1	6	acknowledgements	acknowledgement	NOUN
ajlm-1296	1	7	references	reference	NOUN
ajlm-1296	1	8	about	about	ADP
ajlm-1296	1	9	the	the	DET
ajlm-1296	1	10	author(s	author(s	PROPN
ajlm-1296	1	11	)	)	PUNCT
ajlm-1296	1	12	asmaa	asmaa	PROPN
ajlm-1296	1	13	m.	m.	PROPN
ajlm-1296	1	14	zahran	zahran	PROPN
ajlm-1296	1	15	department	department	PROPN
ajlm-1296	1	16	of	of	ADP
ajlm-1296	1	17	clinical	clinical	ADJ
ajlm-1296	1	18	pathology	pathology	NOUN
ajlm-1296	1	19	,	,	PUNCT
ajlm-1296	1	20	south	south	PROPN
ajlm-1296	1	21	egypt	egypt	PROPN
ajlm-1296	1	22	cancer	cancer	PROPN
ajlm-1296	1	23	institute	institute	PROPN
ajlm-1296	1	24	,	,	PUNCT
ajlm-1296	1	25	assiut	assiut	PROPN
ajlm-1296	1	26	university	university	PROPN
ajlm-1296	1	27	,	,	PUNCT
ajlm-1296	1	28	assiut	assiut	PROPN
ajlm-1296	1	29	,	,	PUNCT
ajlm-1296	1	30	egypt	egypt	PROPN
ajlm-1296	1	31	hanaa	hanaa	PROPN
ajlm-1296	1	32	nafady	nafady	ADJ
ajlm-1296	1	33	-	-	PUNCT
ajlm-1296	1	34	hego	hego	ADJ
ajlm-1296	1	35	department	department	NOUN
ajlm-1296	1	36	of	of	ADP
ajlm-1296	1	37	microbiology	microbiology	NOUN
ajlm-1296	1	38	and	and	CCONJ
ajlm-1296	1	39	immunology	immunology	NOUN
ajlm-1296	1	40	,	,	PUNCT
ajlm-1296	1	41	faculty	faculty	NOUN
ajlm-1296	1	42	of	of	ADP
ajlm-1296	1	43	medicine	medicine	NOUN
ajlm-1296	1	44	,	,	PUNCT
ajlm-1296	1	45	assiut	assiut	PROPN
ajlm-1296	1	46	university	university	PROPN
ajlm-1296	1	47	,	,	PUNCT
ajlm-1296	1	48	assiut	assiut	PROPN
ajlm-1296	1	49	,	,	PUNCT
ajlm-1296	1	50	egypt	egypt	PROPN
ajlm-1296	1	51	sawsan	sawsan	PROPN
ajlm-1296	1	52	m.	m.	PROPN
ajlm-1296	1	53	moeen	moeen	PROPN
ajlm-1296	1	54	department	department	PROPN
ajlm-1296	1	55	of	of	ADP
ajlm-1296	1	56	internal	internal	ADJ
ajlm-1296	1	57	medicine	medicine	NOUN
ajlm-1296	1	58	,	,	PUNCT
ajlm-1296	1	59	clinical	clinical	ADJ
ajlm-1296	1	60	haematology	haematology	NOUN
ajlm-1296	1	61	unit	unit	NOUN
ajlm-1296	1	62	,	,	PUNCT
ajlm-1296	1	63	faculty	faculty	NOUN
ajlm-1296	1	64	of	of	ADP
ajlm-1296	1	65	medicine	medicine	NOUN
ajlm-1296	1	66	,	,	PUNCT
ajlm-1296	1	67	assiut	assiut	PROPN
ajlm-1296	1	68	university	university	PROPN
ajlm-1296	1	69	,	,	PUNCT
ajlm-1296	1	70	assiut	assiut	PROPN
ajlm-1296	1	71	,	,	PUNCT
ajlm-1296	1	72	egypt	egypt	PROPN
ajlm-1296	1	73	hanan	hanan	PROPN
ajlm-1296	1	74	a.	a.	PROPN
ajlm-1296	1	75	eltyb	eltyb	PROPN
ajlm-1296	1	76	department	department	PROPN
ajlm-1296	1	77	of	of	ADP
ajlm-1296	1	78	medical	medical	ADJ
ajlm-1296	1	79	oncology	oncology	NOUN
ajlm-1296	1	80	,	,	PUNCT
ajlm-1296	1	81	south	south	PROPN
ajlm-1296	1	82	egypt	egypt	PROPN
ajlm-1296	1	83	cancer	cancer	PROPN
ajlm-1296	1	84	institute	institute	PROPN
ajlm-1296	1	85	,	,	PUNCT
ajlm-1296	1	86	assiut	assiut	PROPN
ajlm-1296	1	87	university	university	PROPN
ajlm-1296	1	88	assiut	assiut	NOUN
ajlm-1296	1	89	,	,	PUNCT
ajlm-1296	1	90	egypt	egypt	PROPN
ajlm-1296	1	91	mohammed	mohammed	PROPN
ajlm-1296	1	92	m.	m.	PROPN
ajlm-1296	1	93	wahman	wahman	PROPN
ajlm-1296	1	94	department	department	PROPN
ajlm-1296	1	95	of	of	ADP
ajlm-1296	1	96	clinical	clinical	ADJ
ajlm-1296	1	97	oncology	oncology	NOUN
ajlm-1296	1	98	,	,	PUNCT
ajlm-1296	1	99	south	south	PROPN
ajlm-1296	1	100	valley	valley	PROPN
ajlm-1296	1	101	university	university	PROPN
ajlm-1296	1	102	,	,	PUNCT
ajlm-1296	1	103	qena	qena	PROPN
ajlm-1296	1	104	,	,	PUNCT
ajlm-1296	1	105	egypt	egypt	PROPN
ajlm-1296	1	106	asmaa	asmaa	PROPN
ajlm-1296	1	107	nafady	nafady	PROPN
ajlm-1296	1	108	department	department	PROPN
ajlm-1296	1	109	of	of	ADP
ajlm-1296	1	110	clinical	clinical	ADJ
ajlm-1296	1	111	and	and	CCONJ
ajlm-1296	1	112	chemical	chemical	ADJ
ajlm-1296	1	113	pathology	pathology	NOUN
ajlm-1296	1	114	,	,	PUNCT
ajlm-1296	1	115	qena	qena	PROPN
ajlm-1296	1	116	faculty	faculty	NOUN
ajlm-1296	1	117	of	of	ADP
ajlm-1296	1	118	medicine	medicine	NOUN
ajlm-1296	1	119	,	,	PUNCT
ajlm-1296	1	120	south	south	PROPN
ajlm-1296	1	121	valley	valley	PROPN
ajlm-1296	1	122	university	university	PROPN
ajlm-1296	1	123	,	,	PUNCT
ajlm-1296	1	124	qena	qena	PROPN
ajlm-1296	1	125	,	,	PUNCT
ajlm-1296	1	126	egypt	egypt	PROPN
ajlm-1296	1	127	citation	citation	PROPN
ajlm-1296	1	128	zahran	zahran	PROPN
ajlm-1296	1	129	am	be	AUX
ajlm-1296	1	130	,	,	PUNCT
ajlm-1296	1	131	nafady	nafady	ADJ
ajlm-1296	1	132	-	-	PUNCT
ajlm-1296	1	133	hego	hego	ADJ
ajlm-1296	1	134	h	h	NOUN
ajlm-1296	1	135	,	,	PUNCT
ajlm-1296	1	136	moeen	moeen	PROPN
ajlm-1296	1	137	sm	sm	PROPN
ajlm-1296	1	138	,	,	PUNCT
ajlm-1296	1	139	eltyb	eltyb	VERB
ajlm-1296	1	140	ha	ha	INTJ
ajlm-1296	1	141	,	,	PUNCT
ajlm-1296	1	142	wahman	wahman	ADJ
ajlm-1296	1	143	mm	mm	PROPN
ajlm-1296	1	144	,	,	PUNCT
ajlm-1296	1	145	nafady	nafady	ADJ
ajlm-1296	1	146	a.	a.	NOUN
ajlm-1296	1	147	higher	high	ADJ
ajlm-1296	1	148	proportion	proportion	NOUN
ajlm-1296	1	149	of	of	ADP
ajlm-1296	1	150	non	non	ADJ
ajlm-1296	1	151	-	-	ADJ
ajlm-1296	1	152	classical	classical	ADJ
ajlm-1296	1	153	and	and	CCONJ
ajlm-1296	1	154	intermediate	intermediate	ADJ
ajlm-1296	1	155	monocytes	monocyte	NOUN
ajlm-1296	1	156	in	in	ADP
ajlm-1296	1	157	newly	newly	ADV
ajlm-1296	1	158	diagnosed	diagnose	VERB
ajlm-1296	1	159	multiple	multiple	ADJ
ajlm-1296	1	160	myeloma	myeloma	NOUN
ajlm-1296	1	161	patients	patient	NOUN
ajlm-1296	1	162	in	in	ADP
ajlm-1296	1	163	egypt	egypt	PROPN
ajlm-1296	1	164	:	:	PUNCT
ajlm-1296	1	165	a	a	DET
ajlm-1296	1	166	possible	possible	ADJ
ajlm-1296	1	167	prognostic	prognostic	ADJ
ajlm-1296	1	168	marker	marker	NOUN
ajlm-1296	1	169	.	.	PUNCT
ajlm-1296	2	1	afr	afr	PROPN
ajlm-1296	2	2	j	j	PROPN
ajlm-1296	2	3	lab	lab	PROPN
ajlm-1296	2	4	med	med	PROPN
ajlm-1296	2	5	.	.	PUNCT
ajlm-1296	3	1	2021;10(1	2021;10(1	NUM
ajlm-1296	3	2	)	)	PUNCT
ajlm-1296	3	3	,	,	PUNCT
ajlm-1296	3	4	a1296	a1296	PROPN
ajlm-1296	3	5	.	.	PUNCT
ajlm-1296	3	6	https://doi.org/10.4102/ajlm.v10i1.1296	https://doi.org/10.4102/ajlm.v10i1.1296	X
ajlm-1296	3	7	original	original	ADJ
ajlm-1296	3	8	research	research	NOUN
ajlm-1296	3	9	higher	high	ADJ
ajlm-1296	3	10	proportion	proportion	NOUN
ajlm-1296	3	11	of	of	ADP
ajlm-1296	3	12	non	non	ADJ
ajlm-1296	3	13	-	-	ADJ
ajlm-1296	3	14	classical	classical	ADJ
ajlm-1296	3	15	and	and	CCONJ
ajlm-1296	3	16	intermediate	intermediate	ADJ
ajlm-1296	3	17	monocytes	monocyte	NOUN
ajlm-1296	3	18	in	in	ADP
ajlm-1296	3	19	newly	newly	ADV
ajlm-1296	3	20	diagnosed	diagnose	VERB
ajlm-1296	3	21	multiple	multiple	ADJ
ajlm-1296	3	22	myeloma	myeloma	NOUN
ajlm-1296	3	23	patients	patient	NOUN
ajlm-1296	3	24	in	in	ADP
ajlm-1296	3	25	egypt	egypt	PROPN
ajlm-1296	3	26	:	:	PUNCT
ajlm-1296	3	27	a	a	DET
ajlm-1296	3	28	possible	possible	ADJ
ajlm-1296	3	29	prognostic	prognostic	ADJ
ajlm-1296	3	30	marker	marker	NOUN
ajlm-1296	3	31	asmaa	asmaa	PROPN
ajlm-1296	3	32	m.	m.	PROPN
ajlm-1296	3	33	zahran	zahran	PROPN
ajlm-1296	3	34	,	,	PUNCT
ajlm-1296	3	35	hanaa	hanaa	PROPN
ajlm-1296	3	36	nafady	nafady	ADV
ajlm-1296	3	37	-	-	PUNCT
ajlm-1296	3	38	hego	hego	ADJ
ajlm-1296	3	39	,	,	PUNCT
ajlm-1296	3	40	sawsan	sawsan	ADJ
ajlm-1296	3	41	m.	m.	PROPN
ajlm-1296	3	42	moeen	moeen	PROPN
ajlm-1296	3	43	,	,	PUNCT
ajlm-1296	3	44	hanan	hanan	PROPN
ajlm-1296	3	45	a.	a.	PROPN
ajlm-1296	3	46	eltyb	eltyb	PROPN
ajlm-1296	3	47	,	,	PUNCT
ajlm-1296	3	48	mohammed	mohammed	PROPN
ajlm-1296	3	49	m.	m.	PROPN
ajlm-1296	3	50	wahman	wahman	PROPN
ajlm-1296	3	51	,	,	PUNCT
ajlm-1296	3	52	asmaa	asmaa	PROPN
ajlm-1296	3	53	nafady	nafady	ADV
ajlm-1296	3	54	received	receive	VERB
ajlm-1296	3	55	:	:	PUNCT
ajlm-1296	3	56	09	09	NUM
ajlm-1296	3	57	june	june	PROPN
ajlm-1296	3	58	2020	2020	NUM
ajlm-1296	3	59	;	;	PUNCT
ajlm-1296	3	60	accepted	accept	VERB
ajlm-1296	3	61	:	:	PUNCT
ajlm-1296	3	62	11	11	NUM
ajlm-1296	3	63	may	may	PROPN
ajlm-1296	3	64	2021	2021	NUM
ajlm-1296	3	65	;	;	PUNCT
ajlm-1296	3	66	published	publish	VERB
ajlm-1296	3	67	:	:	PUNCT
ajlm-1296	4	1	25	25	NUM
ajlm-1296	4	2	aug	aug	PROPN
ajlm-1296	4	3	.	.	PROPN
ajlm-1296	4	4	2021	2021	NUM
ajlm-1296	4	5	copyright	copyright	NOUN
ajlm-1296	4	6	:	:	PUNCT
ajlm-1296	4	7	©	©	PROPN
ajlm-1296	4	8	2021	2021	NUM
ajlm-1296	4	9	.	.	PUNCT
ajlm-1296	5	1	the	the	DET
ajlm-1296	5	2	author(s	author(s	PROPN
ajlm-1296	5	3	)	)	PUNCT
ajlm-1296	5	4	.	.	PUNCT
ajlm-1296	6	1	licensee	licensee	NOUN
ajlm-1296	6	2	:	:	PUNCT
ajlm-1296	6	3	aosis	aosis	NOUN
ajlm-1296	6	4	.	.	PUNCT
ajlm-1296	7	1	this	this	PRON
ajlm-1296	7	2	is	be	AUX
ajlm-1296	7	3	an	an	DET
ajlm-1296	7	4	open	open	ADJ
ajlm-1296	7	5	access	access	NOUN
ajlm-1296	7	6	article	article	NOUN
ajlm-1296	7	7	distributed	distribute	VERB
ajlm-1296	7	8	under	under	ADP
ajlm-1296	7	9	the	the	DET
ajlm-1296	7	10	terms	term	NOUN
ajlm-1296	7	11	of	of	ADP
ajlm-1296	7	12	the	the	DET
ajlm-1296	7	13	creative	creative	ADJ
ajlm-1296	7	14	commons	common	NOUN
ajlm-1296	7	15	attribution	attribution	NOUN
ajlm-1296	7	16	license	license	NOUN
ajlm-1296	7	17	,	,	PUNCT
ajlm-1296	7	18	which	which	PRON
ajlm-1296	7	19	permits	permit	VERB
ajlm-1296	7	20	unrestricted	unrestricted	ADJ
ajlm-1296	7	21	use	use	NOUN
ajlm-1296	7	22	,	,	PUNCT
ajlm-1296	7	23	distribution	distribution	NOUN
ajlm-1296	7	24	,	,	PUNCT
ajlm-1296	7	25	and	and	CCONJ
ajlm-1296	7	26	reproduction	reproduction	NOUN
ajlm-1296	7	27	in	in	ADP
ajlm-1296	7	28	any	any	DET
ajlm-1296	7	29	medium	medium	NOUN
ajlm-1296	7	30	,	,	PUNCT
ajlm-1296	7	31	provided	provide	VERB
ajlm-1296	7	32	the	the	DET
ajlm-1296	7	33	original	original	ADJ
ajlm-1296	7	34	work	work	NOUN
ajlm-1296	7	35	is	be	AUX
ajlm-1296	7	36	properly	properly	ADV
ajlm-1296	7	37	cited	cite	VERB
ajlm-1296	7	38	.	.	PUNCT
ajlm-1296	8	1	abstract	abstract	ADJ
ajlm-1296	8	2	background	background	NOUN
ajlm-1296	8	3	:	:	PUNCT
ajlm-1296	8	4	interaction	interaction	NOUN
ajlm-1296	8	5	between	between	ADP
ajlm-1296	8	6	multiple	multiple	ADJ
ajlm-1296	8	7	myeloma	myeloma	NOUN
ajlm-1296	8	8	(	(	PUNCT
ajlm-1296	8	9	mm	mm	NOUN
ajlm-1296	8	10	)	)	PUNCT
ajlm-1296	8	11	cells	cell	NOUN
ajlm-1296	8	12	and	and	CCONJ
ajlm-1296	8	13	proximal	proximal	ADJ
ajlm-1296	8	14	monocytes	monocyte	NOUN
ajlm-1296	8	15	is	be	AUX
ajlm-1296	8	16	expected	expect	VERB
ajlm-1296	8	17	during	during	ADP
ajlm-1296	8	18	plasma	plasma	NOUN
ajlm-1296	8	19	cell	cell	NOUN
ajlm-1296	8	20	proliferation	proliferation	NOUN
ajlm-1296	8	21	.	.	PUNCT
ajlm-1296	9	1	however	however	ADV
ajlm-1296	9	2	,	,	PUNCT
ajlm-1296	9	3	the	the	DET
ajlm-1296	9	4	role	role	NOUN
ajlm-1296	9	5	of	of	ADP
ajlm-1296	9	6	monocyte	monocyte	NOUN
ajlm-1296	9	7	subsets	subset	NOUN
ajlm-1296	9	8	in	in	ADP
ajlm-1296	9	9	the	the	DET
ajlm-1296	9	10	disease	disease	NOUN
ajlm-1296	9	11	progression	progression	NOUN
ajlm-1296	9	12	is	be	AUX
ajlm-1296	9	13	unknown	unknown	ADJ
ajlm-1296	9	14	.	.	PUNCT
ajlm-1296	10	1	objective	objective	NOUN
ajlm-1296	10	2	:	:	PUNCT
ajlm-1296	10	3	this	this	DET
ajlm-1296	10	4	study	study	NOUN
ajlm-1296	10	5	evaluated	evaluate	VERB
ajlm-1296	10	6	circulating	circulate	VERB
ajlm-1296	10	7	monocyte	monocyte	NOUN
ajlm-1296	10	8	populations	population	NOUN
ajlm-1296	10	9	in	in	ADP
ajlm-1296	10	10	mm	mm	PROPN
ajlm-1296	10	11	patients	patient	NOUN
ajlm-1296	10	12	and	and	CCONJ
ajlm-1296	10	13	their	their	PRON
ajlm-1296	10	14	correlation	correlation	NOUN
ajlm-1296	10	15	with	with	ADP
ajlm-1296	10	16	disease	disease	NOUN
ajlm-1296	10	17	severity	severity	NOUN
ajlm-1296	10	18	.	.	PUNCT
ajlm-1296	11	1	methods	method	NOUN
ajlm-1296	11	2	:	:	PUNCT
ajlm-1296	11	3	peripheral	peripheral	ADJ
ajlm-1296	11	4	monocytes	monocyte	VERB
ajlm-1296	11	5	from	from	ADP
ajlm-1296	11	6	20	20	NUM
ajlm-1296	11	7	patients	patient	NOUN
ajlm-1296	11	8	with	with	ADP
ajlm-1296	11	9	mm	mm	NOUN
ajlm-1296	11	10	attending	attend	VERB
ajlm-1296	11	11	assiut	assiut	PROPN
ajlm-1296	11	12	university	university	NOUN
ajlm-1296	11	13	hospital	hospital	NOUN
ajlm-1296	11	14	in	in	ADP
ajlm-1296	11	15	assiut	assiut	PROPN
ajlm-1296	11	16	,	,	PUNCT
ajlm-1296	11	17	egypt	egypt	PROPN
ajlm-1296	11	18	,	,	PUNCT
ajlm-1296	11	19	between	between	ADP
ajlm-1296	11	20	october	october	PROPN
ajlm-1296	11	21	2018	2018	NUM
ajlm-1296	11	22	and	and	CCONJ
ajlm-1296	11	23	august	august	PROPN
ajlm-1296	11	24	2019	2019	NUM
ajlm-1296	11	25	were	be	AUX
ajlm-1296	11	26	processed	process	VERB
ajlm-1296	11	27	using	use	VERB
ajlm-1296	11	28	a	a	DET
ajlm-1296	11	29	flow	flow	NOUN
ajlm-1296	11	30	cytometry	cytometry	NOUN
ajlm-1296	11	31	procedure	procedure	NOUN
ajlm-1296	11	32	and	and	CCONJ
ajlm-1296	11	33	stratified	stratify	VERB
ajlm-1296	11	34	using	use	VERB
ajlm-1296	11	35	the	the	DET
ajlm-1296	11	36	intensity	intensity	NOUN
ajlm-1296	11	37	of	of	ADP
ajlm-1296	11	38	expression	expression	NOUN
ajlm-1296	11	39	of	of	ADP
ajlm-1296	11	40	cd14	cd14	PROPN
ajlm-1296	11	41	and	and	CCONJ
ajlm-1296	11	42	cd16	cd16	PROPN
ajlm-1296	11	43	into	into	ADP
ajlm-1296	11	44	classical	classical	ADJ
ajlm-1296	11	45	(	(	PUNCT
ajlm-1296	11	46	cd16−cd14++	cd16−cd14++	PROPN
ajlm-1296	11	47	)	)	PUNCT
ajlm-1296	11	48	,	,	PUNCT
ajlm-1296	11	49	intermediate	intermediate	ADJ
ajlm-1296	11	50	(	(	PUNCT
ajlm-1296	11	51	cd16+cd14++	cd16+cd14++	PROPN
ajlm-1296	11	52	)	)	PUNCT
ajlm-1296	11	53	,	,	PUNCT
ajlm-1296	11	54	and	and	CCONJ
ajlm-1296	11	55	non	non	ADJ
ajlm-1296	11	56	-	-	ADJ
ajlm-1296	11	57	classical	classical	ADJ
ajlm-1296	11	58	(	(	PUNCT
ajlm-1296	11	59	cd16++cd14	cd16++cd14	NOUN
ajlm-1296	11	60	+	+	NOUN
ajlm-1296	11	61	)	)	PUNCT
ajlm-1296	11	62	subsets	subset	NOUN
ajlm-1296	11	63	.	.	PUNCT
ajlm-1296	12	1	the	the	DET
ajlm-1296	12	2	data	datum	NOUN
ajlm-1296	12	3	were	be	AUX
ajlm-1296	12	4	compared	compare	VERB
ajlm-1296	12	5	with	with	ADP
ajlm-1296	12	6	data	datum	NOUN
ajlm-1296	12	7	from	from	ADP
ajlm-1296	12	8	20	20	NUM
ajlm-1296	12	9	healthy	healthy	ADJ
ajlm-1296	12	10	control	control	NOUN
ajlm-1296	12	11	participants	participant	NOUN
ajlm-1296	12	12	with	with	ADP
ajlm-1296	12	13	comparable	comparable	ADJ
ajlm-1296	12	14	age	age	NOUN
ajlm-1296	12	15	and	and	CCONJ
ajlm-1296	12	16	sex	sex	NOUN
ajlm-1296	12	17	.	.	PUNCT
ajlm-1296	13	1	results	result	NOUN
ajlm-1296	13	2	:	:	PUNCT
ajlm-1296	13	3	in	in	ADP
ajlm-1296	13	4	patients	patient	NOUN
ajlm-1296	13	5	with	with	ADP
ajlm-1296	13	6	mm	mm	PROPN
ajlm-1296	13	7	,	,	PUNCT
ajlm-1296	13	8	the	the	DET
ajlm-1296	13	9	percentage	percentage	NOUN
ajlm-1296	13	10	of	of	ADP
ajlm-1296	13	11	classical	classical	ADJ
ajlm-1296	13	12	monocytes	monocyte	NOUN
ajlm-1296	13	13	was	be	AUX
ajlm-1296	13	14	significantly	significantly	ADV
ajlm-1296	13	15	lower	low	ADJ
ajlm-1296	13	16	(	(	PUNCT
ajlm-1296	13	17	mean	mean	PROPN
ajlm-1296	13	18	±	±	NUM
ajlm-1296	13	19	standard	standard	PROPN
ajlm-1296	13	20	error	error	NOUN
ajlm-1296	13	21	:	:	PUNCT
ajlm-1296	13	22	77.24	77.24	NUM
ajlm-1296	13	23	±	±	NUM
ajlm-1296	13	24	0.66	0.66	NUM
ajlm-1296	13	25	vs	vs	ADP
ajlm-1296	13	26	83.75	83.75	NUM
ajlm-1296	13	27	±	±	NUM
ajlm-1296	13	28	0.5	0.5	NUM
ajlm-1296	13	29	)	)	PUNCT
ajlm-1296	13	30	,	,	PUNCT
ajlm-1296	13	31	while	while	SCONJ
ajlm-1296	13	32	those	those	PRON
ajlm-1296	13	33	of	of	ADP
ajlm-1296	13	34	non	non	ADJ
ajlm-1296	13	35	-	-	ADJ
ajlm-1296	13	36	classical	classical	ADJ
ajlm-1296	13	37	(	(	PUNCT
ajlm-1296	13	38	12.44	12.44	NUM
ajlm-1296	13	39	±	±	NUM
ajlm-1296	13	40	0.5	0.5	NUM
ajlm-1296	13	41	vs	vs	ADP
ajlm-1296	13	42	8.9	8.9	NUM
ajlm-1296	13	43	±	±	NUM
ajlm-1296	13	44	0.34	0.34	NUM
ajlm-1296	13	45	)	)	PUNCT
ajlm-1296	13	46	and	and	CCONJ
ajlm-1296	13	47	intermediate	intermediate	ADJ
ajlm-1296	13	48	(	(	PUNCT
ajlm-1296	13	49	10.3	10.3	NUM
ajlm-1296	13	50	±	±	NUM
ajlm-1296	13	51	0.24	0.24	NUM
ajlm-1296	13	52	vs	vs	ADP
ajlm-1296	13	53	7.4	7.4	NUM
ajlm-1296	13	54	±	±	NUM
ajlm-1296	13	55	0.29	0.29	NUM
ajlm-1296	13	56	)	)	PUNCT
ajlm-1296	13	57	monocytes	monocyte	NOUN
ajlm-1296	13	58	were	be	AUX
ajlm-1296	13	59	significantly	significantly	ADV
ajlm-1296	13	60	higher	high	ADJ
ajlm-1296	13	61	when	when	SCONJ
ajlm-1296	13	62	compared	compare	VERB
ajlm-1296	13	63	with	with	ADP
ajlm-1296	13	64	those	those	PRON
ajlm-1296	13	65	of	of	ADP
ajlm-1296	13	66	controls	control	NOUN
ajlm-1296	13	67	(	(	PUNCT
ajlm-1296	14	1	all	all	PRON
ajlm-1296	14	2	p	p	X
ajlm-1296	14	3	<	<	X
ajlm-1296	14	4	0.0001	0.0001	NUM
ajlm-1296	14	5	)	)	PUNCT
ajlm-1296	14	6	.	.	PUNCT
ajlm-1296	15	1	proportions	proportion	NOUN
ajlm-1296	15	2	of	of	ADP
ajlm-1296	15	3	non	non	ADJ
ajlm-1296	15	4	-	-	ADJ
ajlm-1296	15	5	classical	classical	ADJ
ajlm-1296	15	6	and	and	CCONJ
ajlm-1296	15	7	intermediate	intermediate	ADJ
ajlm-1296	15	8	monocytes	monocyte	NOUN
ajlm-1296	15	9	correlated	correlate	VERB
ajlm-1296	15	10	positively	positively	ADV
ajlm-1296	15	11	with	with	ADP
ajlm-1296	15	12	serum	serum	NOUN
ajlm-1296	15	13	levels	level	NOUN
ajlm-1296	15	14	of	of	ADP
ajlm-1296	15	15	plasma	plasma	NOUN
ajlm-1296	15	16	cells	cell	NOUN
ajlm-1296	15	17	,	,	PUNCT
ajlm-1296	15	18	m	m	NOUN
ajlm-1296	15	19	-	-	NOUN
ajlm-1296	15	20	protein	protein	NOUN
ajlm-1296	15	21	,	,	PUNCT
ajlm-1296	15	22	calcium	calcium	NOUN
ajlm-1296	15	23	,	,	PUNCT
ajlm-1296	15	24	creatinine	creatinine	NOUN
ajlm-1296	15	25	and	and	CCONJ
ajlm-1296	15	26	lactate	lactate	NOUN
ajlm-1296	15	27	dehydrogenase	dehydrogenase	NOUN
ajlm-1296	15	28	,	,	PUNCT
ajlm-1296	15	29	and	and	CCONJ
ajlm-1296	15	30	correlated	correlate	VERB
ajlm-1296	15	31	negatively	negatively	ADV
ajlm-1296	15	32	with	with	ADP
ajlm-1296	15	33	the	the	DET
ajlm-1296	15	34	serum	serum	NOUN
ajlm-1296	15	35	albumin	albumin	ADJ
ajlm-1296	15	36	level	level	NOUN
ajlm-1296	15	37	.	.	PUNCT
ajlm-1296	16	1	proportions	proportion	NOUN
ajlm-1296	16	2	of	of	ADP
ajlm-1296	16	3	classical	classical	ADJ
ajlm-1296	16	4	monocytes	monocyte	NOUN
ajlm-1296	16	5	correlated	correlate	VERB
ajlm-1296	16	6	positively	positively	ADV
ajlm-1296	16	7	with	with	ADP
ajlm-1296	16	8	albumin	albumin	ADJ
ajlm-1296	16	9	level	level	NOUN
ajlm-1296	16	10	and	and	CCONJ
ajlm-1296	16	11	negatively	negatively	ADV
ajlm-1296	16	12	correlated	correlate	VERB
ajlm-1296	16	13	with	with	ADP
ajlm-1296	16	14	serum	serum	NOUN
ajlm-1296	16	15	levels	level	NOUN
ajlm-1296	16	16	of	of	ADP
ajlm-1296	16	17	m	m	NOUN
ajlm-1296	16	18	-	-	NOUN
ajlm-1296	16	19	protein	protein	NOUN
ajlm-1296	16	20	,	,	PUNCT
ajlm-1296	16	21	plasma	plasma	NOUN
ajlm-1296	16	22	cells	cell	NOUN
ajlm-1296	16	23	,	,	PUNCT
ajlm-1296	16	24	calcium	calcium	NOUN
ajlm-1296	16	25	,	,	PUNCT
ajlm-1296	16	26	creatinine	creatinine	NOUN
ajlm-1296	16	27	,	,	PUNCT
ajlm-1296	16	28	and	and	CCONJ
ajlm-1296	16	29	lactate	lactate	PROPN
ajlm-1296	16	30	dehydrogenase	dehydrogenase	NOUN
ajlm-1296	16	31	.	.	PUNCT
ajlm-1296	17	1	conclusion	conclusion	NOUN
ajlm-1296	17	2	:	:	PUNCT
ajlm-1296	17	3	circulating	circulate	VERB
ajlm-1296	17	4	monocyte	monocyte	NOUN
ajlm-1296	17	5	subpopulations	subpopulation	NOUN
ajlm-1296	17	6	are	be	AUX
ajlm-1296	17	7	skewed	skewed	ADJ
ajlm-1296	17	8	towards	towards	ADP
ajlm-1296	17	9	non	non	ADJ
ajlm-1296	17	10	-	-	ADJ
ajlm-1296	17	11	classical	classical	ADJ
ajlm-1296	17	12	and	and	CCONJ
ajlm-1296	17	13	intermediate	intermediate	ADJ
ajlm-1296	17	14	monocytes	monocyte	NOUN
ajlm-1296	17	15	in	in	ADP
ajlm-1296	17	16	mm	mm	NOUN
ajlm-1296	17	17	patients	patient	NOUN
ajlm-1296	17	18	,	,	PUNCT
ajlm-1296	17	19	and	and	CCONJ
ajlm-1296	17	20	the	the	DET
ajlm-1296	17	21	intensity	intensity	NOUN
ajlm-1296	17	22	of	of	ADP
ajlm-1296	17	23	this	this	DET
ajlm-1296	17	24	skewness	skewness	NOUN
ajlm-1296	17	25	increases	increase	VERB
ajlm-1296	17	26	with	with	ADP
ajlm-1296	17	27	disease	disease	NOUN
ajlm-1296	17	28	severity	severity	NOUN
ajlm-1296	17	29	.	.	PUNCT
ajlm-1296	18	1	keywords	keyword	NOUN
ajlm-1296	18	2	:	:	PUNCT
ajlm-1296	18	3	multiple	multiple	ADJ
ajlm-1296	18	4	myeloma	myeloma	NOUN
ajlm-1296	18	5	;	;	PUNCT
ajlm-1296	18	6	classical	classical	ADJ
ajlm-1296	18	7	monocytes	monocyte	NOUN
ajlm-1296	18	8	;	;	PUNCT
ajlm-1296	18	9	intermediate	intermediate	ADJ
ajlm-1296	18	10	monocytes	monocyte	NOUN
ajlm-1296	18	11	;	;	PUNCT
ajlm-1296	18	12	non	non	ADJ
ajlm-1296	18	13	-	-	ADJ
ajlm-1296	18	14	classical	classical	ADJ
ajlm-1296	18	15	monocytes	monocyte	NOUN
ajlm-1296	18	16	;	;	PUNCT
ajlm-1296	18	17	flow	flow	NOUN
ajlm-1296	18	18	cytometry	cytometry	NOUN
ajlm-1296	18	19	.	.	PUNCT
ajlm-1296	19	1	introduction	introduction	NOUN
ajlm-1296	19	2	multiple	multiple	ADJ
ajlm-1296	19	3	myeloma	myeloma	NOUN
ajlm-1296	19	4	(	(	PUNCT
ajlm-1296	19	5	mm	mm	NOUN
ajlm-1296	19	6	)	)	PUNCT
ajlm-1296	19	7	is	be	AUX
ajlm-1296	19	8	a	a	DET
ajlm-1296	19	9	cancer	cancer	NOUN
ajlm-1296	19	10	that	that	PRON
ajlm-1296	19	11	affects	affect	VERB
ajlm-1296	19	12	b	b	NOUN
ajlm-1296	19	13	-	-	PUNCT
ajlm-1296	19	14	cells	cell	NOUN
ajlm-1296	19	15	,	,	PUNCT
ajlm-1296	19	16	particularly	particularly	ADV
ajlm-1296	19	17	plasma	plasma	NOUN
ajlm-1296	19	18	cells	cell	NOUN
ajlm-1296	19	19	,	,	PUNCT
ajlm-1296	19	20	leading	lead	VERB
ajlm-1296	19	21	to	to	ADP
ajlm-1296	19	22	their	their	PRON
ajlm-1296	19	23	expansion	expansion	NOUN
ajlm-1296	19	24	and	and	CCONJ
ajlm-1296	19	25	the	the	DET
ajlm-1296	19	26	excessive	excessive	ADJ
ajlm-1296	19	27	production	production	NOUN
ajlm-1296	19	28	of	of	ADP
ajlm-1296	19	29	immunoglobulins	immunoglobulin	NOUN
ajlm-1296	19	30	.	.	PUNCT
ajlm-1296	20	1	malignant	malignant	ADJ
ajlm-1296	20	2	plasma	plasma	NOUN
ajlm-1296	20	3	cells	cell	NOUN
ajlm-1296	20	4	may	may	AUX
ajlm-1296	20	5	control	control	VERB
ajlm-1296	20	6	the	the	DET
ajlm-1296	20	7	quality	quality	NOUN
ajlm-1296	20	8	of	of	ADP
ajlm-1296	20	9	the	the	DET
ajlm-1296	20	10	immune	immune	ADJ
ajlm-1296	20	11	cells	cell	NOUN
ajlm-1296	20	12	in	in	ADP
ajlm-1296	20	13	the	the	DET
ajlm-1296	20	14	bone	bone	NOUN
ajlm-1296	20	15	marrow	marrow	NOUN
ajlm-1296	20	16	and	and	CCONJ
ajlm-1296	20	17	produce	produce	VERB
ajlm-1296	20	18	immunoglobulins	immunoglobulin	NOUN
ajlm-1296	20	19	that	that	PRON
ajlm-1296	20	20	can	can	AUX
ajlm-1296	20	21	act	act	VERB
ajlm-1296	20	22	as	as	ADP
ajlm-1296	20	23	tumour	tumour	NOUN
ajlm-1296	20	24	-	-	PUNCT
ajlm-1296	20	25	associated	associate	VERB
ajlm-1296	20	26	antigens	antigen	NOUN
ajlm-1296	20	27	which	which	PRON
ajlm-1296	20	28	are	be	AUX
ajlm-1296	20	29	further	far	ADV
ajlm-1296	20	30	processed	process	VERB
ajlm-1296	20	31	by	by	ADP
ajlm-1296	20	32	antigen	antigen	NOUN
ajlm-1296	20	33	-	-	PUNCT
ajlm-1296	20	34	presenting	present	VERB
ajlm-1296	20	35	cells	cell	NOUN
ajlm-1296	20	36	to	to	PART
ajlm-1296	20	37	stimulate	stimulate	VERB
ajlm-1296	20	38	specific	specific	ADJ
ajlm-1296	20	39	anti	anti	ADJ
ajlm-1296	20	40	-	-	ADJ
ajlm-1296	20	41	tumour	tumour	ADJ
ajlm-1296	20	42	t	t	NOUN
ajlm-1296	20	43	-	-	PUNCT
ajlm-1296	20	44	cell	cell	NOUN
ajlm-1296	20	45	responses.1	responses.1	NOUN
ajlm-1296	20	46	monocytes	monocyte	NOUN
ajlm-1296	20	47	and	and	CCONJ
ajlm-1296	20	48	macrophages	macrophage	NOUN
ajlm-1296	20	49	play	play	VERB
ajlm-1296	20	50	a	a	DET
ajlm-1296	20	51	fundamental	fundamental	ADJ
ajlm-1296	20	52	role	role	NOUN
ajlm-1296	20	53	in	in	ADP
ajlm-1296	20	54	this	this	DET
ajlm-1296	20	55	inflammatory	inflammatory	ADJ
ajlm-1296	20	56	response	response	NOUN
ajlm-1296	20	57	,	,	PUNCT
ajlm-1296	20	58	possibly	possibly	ADV
ajlm-1296	20	59	through	through	ADP
ajlm-1296	20	60	bone	bone	NOUN
ajlm-1296	20	61	marrow	marrow	NOUN
ajlm-1296	20	62	expansion	expansion	NOUN
ajlm-1296	20	63	and	and	CCONJ
ajlm-1296	20	64	cytokine	cytokine	ADJ
ajlm-1296	20	65	production	production	NOUN
ajlm-1296	20	66	in	in	ADP
ajlm-1296	20	67	myeloma	myeloma	NOUN
ajlm-1296	20	68	patients.2,3,4,5	patients.2,3,4,5	NOUN
ajlm-1296	20	69	this	this	PRON
ajlm-1296	20	70	is	be	AUX
ajlm-1296	20	71	corroborated	corroborate	VERB
ajlm-1296	20	72	by	by	ADP
ajlm-1296	20	73	findings	finding	NOUN
ajlm-1296	20	74	from	from	ADP
ajlm-1296	20	75	in	in	ADP
ajlm-1296	20	76	-	-	PUNCT
ajlm-1296	20	77	vitro	vitro	X
ajlm-1296	20	78	studies.6,7	studies.6,7	PROPN
ajlm-1296	20	79	the	the	DET
ajlm-1296	20	80	increased	increase	VERB
ajlm-1296	20	81	peripheral	peripheral	ADJ
ajlm-1296	20	82	monocytes	monocyte	NOUN
ajlm-1296	20	83	in	in	ADP
ajlm-1296	20	84	mm	mm	PROPN
ajlm-1296	20	85	patients	patient	NOUN
ajlm-1296	20	86	may	may	AUX
ajlm-1296	20	87	inhibit	inhibit	VERB
ajlm-1296	20	88	antitumor	antitumor	PROPN
ajlm-1296	20	89	immune	immune	ADJ
ajlm-1296	20	90	responses	response	NOUN
ajlm-1296	20	91	and	and	CCONJ
ajlm-1296	20	92	increase	increase	VERB
ajlm-1296	20	93	tumour	tumour	NOUN
ajlm-1296	20	94	aggression.2,3	aggression.2,3	PROPN
ajlm-1296	20	95	human	human	ADJ
ajlm-1296	20	96	peripheral	peripheral	ADJ
ajlm-1296	20	97	blood	blood	NOUN
ajlm-1296	21	1	monocytes	monocyte	VERB
ajlm-1296	21	2	are	be	AUX
ajlm-1296	21	3	a	a	DET
ajlm-1296	21	4	heterogeneous	heterogeneous	ADJ
ajlm-1296	21	5	population	population	NOUN
ajlm-1296	21	6	,	,	PUNCT
ajlm-1296	21	7	as	as	SCONJ
ajlm-1296	21	8	they	they	PRON
ajlm-1296	21	9	differ	differ	VERB
ajlm-1296	21	10	in	in	ADP
ajlm-1296	21	11	their	their	PRON
ajlm-1296	21	12	phenotype	phenotype	NOUN
ajlm-1296	21	13	,	,	PUNCT
ajlm-1296	21	14	surface	surface	NOUN
ajlm-1296	21	15	marker	marker	NOUN
ajlm-1296	21	16	expression	expression	NOUN
ajlm-1296	21	17	,	,	PUNCT
ajlm-1296	21	18	and	and	CCONJ
ajlm-1296	21	19	function.8	function.8	NOUN
ajlm-1296	21	20	they	they	PRON
ajlm-1296	21	21	can	can	AUX
ajlm-1296	21	22	be	be	AUX
ajlm-1296	21	23	classified	classify	VERB
ajlm-1296	21	24	based	base	VERB
ajlm-1296	21	25	on	on	ADP
ajlm-1296	21	26	the	the	DET
ajlm-1296	21	27	fluorescent	fluorescent	ADJ
ajlm-1296	21	28	intensities	intensity	NOUN
ajlm-1296	21	29	of	of	ADP
ajlm-1296	21	30	cd16	cd16	PROPN
ajlm-1296	21	31	and	and	CCONJ
ajlm-1296	21	32	cd14	cd14	PROPN
ajlm-1296	21	33	into	into	ADP
ajlm-1296	21	34	three	three	NUM
ajlm-1296	21	35	distinct	distinct	ADJ
ajlm-1296	21	36	populations	population	NOUN
ajlm-1296	21	37	,	,	PUNCT
ajlm-1296	21	38	including	include	VERB
ajlm-1296	21	39	classical	classical	ADJ
ajlm-1296	21	40	monocytes	monocyte	NOUN
ajlm-1296	21	41	(	(	PUNCT
ajlm-1296	21	42	cd16−cd14++	cd16−cd14++	PROPN
ajlm-1296	21	43	)	)	PUNCT
ajlm-1296	21	44	,	,	PUNCT
ajlm-1296	21	45	intermediate	intermediate	ADJ
ajlm-1296	21	46	monocytes	monocyte	NOUN
ajlm-1296	21	47	(	(	PUNCT
ajlm-1296	21	48	cd16+cd14++	cd16+cd14++	PROPN
ajlm-1296	21	49	)	)	PUNCT
ajlm-1296	21	50	,	,	PUNCT
ajlm-1296	21	51	and	and	CCONJ
ajlm-1296	21	52	non	non	ADJ
ajlm-1296	21	53	-	-	ADJ
ajlm-1296	21	54	classical	classical	ADJ
ajlm-1296	21	55	monocytes	monocyte	NOUN
ajlm-1296	21	56	(	(	PUNCT
ajlm-1296	21	57	cd16++cd14+).9	cd16++cd14+).9	NOUN
ajlm-1296	21	58	circulating	circulate	VERB
ajlm-1296	21	59	non	non	ADJ
ajlm-1296	21	60	-	-	ADJ
ajlm-1296	21	61	classical	classical	ADJ
ajlm-1296	21	62	monocytes	monocyte	NOUN
ajlm-1296	21	63	have	have	AUX
ajlm-1296	21	64	been	be	AUX
ajlm-1296	21	65	observed	observe	VERB
ajlm-1296	21	66	to	to	PART
ajlm-1296	21	67	increase	increase	VERB
ajlm-1296	21	68	in	in	ADP
ajlm-1296	21	69	some	some	DET
ajlm-1296	21	70	autoimmune	autoimmune	ADJ
ajlm-1296	21	71	diseases	disease	NOUN
ajlm-1296	21	72	such	such	ADJ
ajlm-1296	21	73	as	as	ADP
ajlm-1296	21	74	lupus	lupus	NOUN
ajlm-1296	21	75	and	and	CCONJ
ajlm-1296	21	76	rheumatoid	rheumatoid	VERB
ajlm-1296	21	77	arthritis,10,11	arthritis,10,11	NOUN
ajlm-1296	21	78	and	and	CCONJ
ajlm-1296	21	79	the	the	DET
ajlm-1296	21	80	frequency	frequency	NOUN
ajlm-1296	21	81	of	of	ADP
ajlm-1296	21	82	intermediate	intermediate	ADJ
ajlm-1296	21	83	monocytes	monocyte	NOUN
ajlm-1296	21	84	has	have	AUX
ajlm-1296	21	85	been	be	AUX
ajlm-1296	21	86	associated	associate	VERB
ajlm-1296	21	87	with	with	ADP
ajlm-1296	21	88	bone	bone	NOUN
ajlm-1296	21	89	erosion	erosion	NOUN
ajlm-1296	21	90	in	in	ADP
ajlm-1296	21	91	patients	patient	NOUN
ajlm-1296	21	92	with	with	ADP
ajlm-1296	21	93	psoriatic	psoriatic	ADJ
ajlm-1296	21	94	arthritis.12	arthritis.12	NOUN
ajlm-1296	21	95	in	in	ADP
ajlm-1296	21	96	oncology	oncology	NOUN
ajlm-1296	21	97	settings	setting	NOUN
ajlm-1296	21	98	,	,	PUNCT
ajlm-1296	21	99	the	the	DET
ajlm-1296	21	100	intermediate	intermediate	ADJ
ajlm-1296	21	101	monocytes	monocyte	NOUN
ajlm-1296	21	102	have	have	AUX
ajlm-1296	21	103	been	be	AUX
ajlm-1296	21	104	reported	report	VERB
ajlm-1296	21	105	to	to	PART
ajlm-1296	21	106	play	play	VERB
ajlm-1296	21	107	a	a	DET
ajlm-1296	21	108	crucial	crucial	ADJ
ajlm-1296	21	109	role	role	NOUN
ajlm-1296	21	110	in	in	ADP
ajlm-1296	21	111	patients	patient	NOUN
ajlm-1296	21	112	with	with	ADP
ajlm-1296	21	113	mm,9,13	mm,9,13	NOUN
ajlm-1296	21	114	and	and	CCONJ
ajlm-1296	21	115	the	the	DET
ajlm-1296	21	116	proportion	proportion	NOUN
ajlm-1296	21	117	of	of	ADP
ajlm-1296	21	118	intermediate	intermediate	ADJ
ajlm-1296	21	119	monocytes	monocyte	NOUN
ajlm-1296	21	120	increased	increase	VERB
ajlm-1296	21	121	proportionately	proportionately	ADV
ajlm-1296	21	122	with	with	SCONJ
ajlm-1296	21	123	the	the	DET
ajlm-1296	21	124	tumour	tumour	NOUN
ajlm-1296	21	125	load.14,15	load.14,15	ADJ
ajlm-1296	21	126	myeloma	myeloma	PROPN
ajlm-1296	21	127	cells	cell	NOUN
ajlm-1296	21	128	produce	produce	VERB
ajlm-1296	21	129	toll	toll	NOUN
ajlm-1296	21	130	-	-	PUNCT
ajlm-1296	21	131	like	like	ADJ
ajlm-1296	21	132	receptor	receptor	NOUN
ajlm-1296	21	133	ligands	ligand	NOUN
ajlm-1296	21	134	that	that	PRON
ajlm-1296	21	135	cause	cause	VERB
ajlm-1296	21	136	the	the	DET
ajlm-1296	21	137	expansion	expansion	NOUN
ajlm-1296	21	138	of	of	ADP
ajlm-1296	21	139	non	non	ADJ
ajlm-1296	21	140	-	-	ADJ
ajlm-1296	21	141	classical	classical	ADJ
ajlm-1296	21	142	monocytes	monocyte	NOUN
ajlm-1296	21	143	in	in	ADP
ajlm-1296	21	144	mm	mm	PROPN
ajlm-1296	21	145	patients.16	patients.16	NOUN
ajlm-1296	21	146	in	in	ADP
ajlm-1296	21	147	addition	addition	NOUN
ajlm-1296	21	148	,	,	PUNCT
ajlm-1296	21	149	circulating	circulate	VERB
ajlm-1296	21	150	monocytes	monocyte	NOUN
ajlm-1296	21	151	correlate	correlate	VERB
ajlm-1296	21	152	with	with	ADP
ajlm-1296	21	153	the	the	DET
ajlm-1296	21	154	well	well	ADV
ajlm-1296	21	155	-	-	PUNCT
ajlm-1296	21	156	known	know	VERB
ajlm-1296	21	157	prognostic	prognostic	ADJ
ajlm-1296	21	158	factors	factor	NOUN
ajlm-1296	21	159	for	for	ADP
ajlm-1296	21	160	mm	mm	PROPN
ajlm-1296	21	161	,	,	PUNCT
ajlm-1296	21	162	and	and	CCONJ
ajlm-1296	21	163	evaluating	evaluate	VERB
ajlm-1296	21	164	monocyte	monocyte	NOUN
ajlm-1296	21	165	subpopulations	subpopulation	NOUN
ajlm-1296	21	166	can	can	AUX
ajlm-1296	21	167	enhance	enhance	VERB
ajlm-1296	21	168	our	our	PRON
ajlm-1296	21	169	understanding	understanding	NOUN
ajlm-1296	21	170	of	of	ADP
ajlm-1296	21	171	mm	mm	NOUN
ajlm-1296	21	172	mechanisms	mechanism	NOUN
ajlm-1296	21	173	and	and	CCONJ
ajlm-1296	21	174	aid	aid	VERB
ajlm-1296	21	175	patient	patient	ADJ
ajlm-1296	21	176	follow	follow	NOUN
ajlm-1296	21	177	-	-	PUNCT
ajlm-1296	21	178	up	up	NOUN
ajlm-1296	21	179	.	.	PUNCT
ajlm-1296	22	1	although	although	SCONJ
ajlm-1296	22	2	bone	bone	NOUN
ajlm-1296	22	3	marrow	marrow	NOUN
ajlm-1296	22	4	aspirates	aspirate	NOUN
ajlm-1296	22	5	and	and	CCONJ
ajlm-1296	22	6	trephine	trephine	NOUN
ajlm-1296	22	7	biopsies	biopsy	NOUN
ajlm-1296	22	8	provide	provide	VERB
ajlm-1296	22	9	high	high	ADJ
ajlm-1296	22	10	diagnostic	diagnostic	ADJ
ajlm-1296	22	11	yields	yield	NOUN
ajlm-1296	22	12	for	for	ADP
ajlm-1296	22	13	mm	mm	NOUN
ajlm-1296	22	14	detection,17	detection,17	NOUN
ajlm-1296	22	15	finding	find	VERB
ajlm-1296	22	16	a	a	DET
ajlm-1296	22	17	less	less	ADV
ajlm-1296	22	18	invasive	invasive	ADJ
ajlm-1296	22	19	diagnostic	diagnostic	ADJ
ajlm-1296	22	20	procedure	procedure	NOUN
ajlm-1296	22	21	such	such	ADJ
ajlm-1296	22	22	as	as	ADP
ajlm-1296	22	23	flow	flow	NOUN
ajlm-1296	22	24	cytometry	cytometry	NOUN
ajlm-1296	22	25	will	will	AUX
ajlm-1296	22	26	be	be	AUX
ajlm-1296	22	27	a	a	DET
ajlm-1296	22	28	clinical	clinical	ADJ
ajlm-1296	22	29	breakthrough	breakthrough	NOUN
ajlm-1296	22	30	.	.	PUNCT
ajlm-1296	23	1	this	this	DET
ajlm-1296	23	2	study	study	NOUN
ajlm-1296	23	3	aimed	aim	VERB
ajlm-1296	23	4	to	to	PART
ajlm-1296	23	5	describe	describe	VERB
ajlm-1296	23	6	the	the	DET
ajlm-1296	23	7	immunophenotypic	immunophenotypic	ADJ
ajlm-1296	23	8	profile	profile	NOUN
ajlm-1296	23	9	of	of	ADP
ajlm-1296	23	10	the	the	DET
ajlm-1296	23	11	peripheral	peripheral	ADJ
ajlm-1296	23	12	blood	blood	NOUN
ajlm-1296	23	13	monocytes	monocyte	VERB
ajlm-1296	23	14	in	in	ADP
ajlm-1296	23	15	newly	newly	ADV
ajlm-1296	23	16	diagnosed	diagnose	VERB
ajlm-1296	23	17	mm	mm	NOUN
ajlm-1296	23	18	patients	patient	NOUN
ajlm-1296	23	19	at	at	ADP
ajlm-1296	23	20	the	the	DET
ajlm-1296	23	21	assiut	assiut	PROPN
ajlm-1296	23	22	university	university	PROPN
ajlm-1296	23	23	hospital	hospital	NOUN
ajlm-1296	23	24	,	,	PUNCT
ajlm-1296	23	25	assiut	assiut	PROPN
ajlm-1296	23	26	,	,	PUNCT
ajlm-1296	23	27	egypt	egypt	PROPN
ajlm-1296	23	28	.	.	PUNCT
ajlm-1296	24	1	methods	method	NOUN
ajlm-1296	24	2	ethical	ethical	ADJ
ajlm-1296	24	3	considerations	consideration	NOUN
ajlm-1296	24	4	the	the	DET
ajlm-1296	24	5	human	human	ADJ
ajlm-1296	24	6	research	research	PROPN
ajlm-1296	24	7	ethics	ethic	NOUN
ajlm-1296	24	8	committee	committee	PROPN
ajlm-1296	24	9	of	of	ADP
ajlm-1296	24	10	the	the	DET
ajlm-1296	24	11	south	south	PROPN
ajlm-1296	24	12	egypt	egypt	PROPN
ajlm-1296	24	13	cancer	cancer	PROPN
ajlm-1296	24	14	institute	institute	PROPN
ajlm-1296	24	15	,	,	PUNCT
ajlm-1296	24	16	assiut	assiut	PROPN
ajlm-1296	24	17	university	university	PROPN
ajlm-1296	24	18	,	,	PUNCT
ajlm-1296	24	19	approved	approve	VERB
ajlm-1296	24	20	this	this	DET
ajlm-1296	24	21	study	study	NOUN
ajlm-1296	24	22	(	(	PUNCT
ajlm-1296	24	23	seci	seci	PROPN
ajlm-1296	24	24	-	-	PUNCT
ajlm-1296	24	25	irb	irb	NOUN
ajlm-1296	24	26	-	-	PUNCT
ajlm-1296	24	27	iorg0006563	iorg0006563	PROPN
ajlm-1296	24	28	,	,	PUNCT
ajlm-1296	24	29	37:10/1/2018	37:10/1/2018	NUM
ajlm-1296	24	30	)	)	PUNCT
ajlm-1296	24	31	.	.	PUNCT
ajlm-1296	25	1	written	write	VERB
ajlm-1296	25	2	informed	informed	ADJ
ajlm-1296	25	3	consent	consent	NOUN
ajlm-1296	25	4	was	be	AUX
ajlm-1296	25	5	obtained	obtain	VERB
ajlm-1296	25	6	from	from	ADP
ajlm-1296	25	7	patients	patient	NOUN
ajlm-1296	25	8	and	and	CCONJ
ajlm-1296	25	9	healthy	healthy	ADJ
ajlm-1296	25	10	volunteers	volunteer	NOUN
ajlm-1296	25	11	in	in	ADP
ajlm-1296	25	12	accordance	accordance	NOUN
ajlm-1296	25	13	with	with	ADP
ajlm-1296	25	14	the	the	DET
ajlm-1296	25	15	declaration	declaration	NOUN
ajlm-1296	25	16	of	of	ADP
ajlm-1296	25	17	helsinki	helsinki	PROPN
ajlm-1296	25	18	.	.	PUNCT
ajlm-1296	26	1	patients	patient	NOUN
ajlm-1296	26	2	and	and	CCONJ
ajlm-1296	26	3	controls	control	NOUN
ajlm-1296	26	4	provided	provide	VERB
ajlm-1296	26	5	written	write	VERB
ajlm-1296	26	6	informed	inform	VERB
ajlm-1296	26	7	consent	consent	NOUN
ajlm-1296	26	8	and	and	CCONJ
ajlm-1296	26	9	participated	participate	VERB
ajlm-1296	26	10	in	in	ADP
ajlm-1296	26	11	the	the	DET
ajlm-1296	26	12	study	study	NOUN
ajlm-1296	26	13	after	after	ADP
ajlm-1296	26	14	study	study	NOUN
ajlm-1296	26	15	clarification	clarification	NOUN
ajlm-1296	26	16	.	.	PUNCT
ajlm-1296	27	1	patients	patient	NOUN
ajlm-1296	27	2	got	get	VERB
ajlm-1296	27	3	the	the	DET
ajlm-1296	27	4	maximum	maximum	ADJ
ajlm-1296	27	5	care	care	NOUN
ajlm-1296	27	6	,	,	PUNCT
ajlm-1296	27	7	and	and	CCONJ
ajlm-1296	27	8	the	the	DET
ajlm-1296	27	9	study	study	NOUN
ajlm-1296	27	10	procedures	procedure	NOUN
ajlm-1296	27	11	were	be	AUX
ajlm-1296	27	12	in	in	ADP
ajlm-1296	27	13	accordance	accordance	NOUN
ajlm-1296	27	14	with	with	ADP
ajlm-1296	27	15	relevant	relevant	ADJ
ajlm-1296	27	16	guidelines	guideline	NOUN
ajlm-1296	27	17	and	and	CCONJ
ajlm-1296	27	18	the	the	DET
ajlm-1296	27	19	declaration	declaration	NOUN
ajlm-1296	27	20	of	of	ADP
ajlm-1296	27	21	helsinki	helsinki	PROPN
ajlm-1296	27	22	.	.	PUNCT
ajlm-1296	28	1	investigators	investigator	NOUN
ajlm-1296	28	2	and	and	CCONJ
ajlm-1296	28	3	researchers	researcher	NOUN
ajlm-1296	28	4	collected	collect	VERB
ajlm-1296	28	5	data	datum	NOUN
ajlm-1296	28	6	using	use	VERB
ajlm-1296	28	7	paper	paper	NOUN
ajlm-1296	28	8	data	datum	NOUN
ajlm-1296	28	9	collection	collection	NOUN
ajlm-1296	28	10	forms	form	NOUN
ajlm-1296	28	11	.	.	PUNCT
ajlm-1296	29	1	patients	patient	NOUN
ajlm-1296	29	2	were	be	AUX
ajlm-1296	29	3	identified	identify	VERB
ajlm-1296	29	4	by	by	ADP
ajlm-1296	29	5	serial	serial	ADJ
ajlm-1296	29	6	study	study	NOUN
ajlm-1296	29	7	codes	code	NOUN
ajlm-1296	29	8	,	,	PUNCT
ajlm-1296	29	9	which	which	PRON
ajlm-1296	29	10	were	be	AUX
ajlm-1296	29	11	linked	link	VERB
ajlm-1296	29	12	with	with	ADP
ajlm-1296	29	13	patient	patient	ADJ
ajlm-1296	29	14	names	name	NOUN
ajlm-1296	29	15	and	and	CCONJ
ajlm-1296	29	16	hospital	hospital	NOUN
ajlm-1296	29	17	file	file	NOUN
ajlm-1296	29	18	numbers	number	NOUN
ajlm-1296	29	19	on	on	ADP
ajlm-1296	29	20	a	a	DET
ajlm-1296	29	21	separate	separate	ADJ
ajlm-1296	29	22	sheet	sheet	NOUN
ajlm-1296	29	23	and	and	CCONJ
ajlm-1296	29	24	stored	store	VERB
ajlm-1296	29	25	in	in	ADP
ajlm-1296	29	26	a	a	DET
ajlm-1296	29	27	locked	lock	VERB
ajlm-1296	29	28	safe	safe	ADJ
ajlm-1296	29	29	cabinet	cabinet	NOUN
ajlm-1296	29	30	.	.	PUNCT
ajlm-1296	30	1	data	datum	NOUN
ajlm-1296	30	2	analysis	analysis	NOUN
ajlm-1296	30	3	was	be	AUX
ajlm-1296	30	4	performed	perform	VERB
ajlm-1296	30	5	on	on	ADP
ajlm-1296	30	6	the	the	DET
ajlm-1296	30	7	de	de	ADJ
ajlm-1296	30	8	-	-	ADJ
ajlm-1296	30	9	identified	identify	VERB
ajlm-1296	30	10	data	datum	NOUN
ajlm-1296	30	11	.	.	PUNCT
ajlm-1296	31	1	study	study	NOUN
ajlm-1296	31	2	population	population	NOUN
ajlm-1296	31	3	a	a	DET
ajlm-1296	31	4	prospective	prospective	ADJ
ajlm-1296	31	5	case	case	NOUN
ajlm-1296	31	6	-	-	PUNCT
ajlm-1296	31	7	control	control	NOUN
ajlm-1296	31	8	study	study	NOUN
ajlm-1296	31	9	was	be	AUX
ajlm-1296	31	10	conducted	conduct	VERB
ajlm-1296	31	11	at	at	ADP
ajlm-1296	31	12	the	the	DET
ajlm-1296	31	13	clinical	clinical	ADJ
ajlm-1296	31	14	haematology	haematology	NOUN
ajlm-1296	31	15	unit	unit	NOUN
ajlm-1296	31	16	,	,	PUNCT
ajlm-1296	31	17	internal	internal	ADJ
ajlm-1296	31	18	medicine	medicine	NOUN
ajlm-1296	31	19	department	department	PROPN
ajlm-1296	31	20	,	,	PUNCT
ajlm-1296	31	21	assiut	assiut	PROPN
ajlm-1296	31	22	university	university	NOUN
ajlm-1296	31	23	hospital	hospital	NOUN
ajlm-1296	31	24	,	,	PUNCT
ajlm-1296	31	25	and	and	CCONJ
ajlm-1296	31	26	medical	medical	ADJ
ajlm-1296	31	27	oncology	oncology	NOUN
ajlm-1296	31	28	department	department	PROPN
ajlm-1296	31	29	,	,	PUNCT
ajlm-1296	31	30	south	south	PROPN
ajlm-1296	31	31	egypt	egypt	PROPN
ajlm-1296	31	32	cancer	cancer	PROPN
ajlm-1296	31	33	institute	institute	PROPN
ajlm-1296	31	34	,	,	PUNCT
ajlm-1296	31	35	assiut	assiut	PROPN
ajlm-1296	31	36	university	university	PROPN
ajlm-1296	31	37	,	,	PUNCT
ajlm-1296	31	38	in	in	ADP
ajlm-1296	31	39	assiut	assiut	PROPN
ajlm-1296	31	40	,	,	PUNCT
ajlm-1296	31	41	egypt	egypt	PROPN
ajlm-1296	31	42	,	,	PUNCT
ajlm-1296	31	43	from	from	ADP
ajlm-1296	31	44	october	october	PROPN
ajlm-1296	31	45	2018	2018	NUM
ajlm-1296	31	46	to	to	ADP
ajlm-1296	31	47	august	august	PROPN
ajlm-1296	31	48	2019	2019	NUM
ajlm-1296	31	49	.	.	PUNCT
ajlm-1296	32	1	twenty	twenty	NUM
ajlm-1296	32	2	newly	newly	ADV
ajlm-1296	32	3	diagnosed	diagnose	VERB
ajlm-1296	32	4	untreated	untreated	ADJ
ajlm-1296	32	5	mm	mm	PROPN
ajlm-1296	32	6	patients	patient	NOUN
ajlm-1296	32	7	diagnosed	diagnose	VERB
ajlm-1296	32	8	according	accord	VERB
ajlm-1296	32	9	to	to	ADP
ajlm-1296	32	10	the	the	DET
ajlm-1296	32	11	world	world	PROPN
ajlm-1296	32	12	health	health	PROPN
ajlm-1296	32	13	organization	organization	NOUN
ajlm-1296	32	14	criteria	criterion	NOUN
ajlm-1296	32	15	for	for	ADP
ajlm-1296	32	16	mm	mm	PROPN
ajlm-1296	32	17	,	,	PUNCT
ajlm-1296	32	18	and	and	CCONJ
ajlm-1296	32	19	20	20	NUM
ajlm-1296	32	20	matched	match	VERB
ajlm-1296	32	21	(	(	PUNCT
ajlm-1296	32	22	age	age	NOUN
ajlm-1296	32	23	and	and	CCONJ
ajlm-1296	32	24	sex	sex	NOUN
ajlm-1296	32	25	)	)	PUNCT
ajlm-1296	32	26	healthy	healthy	ADJ
ajlm-1296	32	27	volunteers	volunteer	NOUN
ajlm-1296	32	28	were	be	AUX
ajlm-1296	32	29	included	include	VERB
ajlm-1296	32	30	in	in	ADP
ajlm-1296	32	31	this	this	DET
ajlm-1296	32	32	study	study	NOUN
ajlm-1296	32	33	.	.	PUNCT
ajlm-1296	33	1	patients	patient	NOUN
ajlm-1296	33	2	who	who	PRON
ajlm-1296	33	3	were	be	AUX
ajlm-1296	33	4	under	under	ADP
ajlm-1296	33	5	treatment	treatment	NOUN
ajlm-1296	33	6	or	or	CCONJ
ajlm-1296	33	7	refused	refuse	VERB
ajlm-1296	33	8	to	to	PART
ajlm-1296	33	9	participate	participate	VERB
ajlm-1296	33	10	were	be	AUX
ajlm-1296	33	11	not	not	PART
ajlm-1296	33	12	included	include	VERB
ajlm-1296	33	13	.	.	PUNCT
ajlm-1296	34	1	multiple	multiple	ADJ
ajlm-1296	34	2	myeloma	myeloma	NOUN
ajlm-1296	34	3	patients	patient	NOUN
ajlm-1296	34	4	were	be	AUX
ajlm-1296	34	5	classified	classify	VERB
ajlm-1296	34	6	using	use	VERB
ajlm-1296	34	7	the	the	DET
ajlm-1296	34	8	durie	durie	NOUN
ajlm-1296	34	9	-	-	PUNCT
ajlm-1296	34	10	salmon	salmon	NOUN
ajlm-1296	34	11	staging	staging	NOUN
ajlm-1296	34	12	system18	system18	NOUN
ajlm-1296	34	13	that	that	PRON
ajlm-1296	34	14	assesses	assess	VERB
ajlm-1296	34	15	tumour	tumour	NOUN
ajlm-1296	34	16	burden	burden	NOUN
ajlm-1296	34	17	based	base	VERB
ajlm-1296	34	18	on	on	ADP
ajlm-1296	34	19	three	three	NUM
ajlm-1296	34	20	laboratory	laboratory	NOUN
ajlm-1296	34	21	parameters	parameter	NOUN
ajlm-1296	34	22	and	and	CCONJ
ajlm-1296	34	23	evaluates	evaluate	VERB
ajlm-1296	34	24	bone	bone	NOUN
ajlm-1296	34	25	involvement	involvement	NOUN
ajlm-1296	34	26	based	base	VERB
ajlm-1296	34	27	on	on	ADP
ajlm-1296	34	28	a	a	DET
ajlm-1296	34	29	radiographic	radiographic	ADJ
ajlm-1296	34	30	skeletal	skeletal	ADJ
ajlm-1296	34	31	survey	survey	NOUN
ajlm-1296	34	32	.	.	PUNCT
ajlm-1296	35	1	patients	patient	NOUN
ajlm-1296	35	2	who	who	PRON
ajlm-1296	35	3	had	have	VERB
ajlm-1296	35	4	haemoglobin	haemoglobin	NOUN
ajlm-1296	35	5	levels	level	NOUN
ajlm-1296	35	6	over	over	ADP
ajlm-1296	35	7	10	10	NUM
ajlm-1296	35	8	g	g	NOUN
ajlm-1296	35	9	/	/	SYM
ajlm-1296	35	10	dl	dl	PROPN
ajlm-1296	35	11	,	,	PUNCT
ajlm-1296	35	12	normal	normal	ADJ
ajlm-1296	35	13	serum	serum	NOUN
ajlm-1296	35	14	calcium	calcium	NOUN
ajlm-1296	35	15	or	or	CCONJ
ajlm-1296	35	16	less	less	ADJ
ajlm-1296	35	17	than	than	ADP
ajlm-1296	35	18	10.5	10.5	NUM
ajlm-1296	35	19	mg	mg	PROPN
ajlm-1296	35	20	/	/	SYM
ajlm-1296	35	21	dl	dl	PROPN
ajlm-1296	35	22	,	,	PUNCT
ajlm-1296	35	23	normal	normal	ADJ
ajlm-1296	35	24	bone	bone	NOUN
ajlm-1296	35	25	x	x	NOUN
ajlm-1296	35	26	-	-	NOUN
ajlm-1296	35	27	ray	ray	NOUN
ajlm-1296	35	28	or	or	CCONJ
ajlm-1296	35	29	solitary	solitary	ADJ
ajlm-1296	35	30	lytic	lytic	ADJ
ajlm-1296	35	31	lesion	lesion	NOUN
ajlm-1296	35	32	,	,	PUNCT
ajlm-1296	35	33	monoclonal	monoclonal	NOUN
ajlm-1296	35	34	immunoglobulin	immunoglobulin	NOUN
ajlm-1296	35	35	g	g	PROPN
ajlm-1296	35	36	under	under	ADP
ajlm-1296	35	37	5	5	NUM
ajlm-1296	35	38	g	g	NOUN
ajlm-1296	35	39	/	/	SYM
ajlm-1296	35	40	dl	dl	PROPN
ajlm-1296	35	41	,	,	PUNCT
ajlm-1296	35	42	immunoglobulin	immunoglobulin	NOUN
ajlm-1296	35	43	a	a	DET
ajlm-1296	35	44	under	under	ADP
ajlm-1296	35	45	3	3	NUM
ajlm-1296	35	46	g	g	NOUN
ajlm-1296	35	47	/	/	SYM
ajlm-1296	35	48	dl	dl	PROPN
ajlm-1296	35	49	,	,	PUNCT
ajlm-1296	35	50	and	and	CCONJ
ajlm-1296	35	51	bence	bence	NOUN
ajlm-1296	35	52	jones	jones	NOUN
ajlm-1296	35	53	protein	protein	NOUN
ajlm-1296	35	54	under	under	ADP
ajlm-1296	35	55	4	4	NUM
ajlm-1296	35	56	g/24	g/24	NOUN
ajlm-1296	35	57	h	h	NOUN
ajlm-1296	35	58	were	be	AUX
ajlm-1296	35	59	classified	classify	VERB
ajlm-1296	35	60	as	as	ADP
ajlm-1296	35	61	stage	stage	NOUN
ajlm-1296	35	62	i.	i.	PROPN
ajlm-1296	35	63	stage	stage	PROPN
ajlm-1296	35	64	ii	ii	PROPN
ajlm-1296	35	65	patients	patient	NOUN
ajlm-1296	35	66	were	be	AUX
ajlm-1296	35	67	patients	patient	NOUN
ajlm-1296	35	68	with	with	ADP
ajlm-1296	35	69	a	a	DET
ajlm-1296	35	70	moderate	moderate	ADJ
ajlm-1296	35	71	number	number	NOUN
ajlm-1296	35	72	of	of	ADP
ajlm-1296	35	73	myeloma	myeloma	NOUN
ajlm-1296	35	74	cells	cell	NOUN
ajlm-1296	35	75	that	that	PRON
ajlm-1296	35	76	did	do	AUX
ajlm-1296	35	77	not	not	PART
ajlm-1296	35	78	meet	meet	VERB
ajlm-1296	35	79	either	either	CCONJ
ajlm-1296	35	80	stage	stage	NOUN
ajlm-1296	35	81	i	i	PRON
ajlm-1296	35	82	or	or	CCONJ
ajlm-1296	35	83	stage	stage	NOUN
ajlm-1296	35	84	iii	iii	NUM
ajlm-1296	35	85	criteria	criterion	NOUN
ajlm-1296	35	86	.	.	PUNCT
ajlm-1296	36	1	stage	stage	NOUN
ajlm-1296	36	2	iii	iii	NUM
ajlm-1296	36	3	patients	patient	NOUN
ajlm-1296	36	4	were	be	AUX
ajlm-1296	36	5	those	those	PRON
ajlm-1296	36	6	who	who	PRON
ajlm-1296	36	7	met	meet	VERB
ajlm-1296	36	8	one	one	NUM
ajlm-1296	36	9	or	or	CCONJ
ajlm-1296	36	10	more	more	ADJ
ajlm-1296	36	11	of	of	ADP
ajlm-1296	36	12	the	the	DET
ajlm-1296	36	13	following	follow	VERB
ajlm-1296	36	14	criteria	criterion	NOUN
ajlm-1296	36	15	:	:	PUNCT
ajlm-1296	36	16	haemoglobin	haemoglobin	NOUN
ajlm-1296	36	17	under	under	ADP
ajlm-1296	36	18	8.5	8.5	NUM
ajlm-1296	36	19	g	g	NOUN
ajlm-1296	36	20	/	/	SYM
ajlm-1296	36	21	dl	dl	PROPN
ajlm-1296	36	22	,	,	PUNCT
ajlm-1296	36	23	serum	serum	NOUN
ajlm-1296	36	24	calcium	calcium	NOUN
ajlm-1296	36	25	value	value	NOUN
ajlm-1296	36	26	over	over	ADP
ajlm-1296	36	27	12	12	NUM
ajlm-1296	36	28	mg	mg	PROPN
ajlm-1296	36	29	/	/	SYM
ajlm-1296	36	30	dl	dl	PROPN
ajlm-1296	36	31	,	,	PUNCT
ajlm-1296	36	32	advanced	advanced	ADJ
ajlm-1296	36	33	lytic	lytic	ADJ
ajlm-1296	36	34	bone	bone	NOUN
ajlm-1296	36	35	lesions	lesion	NOUN
ajlm-1296	36	36	,	,	PUNCT
ajlm-1296	36	37	monoclonal	monoclonal	NOUN
ajlm-1296	36	38	immunoglobulin	immunoglobulin	NOUN
ajlm-1296	36	39	g	g	PROPN
ajlm-1296	36	40	over	over	ADP
ajlm-1296	36	41	7	7	NUM
ajlm-1296	36	42	g	g	PROPN
ajlm-1296	36	43	/	/	SYM
ajlm-1296	36	44	dl	dl	PROPN
ajlm-1296	36	45	,	,	PUNCT
ajlm-1296	36	46	immunoglobulin	immunoglobulin	NOUN
ajlm-1296	36	47	a	a	DET
ajlm-1296	36	48	over	over	ADP
ajlm-1296	36	49	5	5	NUM
ajlm-1296	36	50	g	g	NOUN
ajlm-1296	36	51	/	/	SYM
ajlm-1296	36	52	dl	dl	PROPN
ajlm-1296	36	53	,	,	PUNCT
ajlm-1296	36	54	and	and	CCONJ
ajlm-1296	36	55	bence	bence	NOUN
ajlm-1296	36	56	jones	jones	NOUN
ajlm-1296	36	57	protein	protein	NOUN
ajlm-1296	36	58	over	over	ADP
ajlm-1296	36	59	12	12	NUM
ajlm-1296	36	60	g/24	g/24	NOUN
ajlm-1296	36	61	h.	h.	NOUN
ajlm-1296	36	62	as	as	SCONJ
ajlm-1296	36	63	the	the	DET
ajlm-1296	36	64	durie	durie	NOUN
ajlm-1296	36	65	-	-	PUNCT
ajlm-1296	36	66	salmon	salmon	NOUN
ajlm-1296	36	67	scoring	scoring	NOUN
ajlm-1296	36	68	may	may	AUX
ajlm-1296	36	69	not	not	PART
ajlm-1296	36	70	provide	provide	VERB
ajlm-1296	36	71	good	good	ADJ
ajlm-1296	36	72	prognostic	prognostic	ADJ
ajlm-1296	36	73	discrimination	discrimination	NOUN
ajlm-1296	36	74	,	,	PUNCT
ajlm-1296	36	75	the	the	DET
ajlm-1296	36	76	international	international	ADJ
ajlm-1296	36	77	staging	staging	NOUN
ajlm-1296	36	78	system	system	NOUN
ajlm-1296	36	79	was	be	AUX
ajlm-1296	36	80	used	use	VERB
ajlm-1296	36	81	in	in	ADP
ajlm-1296	36	82	this	this	DET
ajlm-1296	36	83	study	study	NOUN
ajlm-1296	36	84	to	to	ADP
ajlm-1296	36	85	group	group	NOUN
ajlm-1296	36	86	mm	mm	PROPN
ajlm-1296	36	87	patients	patient	NOUN
ajlm-1296	36	88	according	accord	VERB
ajlm-1296	36	89	to	to	ADP
ajlm-1296	36	90	the	the	DET
ajlm-1296	36	91	serum	serum	NOUN
ajlm-1296	36	92	β2	β2	PROPN
ajlm-1296	36	93	-	-	PUNCT
ajlm-1296	36	94	microglobulin	microglobulin	PROPN
ajlm-1296	36	95	(	(	PUNCT
ajlm-1296	36	96	β2	β2	PROPN
ajlm-1296	36	97	m	m	PROPN
ajlm-1296	36	98	)	)	PUNCT
ajlm-1296	36	99	and	and	CCONJ
ajlm-1296	36	100	serum	serum	NOUN
ajlm-1296	36	101	albumin	albumin	NOUN
ajlm-1296	36	102	into	into	ADP
ajlm-1296	36	103	3	3	NUM
ajlm-1296	36	104	stages	stage	NOUN
ajlm-1296	36	105	:	:	PUNCT
ajlm-1296	36	106	stage	stage	NOUN
ajlm-1296	36	107	i	i	PRON
ajlm-1296	36	108	characterised	characterise	VERB
ajlm-1296	36	109	by	by	ADP
ajlm-1296	36	110	serum	serum	NOUN
ajlm-1296	36	111	β2	β2	PROPN
ajlm-1296	36	112	m	m	PROPN
ajlm-1296	36	113	less	less	ADJ
ajlm-1296	36	114	than	than	ADP
ajlm-1296	36	115	3.5	3.5	NUM
ajlm-1296	36	116	mg	mg	NUM
ajlm-1296	36	117	/	/	SYM
ajlm-1296	36	118	l	l	NOUN
ajlm-1296	36	119	and	and	CCONJ
ajlm-1296	36	120	serum	serum	NOUN
ajlm-1296	36	121	albumin	albumin	NOUN
ajlm-1296	36	122	3.5	3.5	NUM
ajlm-1296	36	123	g	g	NOUN
ajlm-1296	36	124	/	/	SYM
ajlm-1296	36	125	dl	dl	PROPN
ajlm-1296	36	126	or	or	CCONJ
ajlm-1296	36	127	higher	high	ADJ
ajlm-1296	36	128	,	,	PUNCT
ajlm-1296	36	129	stage	stage	NOUN
ajlm-1296	36	130	ii	ii	PROPN
ajlm-1296	36	131	in	in	ADP
ajlm-1296	36	132	which	which	PRON
ajlm-1296	36	133	serum	serum	NOUN
ajlm-1296	36	134	β2	β2	PROPN
ajlm-1296	36	135	m	m	PROPN
ajlm-1296	36	136	was	be	AUX
ajlm-1296	36	137	less	less	ADJ
ajlm-1296	36	138	than	than	ADP
ajlm-1296	36	139	3.5	3.5	NUM
ajlm-1296	36	140	mg	mg	NUM
ajlm-1296	36	141	/	/	SYM
ajlm-1296	36	142	l	l	NOUN
ajlm-1296	36	143	and	and	CCONJ
ajlm-1296	36	144	serum	serum	NOUN
ajlm-1296	36	145	albumin	albumin	NOUN
ajlm-1296	36	146	was	be	AUX
ajlm-1296	36	147	less	less	ADJ
ajlm-1296	36	148	than	than	ADP
ajlm-1296	36	149	3.5	3.5	NUM
ajlm-1296	36	150	g	g	NOUN
ajlm-1296	36	151	/	/	SYM
ajlm-1296	36	152	dl	dl	PROPN
ajlm-1296	36	153	or	or	CCONJ
ajlm-1296	36	154	β2	β2	PROPN
ajlm-1296	36	155	m	m	PROPN
ajlm-1296	36	156	was	be	AUX
ajlm-1296	36	157	between	between	ADP
ajlm-1296	36	158	3.5	3.5	NUM
ajlm-1296	36	159	mg	mg	NUM
ajlm-1296	36	160	/	/	SYM
ajlm-1296	36	161	l	l	NOUN
ajlm-1296	36	162	and	and	CCONJ
ajlm-1296	36	163	5.5	5.5	NUM
ajlm-1296	36	164	mg	mg	NUM
ajlm-1296	36	165	/	/	SYM
ajlm-1296	36	166	l	l	NOUN
ajlm-1296	36	167	,	,	PUNCT
ajlm-1296	36	168	and	and	CCONJ
ajlm-1296	36	169	stage	stage	NOUN
ajlm-1296	36	170	iii	iii	NUM
ajlm-1296	36	171	in	in	ADP
ajlm-1296	36	172	which	which	PRON
ajlm-1296	36	173	serum	serum	NOUN
ajlm-1296	36	174	β2	β2	PROPN
ajlm-1296	36	175	m	m	PROPN
ajlm-1296	36	176	was	be	AUX
ajlm-1296	36	177	5.5	5.5	NUM
ajlm-1296	36	178	mg	mg	NOUN
ajlm-1296	36	179	/	/	SYM
ajlm-1296	36	180	l	l	NOUN
ajlm-1296	36	181	or	or	CCONJ
ajlm-1296	36	182	higher.19	higher.19	NOUN
ajlm-1296	36	183	patient	patient	NOUN
ajlm-1296	36	184	data	datum	NOUN
ajlm-1296	36	185	were	be	AUX
ajlm-1296	36	186	also	also	ADV
ajlm-1296	36	187	collected	collect	VERB
ajlm-1296	36	188	for	for	ADP
ajlm-1296	36	189	the	the	DET
ajlm-1296	36	190	study	study	NOUN
ajlm-1296	36	191	;	;	PUNCT
ajlm-1296	36	192	these	these	PRON
ajlm-1296	36	193	included	include	VERB
ajlm-1296	36	194	age	age	NOUN
ajlm-1296	36	195	,	,	PUNCT
ajlm-1296	36	196	sex	sex	NOUN
ajlm-1296	36	197	,	,	PUNCT
ajlm-1296	36	198	and	and	CCONJ
ajlm-1296	36	199	clinical	clinical	ADJ
ajlm-1296	36	200	history	history	NOUN
ajlm-1296	36	201	of	of	ADP
ajlm-1296	36	202	bone	bone	NOUN
ajlm-1296	36	203	pain	pain	NOUN
ajlm-1296	36	204	,	,	PUNCT
ajlm-1296	36	205	pathological	pathological	ADJ
ajlm-1296	36	206	fracture	fracture	NOUN
ajlm-1296	36	207	,	,	PUNCT
ajlm-1296	36	208	weakness	weakness	NOUN
ajlm-1296	36	209	and	and	CCONJ
ajlm-1296	36	210	fatigue	fatigue	NOUN
ajlm-1296	36	211	,	,	PUNCT
ajlm-1296	36	212	recurrent	recurrent	ADJ
ajlm-1296	36	213	infection	infection	NOUN
ajlm-1296	36	214	,	,	PUNCT
ajlm-1296	36	215	manifestation	manifestation	NOUN
ajlm-1296	36	216	of	of	ADP
ajlm-1296	36	217	hypercalcemia	hypercalcemia	NOUN
ajlm-1296	36	218	such	such	ADJ
ajlm-1296	36	219	as	as	ADP
ajlm-1296	36	220	thirst	thirst	NOUN
ajlm-1296	36	221	,	,	PUNCT
ajlm-1296	36	222	polyuria	polyuria	NOUN
ajlm-1296	36	223	,	,	PUNCT
ajlm-1296	36	224	manifestation	manifestation	NOUN
ajlm-1296	36	225	of	of	ADP
ajlm-1296	36	226	hyperviscosity	hyperviscosity	NOUN
ajlm-1296	36	227	(	(	PUNCT
ajlm-1296	36	228	blurring	blurring	NOUN
ajlm-1296	36	229	of	of	ADP
ajlm-1296	36	230	vision	vision	NOUN
ajlm-1296	36	231	,	,	PUNCT
ajlm-1296	36	232	mental	mental	ADJ
ajlm-1296	36	233	confusion	confusion	NOUN
ajlm-1296	36	234	)	)	PUNCT
ajlm-1296	36	235	,	,	PUNCT
ajlm-1296	36	236	bleeding	bleed	VERB
ajlm-1296	36	237	tendency	tendency	NOUN
ajlm-1296	36	238	,	,	PUNCT
ajlm-1296	36	239	and	and	CCONJ
ajlm-1296	36	240	neuropathy	neuropathy	ADJ
ajlm-1296	36	241	.	.	PUNCT
ajlm-1296	37	1	clinical	clinical	ADJ
ajlm-1296	37	2	signs	sign	NOUN
ajlm-1296	37	3	of	of	ADP
ajlm-1296	37	4	anaemia	anaemia	NOUN
ajlm-1296	37	5	,	,	PUNCT
ajlm-1296	37	6	oedema	oedema	NOUN
ajlm-1296	37	7	,	,	PUNCT
ajlm-1296	37	8	and	and	CCONJ
ajlm-1296	37	9	renal	renal	ADJ
ajlm-1296	37	10	impairment	impairment	NOUN
ajlm-1296	37	11	were	be	AUX
ajlm-1296	37	12	carefully	carefully	ADV
ajlm-1296	37	13	assessed	assess	VERB
ajlm-1296	37	14	in	in	ADP
ajlm-1296	37	15	all	all	DET
ajlm-1296	37	16	patients	patient	NOUN
ajlm-1296	37	17	.	.	PUNCT
ajlm-1296	38	1	a	a	DET
ajlm-1296	38	2	radiographic	radiographic	ADJ
ajlm-1296	38	3	skeletal	skeletal	ADJ
ajlm-1296	38	4	survey	survey	NOUN
ajlm-1296	38	5	of	of	ADP
ajlm-1296	38	6	the	the	DET
ajlm-1296	38	7	skull	skull	NOUN
ajlm-1296	38	8	and	and	CCONJ
ajlm-1296	38	9	long	long	ADJ
ajlm-1296	38	10	bones	bone	NOUN
ajlm-1296	38	11	was	be	AUX
ajlm-1296	38	12	also	also	ADV
ajlm-1296	38	13	done	do	VERB
ajlm-1296	38	14	to	to	PART
ajlm-1296	38	15	detect	detect	VERB
ajlm-1296	38	16	lytic	lytic	ADJ
ajlm-1296	38	17	bone	bone	NOUN
ajlm-1296	38	18	lesions	lesion	NOUN
ajlm-1296	38	19	,	,	PUNCT
ajlm-1296	38	20	pathological	pathological	ADJ
ajlm-1296	38	21	fractures	fracture	NOUN
ajlm-1296	38	22	,	,	PUNCT
ajlm-1296	38	23	and	and	CCONJ
ajlm-1296	38	24	abdominal	abdominal	ADJ
ajlm-1296	38	25	ultrasound	ultrasound	NOUN
ajlm-1296	38	26	.	.	PUNCT
ajlm-1296	39	1	complete	complete	ADJ
ajlm-1296	39	2	blood	blood	NOUN
ajlm-1296	39	3	count	count	NOUN
ajlm-1296	39	4	with	with	ADP
ajlm-1296	39	5	differential	differential	NOUN
ajlm-1296	39	6	was	be	AUX
ajlm-1296	39	7	done	do	VERB
ajlm-1296	39	8	using	use	VERB
ajlm-1296	39	9	the	the	DET
ajlm-1296	39	10	cell	cell	NOUN
ajlm-1296	39	11	-	-	PUNCT
ajlm-1296	39	12	dyn	dyn	NOUN
ajlm-1296	39	13	ruby	ruby	NOUN
ajlm-1296	39	14	fully	fully	ADV
ajlm-1296	39	15	automated	automate	VERB
ajlm-1296	39	16	blood	blood	NOUN
ajlm-1296	39	17	counter	counter	NOUN
ajlm-1296	39	18	(	(	PUNCT
ajlm-1296	39	19	cell	cell	NOUN
ajlm-1296	39	20	-	-	PUNCT
ajlm-1296	39	21	dyn	dyn	NOUN
ajlm-1296	39	22	ruby	ruby	NOUN
ajlm-1296	39	23	system	system	NOUN
ajlm-1296	39	24	,	,	PUNCT
ajlm-1296	39	25	abbott	abbott	PROPN
ajlm-1296	39	26	diagnostics	diagnostics	PROPN
ajlm-1296	39	27	,	,	PUNCT
ajlm-1296	39	28	chicago	chicago	PROPN
ajlm-1296	39	29	,	,	PUNCT
ajlm-1296	39	30	illinois	illinois	PROPN
ajlm-1296	39	31	,	,	PUNCT
ajlm-1296	39	32	united	united	PROPN
ajlm-1296	39	33	states	states	PROPN
ajlm-1296	39	34	;	;	PUNCT
ajlm-1296	39	35	serial	serial	ADJ
ajlm-1296	39	36	number	number	NOUN
ajlm-1296	39	37	:	:	PUNCT
ajlm-1296	39	38	36026bg	36026bg	NOUN
ajlm-1296	39	39	)	)	PUNCT
ajlm-1296	39	40	.	.	PUNCT
ajlm-1296	40	1	examination	examination	NOUN
ajlm-1296	40	2	of	of	ADP
ajlm-1296	40	3	peripheral	peripheral	ADJ
ajlm-1296	40	4	blood	blood	NOUN
ajlm-1296	40	5	smear	smear	NOUN
ajlm-1296	40	6	for	for	ADP
ajlm-1296	40	7	rouleaux	rouleaux	ADJ
ajlm-1296	40	8	formation	formation	NOUN
ajlm-1296	40	9	was	be	AUX
ajlm-1296	40	10	done	do	VERB
ajlm-1296	40	11	as	as	ADP
ajlm-1296	40	12	part	part	NOUN
ajlm-1296	40	13	of	of	ADP
ajlm-1296	40	14	routine	routine	ADJ
ajlm-1296	40	15	care	care	NOUN
ajlm-1296	40	16	.	.	PUNCT
ajlm-1296	41	1	blood	blood	NOUN
ajlm-1296	41	2	urea	urea	NOUN
ajlm-1296	41	3	,	,	PUNCT
ajlm-1296	41	4	serum	serum	NOUN
ajlm-1296	41	5	creatinine	creatinine	NOUN
ajlm-1296	41	6	,	,	PUNCT
ajlm-1296	41	7	total	total	ADJ
ajlm-1296	41	8	protein	protein	NOUN
ajlm-1296	41	9	,	,	PUNCT
ajlm-1296	41	10	albumin	albumin	NOUN
ajlm-1296	41	11	,	,	PUNCT
ajlm-1296	41	12	and	and	CCONJ
ajlm-1296	41	13	lactate	lactate	NOUN
ajlm-1296	41	14	dehydrogenase	dehydrogenase	NOUN
ajlm-1296	41	15	(	(	PUNCT
ajlm-1296	41	16	ldh	ldh	NOUN
ajlm-1296	41	17	)	)	PUNCT
ajlm-1296	41	18	tests	test	NOUN
ajlm-1296	41	19	were	be	AUX
ajlm-1296	41	20	done	do	VERB
ajlm-1296	41	21	using	use	VERB
ajlm-1296	41	22	the	the	DET
ajlm-1296	41	23	cobas	cobas	PROPN
ajlm-1296	41	24	integra	integra	PROPN
ajlm-1296	41	25	400	400	NUM
ajlm-1296	41	26	automated	automate	VERB
ajlm-1296	41	27	chemical	chemical	NOUN
ajlm-1296	41	28	analyser	analyser	NOUN
ajlm-1296	41	29	(	(	PUNCT
ajlm-1296	41	30	roche	roche	PROPN
ajlm-1296	41	31	diagnostics	diagnostic	NOUN
ajlm-1296	41	32	gmbh	gmbh	PROPN
ajlm-1296	41	33	,	,	PUNCT
ajlm-1296	41	34	mannheim	mannheim	PROPN
ajlm-1296	41	35	,	,	PUNCT
ajlm-1296	41	36	germany	germany	PROPN
ajlm-1296	41	37	;	;	PUNCT
ajlm-1296	41	38	serial	serial	ADJ
ajlm-1296	41	39	number	number	NOUN
ajlm-1296	41	40	:	:	PUNCT
ajlm-1296	41	41	500558	500558	NUM
ajlm-1296	41	42	)	)	PUNCT
ajlm-1296	41	43	.	.	PUNCT
ajlm-1296	42	1	serum	serum	NOUN
ajlm-1296	42	2	protein	protein	NOUN
ajlm-1296	42	3	electrophoresis	electrophoresis	NOUN
ajlm-1296	42	4	with	with	ADP
ajlm-1296	42	5	immunofixation	immunofixation	NOUN
ajlm-1296	42	6	was	be	AUX
ajlm-1296	42	7	performed	perform	VERB
ajlm-1296	42	8	to	to	PART
ajlm-1296	42	9	identify	identify	VERB
ajlm-1296	42	10	monoclonal	monoclonal	NOUN
ajlm-1296	42	11	protein	protein	NOUN
ajlm-1296	42	12	(	(	PUNCT
ajlm-1296	42	13	m	m	NOUN
ajlm-1296	42	14	-	-	ADJ
ajlm-1296	42	15	protein	protein	NOUN
ajlm-1296	42	16	)	)	PUNCT
ajlm-1296	42	17	types	type	NOUN
ajlm-1296	42	18	among	among	ADP
ajlm-1296	42	19	patients	patient	NOUN
ajlm-1296	42	20	at	at	ADP
ajlm-1296	42	21	diagnosis	diagnosis	NOUN
ajlm-1296	42	22	using	use	VERB
ajlm-1296	42	23	the	the	DET
ajlm-1296	42	24	pretty	pretty	ADJ
ajlm-1296	42	25	interlab	interlab	NOUN
ajlm-1296	42	26	device	device	NOUN
ajlm-1296	42	27	(	(	PUNCT
ajlm-1296	42	28	interlab	interlab	NOUN
ajlm-1296	42	29	,	,	PUNCT
ajlm-1296	42	30	rome	rome	PROPN
ajlm-1296	42	31	,	,	PUNCT
ajlm-1296	42	32	italy	italy	PROPN
ajlm-1296	42	33	;	;	PUNCT
ajlm-1296	42	34	serial	serial	ADJ
ajlm-1296	42	35	number	number	NOUN
ajlm-1296	42	36	:	:	PUNCT
ajlm-1296	42	37	38405301	38405301	NUM
ajlm-1296	42	38	)	)	PUNCT
ajlm-1296	42	39	.	.	PUNCT
ajlm-1296	43	1	bone	bone	NOUN
ajlm-1296	43	2	marrow	marrow	NOUN
ajlm-1296	43	3	aspiration	aspiration	NOUN
ajlm-1296	43	4	and	and	CCONJ
ajlm-1296	43	5	biopsy	biopsy	NOUN
ajlm-1296	43	6	to	to	PART
ajlm-1296	43	7	evaluate	evaluate	VERB
ajlm-1296	43	8	and	and	CCONJ
ajlm-1296	43	9	quantify	quantify	VERB
ajlm-1296	43	10	bone	bone	NOUN
ajlm-1296	43	11	marrow	marrow	NOUN
ajlm-1296	43	12	plasma	plasma	NOUN
ajlm-1296	43	13	cell	cell	NOUN
ajlm-1296	43	14	infiltration	infiltration	NOUN
ajlm-1296	43	15	were	be	AUX
ajlm-1296	43	16	done	do	VERB
ajlm-1296	43	17	on	on	ADP
ajlm-1296	43	18	all	all	DET
ajlm-1296	43	19	recruited	recruited	ADJ
ajlm-1296	43	20	patients	patient	NOUN
ajlm-1296	43	21	.	.	PUNCT
ajlm-1296	44	1	all	all	DET
ajlm-1296	44	2	these	these	DET
ajlm-1296	44	3	investigations	investigation	NOUN
ajlm-1296	44	4	were	be	AUX
ajlm-1296	44	5	done	do	VERB
ajlm-1296	44	6	as	as	ADP
ajlm-1296	44	7	routine	routine	ADJ
ajlm-1296	44	8	services	service	NOUN
ajlm-1296	44	9	for	for	ADP
ajlm-1296	44	10	newly	newly	ADV
ajlm-1296	44	11	diagnosed	diagnose	VERB
ajlm-1296	44	12	mm	mm	NOUN
ajlm-1296	44	13	cases	case	NOUN
ajlm-1296	44	14	.	.	PUNCT
ajlm-1296	45	1	flow	flow	VERB
ajlm-1296	45	2	cytometric	cytometric	ADJ
ajlm-1296	45	3	detection	detection	NOUN
ajlm-1296	45	4	of	of	ADP
ajlm-1296	45	5	monocytes	monocyte	NOUN
ajlm-1296	45	6	subtypes	subtype	NOUN
ajlm-1296	45	7	fifty	fifty	NUM
ajlm-1296	45	8	microlitres	microlitre	NOUN
ajlm-1296	45	9	of	of	ADP
ajlm-1296	45	10	remnant	remnant	ADJ
ajlm-1296	45	11	routine	routine	ADJ
ajlm-1296	45	12	complete	complete	ADJ
ajlm-1296	45	13	blood	blood	NOUN
ajlm-1296	45	14	count	count	NOUN
ajlm-1296	45	15	samples	sample	NOUN
ajlm-1296	45	16	were	be	AUX
ajlm-1296	45	17	added	add	VERB
ajlm-1296	45	18	to	to	ADP
ajlm-1296	45	19	5	5	NUM
ajlm-1296	45	20	µl	µl	NOUN
ajlm-1296	45	21	of	of	ADP
ajlm-1296	45	22	cd14	cd14	PROPN
ajlm-1296	45	23	fluoroisothiocyanate	fluoroisothiocyanate	NOUN
ajlm-1296	45	24	-	-	PUNCT
ajlm-1296	45	25	conjugated	conjugate	VERB
ajlm-1296	45	26	and	and	CCONJ
ajlm-1296	45	27	cd16	cd16	PROPN
ajlm-1296	45	28	phycoerythrinconjugated	phycoerythrinconjugate	VERB
ajlm-1296	45	29	(	(	PUNCT
ajlm-1296	45	30	becton	becton	PROPN
ajlm-1296	45	31	dickinson	dickinson	PROPN
ajlm-1296	46	1	[	[	X
ajlm-1296	46	2	bd	bd	X
ajlm-1296	46	3	]	]	X
ajlm-1296	46	4	biosciences	bioscience	NOUN
ajlm-1296	46	5	,	,	PUNCT
ajlm-1296	46	6	san	san	PROPN
ajlm-1296	46	7	jose	jose	PROPN
ajlm-1296	46	8	,	,	PUNCT
ajlm-1296	46	9	california	california	PROPN
ajlm-1296	46	10	,	,	PUNCT
ajlm-1296	46	11	united	united	PROPN
ajlm-1296	46	12	states	states	PROPN
ajlm-1296	46	13	)	)	PUNCT
ajlm-1296	46	14	.	.	PUNCT
ajlm-1296	47	1	after	after	SCONJ
ajlm-1296	47	2	15	15	NUM
ajlm-1296	47	3	min	min	NOUN
ajlm-1296	47	4	of	of	ADP
ajlm-1296	47	5	incubation	incubation	NOUN
ajlm-1296	47	6	at	at	ADP
ajlm-1296	47	7	room	room	NOUN
ajlm-1296	47	8	temperature	temperature	NOUN
ajlm-1296	47	9	in	in	ADP
ajlm-1296	47	10	the	the	DET
ajlm-1296	47	11	dark	dark	ADJ
ajlm-1296	47	12	,	,	PUNCT
ajlm-1296	47	13	lysis	lysis	NOUN
ajlm-1296	47	14	and	and	CCONJ
ajlm-1296	47	15	washing	washing	NOUN
ajlm-1296	47	16	of	of	ADP
ajlm-1296	47	17	erythrocytes	erythrocyte	NOUN
ajlm-1296	47	18	was	be	AUX
ajlm-1296	47	19	done	do	VERB
ajlm-1296	47	20	.	.	PUNCT
ajlm-1296	48	1	the	the	DET
ajlm-1296	48	2	cells	cell	NOUN
ajlm-1296	48	3	were	be	AUX
ajlm-1296	48	4	then	then	ADV
ajlm-1296	48	5	re	re	VERB
ajlm-1296	48	6	-	-	VERB
ajlm-1296	48	7	suspended	suspend	VERB
ajlm-1296	48	8	in	in	ADP
ajlm-1296	48	9	phosphate	phosphate	NOUN
ajlm-1296	48	10	-	-	PUNCT
ajlm-1296	48	11	buffered	buffer	VERB
ajlm-1296	48	12	saline	saline	NOUN
ajlm-1296	48	13	,	,	PUNCT
ajlm-1296	48	14	and	and	CCONJ
ajlm-1296	48	15	cells	cell	NOUN
ajlm-1296	48	16	were	be	AUX
ajlm-1296	48	17	acquired	acquire	VERB
ajlm-1296	48	18	using	use	VERB
ajlm-1296	48	19	the	the	DET
ajlm-1296	48	20	bd	bd	PROPN
ajlm-1296	48	21	facscalibur	facscalibur	PROPN
ajlm-1296	48	22	flow	flow	NOUN
ajlm-1296	48	23	cytometry	cytometry	NOUN
ajlm-1296	48	24	system	system	NOUN
ajlm-1296	48	25	(	(	PUNCT
ajlm-1296	48	26	bd	bd	PROPN
ajlm-1296	48	27	biosciences	bioscience	NOUN
ajlm-1296	48	28	,	,	PUNCT
ajlm-1296	48	29	san	san	PROPN
ajlm-1296	48	30	jose	jose	PROPN
ajlm-1296	48	31	,	,	PUNCT
ajlm-1296	48	32	california	california	PROPN
ajlm-1296	48	33	,	,	PUNCT
ajlm-1296	48	34	united	united	PROPN
ajlm-1296	48	35	states	states	PROPN
ajlm-1296	48	36	)	)	PUNCT
ajlm-1296	48	37	,	,	PUNCT
ajlm-1296	48	38	with	with	ADP
ajlm-1296	48	39	data	datum	NOUN
ajlm-1296	48	40	analysis	analysis	NOUN
ajlm-1296	48	41	done	do	VERB
ajlm-1296	48	42	using	use	VERB
ajlm-1296	48	43	the	the	DET
ajlm-1296	48	44	cellquest	cellqu	ADJ
ajlm-1296	48	45	software	software	NOUN
ajlm-1296	48	46	(	(	PUNCT
ajlm-1296	48	47	bd	bd	PROPN
ajlm-1296	48	48	biosciences	bioscience	NOUN
ajlm-1296	48	49	,	,	PUNCT
ajlm-1296	48	50	san	san	PROPN
ajlm-1296	48	51	jose	jose	PROPN
ajlm-1296	48	52	,	,	PUNCT
ajlm-1296	48	53	california	california	PROPN
ajlm-1296	48	54	,	,	PUNCT
ajlm-1296	48	55	united	united	PROPN
ajlm-1296	48	56	states	states	PROPN
ajlm-1296	48	57	)	)	PUNCT
ajlm-1296	48	58	.	.	PUNCT
ajlm-1296	49	1	an	an	DET
ajlm-1296	49	2	anti	anti	ADJ
ajlm-1296	49	3	-	-	ADJ
ajlm-1296	49	4	human	human	ADJ
ajlm-1296	49	5	immunoglobulin	immunoglobulin	NOUN
ajlm-1296	49	6	g	g	PROPN
ajlm-1296	49	7	isotype	isotype	NOUN
ajlm-1296	49	8	-	-	PUNCT
ajlm-1296	49	9	matched	match	VERB
ajlm-1296	49	10	negative	negative	ADJ
ajlm-1296	49	11	control	control	NOUN
ajlm-1296	49	12	was	be	AUX
ajlm-1296	49	13	used	use	VERB
ajlm-1296	49	14	for	for	ADP
ajlm-1296	49	15	each	each	DET
ajlm-1296	49	16	flow	flow	NOUN
ajlm-1296	49	17	cytometry	cytometry	NOUN
ajlm-1296	49	18	experiment	experiment	NOUN
ajlm-1296	49	19	.	.	PUNCT
ajlm-1296	50	1	forward	forward	ADV
ajlm-1296	50	2	and	and	CCONJ
ajlm-1296	50	3	side	side	NOUN
ajlm-1296	50	4	scatter	scatter	NOUN
ajlm-1296	50	5	histograms	histogram	NOUN
ajlm-1296	50	6	were	be	AUX
ajlm-1296	50	7	used	use	VERB
ajlm-1296	50	8	to	to	PART
ajlm-1296	50	9	define	define	VERB
ajlm-1296	50	10	monocytes	monocyte	NOUN
ajlm-1296	50	11	.	.	PUNCT
ajlm-1296	51	1	afterwards	afterwards	ADV
ajlm-1296	51	2	,	,	PUNCT
ajlm-1296	51	3	the	the	DET
ajlm-1296	51	4	expression	expression	NOUN
ajlm-1296	51	5	of	of	ADP
ajlm-1296	51	6	cd14	cd14	PROPN
ajlm-1296	51	7	and	and	CCONJ
ajlm-1296	51	8	cd16	cd16	PROPN
ajlm-1296	51	9	were	be	AUX
ajlm-1296	51	10	assessed	assess	VERB
ajlm-1296	51	11	in	in	ADP
ajlm-1296	51	12	the	the	DET
ajlm-1296	51	13	monocyte	monocyte	NOUN
ajlm-1296	51	14	population	population	NOUN
ajlm-1296	51	15	.	.	PUNCT
ajlm-1296	52	1	the	the	DET
ajlm-1296	52	2	classical	classical	ADJ
ajlm-1296	52	3	subset	subset	NOUN
ajlm-1296	52	4	was	be	AUX
ajlm-1296	52	5	cd14++cd16-	cd14++cd16-	PROPN
ajlm-1296	52	6	,	,	PUNCT
ajlm-1296	52	7	intermediate	intermediate	ADJ
ajlm-1296	52	8	subset	subset	NOUN
ajlm-1296	52	9	was	be	AUX
ajlm-1296	52	10	cd14++cd16	cd14++cd16	PROPN
ajlm-1296	52	11	+	+	PROPN
ajlm-1296	52	12	,	,	PUNCT
ajlm-1296	52	13	and	and	CCONJ
ajlm-1296	52	14	non	non	ADJ
ajlm-1296	52	15	-	-	ADJ
ajlm-1296	52	16	classical	classical	ADJ
ajlm-1296	52	17	subset	subset	NOUN
ajlm-1296	52	18	was	be	AUX
ajlm-1296	52	19	cd14+cd16++	cd14+cd16++	VERB
ajlm-1296	52	20	(	(	PUNCT
ajlm-1296	52	21	figure	figure	NOUN
ajlm-1296	52	22	1	1	NUM
ajlm-1296	52	23	)	)	PUNCT
ajlm-1296	52	24	.	.	PUNCT
ajlm-1296	53	1	monocyte	monocyte	PROPN
ajlm-1296	53	2	subset	subset	NOUN
ajlm-1296	53	3	data	datum	NOUN
ajlm-1296	53	4	are	be	AUX
ajlm-1296	53	5	expressed	express	VERB
ajlm-1296	53	6	as	as	ADP
ajlm-1296	53	7	percentages	percentage	NOUN
ajlm-1296	53	8	of	of	ADP
ajlm-1296	53	9	the	the	DET
ajlm-1296	53	10	total	total	ADJ
ajlm-1296	53	11	monocytes	monocyte	NOUN
ajlm-1296	53	12	.	.	PUNCT
ajlm-1296	54	1	figure	figure	NOUN
ajlm-1296	54	2	1	1	NUM
ajlm-1296	54	3	:	:	PUNCT
ajlm-1296	54	4	monocyte	monocyte	NOUN
ajlm-1296	54	5	subsets	subset	NOUN
ajlm-1296	54	6	in	in	ADP
ajlm-1296	54	7	multiple	multiple	ADJ
ajlm-1296	54	8	myeloma	myeloma	NOUN
ajlm-1296	54	9	patients	patient	NOUN
ajlm-1296	54	10	and	and	CCONJ
ajlm-1296	54	11	healthy	healthy	ADJ
ajlm-1296	54	12	controls	control	NOUN
ajlm-1296	54	13	at	at	ADP
ajlm-1296	54	14	assiut	assiut	PROPN
ajlm-1296	54	15	university	university	PROPN
ajlm-1296	54	16	,	,	PUNCT
ajlm-1296	54	17	assiut	assiut	PROPN
ajlm-1296	54	18	,	,	PUNCT
ajlm-1296	54	19	egypt	egypt	PROPN
ajlm-1296	54	20	from	from	ADP
ajlm-1296	54	21	october	october	PROPN
ajlm-1296	54	22	2018	2018	NUM
ajlm-1296	54	23	to	to	ADP
ajlm-1296	54	24	august	august	PROPN
ajlm-1296	54	25	2019	2019	NUM
ajlm-1296	54	26	.	.	PUNCT
ajlm-1296	55	1	(	(	PUNCT
ajlm-1296	55	2	a	a	X
ajlm-1296	55	3	)	)	PUNCT
ajlm-1296	55	4	flow	flow	NOUN
ajlm-1296	55	5	cytometric	cytometric	ADJ
ajlm-1296	55	6	detection	detection	NOUN
ajlm-1296	55	7	of	of	ADP
ajlm-1296	55	8	monocytes	monocyte	NOUN
ajlm-1296	55	9	subsets	subset	NOUN
ajlm-1296	55	10	.	.	PUNCT
ajlm-1296	56	1	forward	forward	ADJ
ajlm-1296	56	2	scatter	scatter	NOUN
ajlm-1296	56	3	and	and	CCONJ
ajlm-1296	56	4	side	side	NOUN
ajlm-1296	56	5	scatter	scatter	NOUN
ajlm-1296	56	6	dot	dot	NOUN
ajlm-1296	56	7	was	be	AUX
ajlm-1296	56	8	used	use	VERB
ajlm-1296	56	9	to	to	PART
ajlm-1296	56	10	detect	detect	VERB
ajlm-1296	56	11	monocyte	monocyte	NOUN
ajlm-1296	56	12	region	region	NOUN
ajlm-1296	56	13	(	(	PUNCT
ajlm-1296	56	14	r1	r1	PROPN
ajlm-1296	56	15	)	)	PUNCT
ajlm-1296	56	16	(	(	PUNCT
ajlm-1296	56	17	left	leave	VERB
ajlm-1296	56	18	)	)	PUNCT
ajlm-1296	56	19	.	.	PUNCT
ajlm-1296	57	1	cd14	cd14	PROPN
ajlm-1296	57	2	-	-	PUNCT
ajlm-1296	57	3	fluoroisothiocyanateand	fluoroisothiocyanateand	NOUN
ajlm-1296	57	4	cd16	cd16	PROPN
ajlm-1296	57	5	-	-	PUNCT
ajlm-1296	57	6	phycoerythrin	phycoerythrin	NOUN
ajlm-1296	57	7	-	-	PUNCT
ajlm-1296	57	8	positive	positive	ADJ
ajlm-1296	57	9	cells	cell	NOUN
ajlm-1296	57	10	were	be	AUX
ajlm-1296	57	11	identified	identify	VERB
ajlm-1296	57	12	among	among	ADP
ajlm-1296	57	13	monocytes	monocyte	NOUN
ajlm-1296	57	14	and	and	CCONJ
ajlm-1296	57	15	classified	classify	VERB
ajlm-1296	57	16	as	as	ADP
ajlm-1296	57	17	cl	cl	NOUN
ajlm-1296	57	18	-	-	NOUN
ajlm-1296	57	19	mo	mo	ADJ
ajlm-1296	57	20	(	(	PUNCT
ajlm-1296	57	21	classical	classical	ADJ
ajlm-1296	57	22	monocytes	monocyte	NOUN
ajlm-1296	57	23	,	,	PUNCT
ajlm-1296	57	24	cd14++cd16-	cd14++cd16-	PROPN
ajlm-1296	57	25	)	)	PUNCT
ajlm-1296	57	26	,	,	PUNCT
ajlm-1296	57	27	in	in	ADP
ajlm-1296	57	28	-	-	PUNCT
ajlm-1296	57	29	mo	mo	NOUN
ajlm-1296	57	30	(	(	PUNCT
ajlm-1296	57	31	intermediate	intermediate	ADJ
ajlm-1296	57	32	monocytes	monocyte	NOUN
ajlm-1296	57	33	(	(	PUNCT
ajlm-1296	57	34	cd14++cd16	cd14++cd16	PROPN
ajlm-1296	57	35	+	+	NOUN
ajlm-1296	57	36	)	)	PUNCT
ajlm-1296	57	37	and	and	CCONJ
ajlm-1296	57	38	non	non	ADJ
ajlm-1296	57	39	-	-	ADJ
ajlm-1296	57	40	cl	cl	NOUN
ajlm-1296	57	41	-	-	PUNCT
ajlm-1296	57	42	mo	mo	ADJ
ajlm-1296	57	43	(	(	PUNCT
ajlm-1296	57	44	non	non	ADJ
ajlm-1296	57	45	-	-	ADJ
ajlm-1296	57	46	classical	classical	ADJ
ajlm-1296	57	47	monocytes	monocyte	VERB
ajlm-1296	57	48	cd14+cd16++	cd14+cd16++	VERB
ajlm-1296	57	49	)	)	PUNCT
ajlm-1296	57	50	(	(	PUNCT
ajlm-1296	57	51	right	right	NOUN
ajlm-1296	57	52	)	)	PUNCT
ajlm-1296	57	53	.	.	PUNCT
ajlm-1296	58	1	(	(	PUNCT
ajlm-1296	58	2	b	b	X
ajlm-1296	58	3	)	)	PUNCT
ajlm-1296	58	4	the	the	DET
ajlm-1296	58	5	frequency	frequency	NOUN
ajlm-1296	58	6	of	of	ADP
ajlm-1296	58	7	the	the	DET
ajlm-1296	58	8	monocytes	monocyte	NOUN
ajlm-1296	58	9	subsets	subset	NOUN
ajlm-1296	58	10	varies	vary	VERB
ajlm-1296	58	11	significantly	significantly	ADV
ajlm-1296	58	12	between	between	ADP
ajlm-1296	58	13	multiple	multiple	ADJ
ajlm-1296	58	14	myeloma	myeloma	NOUN
ajlm-1296	58	15	patients	patient	NOUN
ajlm-1296	58	16	and	and	CCONJ
ajlm-1296	58	17	healthy	healthy	ADJ
ajlm-1296	58	18	controls	control	NOUN
ajlm-1296	58	19	(	(	PUNCT
ajlm-1296	58	20	classical	classical	ADJ
ajlm-1296	58	21	monocytes	monocyte	NOUN
ajlm-1296	58	22	:	:	PUNCT
ajlm-1296	58	23	mean	mean	VERB
ajlm-1296	58	24	±	±	NUM
ajlm-1296	58	25	standard	standard	ADJ
ajlm-1296	58	26	error	error	NOUN
ajlm-1296	58	27	77.24	77.24	NUM
ajlm-1296	58	28	±	±	NUM
ajlm-1296	58	29	0.66	0.66	NUM
ajlm-1296	58	30	in	in	ADP
ajlm-1296	58	31	multiple	multiple	ADJ
ajlm-1296	58	32	myeloma	myeloma	NOUN
ajlm-1296	58	33	patients	patient	NOUN
ajlm-1296	58	34	vs	vs	ADP
ajlm-1296	58	35	83.75	83.75	NUM
ajlm-1296	58	36	±	±	NUM
ajlm-1296	58	37	0.5	0.5	NUM
ajlm-1296	58	38	among	among	ADP
ajlm-1296	58	39	controls	control	NOUN
ajlm-1296	58	40	,	,	PUNCT
ajlm-1296	58	41	p	p	X
ajlm-1296	58	42	<	<	X
ajlm-1296	58	43	0.0001	0.0001	NUM
ajlm-1296	58	44	;	;	PUNCT
ajlm-1296	58	45	non	non	ADJ
ajlm-1296	58	46	-	-	ADJ
ajlm-1296	58	47	classical	classical	ADJ
ajlm-1296	58	48	monocytes	monocyte	NOUN
ajlm-1296	58	49	:	:	PUNCT
ajlm-1296	58	50	12.44	12.44	NUM
ajlm-1296	58	51	±	±	NUM
ajlm-1296	58	52	0.5	0.5	NUM
ajlm-1296	58	53	in	in	ADP
ajlm-1296	58	54	multiple	multiple	ADJ
ajlm-1296	58	55	myeloma	myeloma	NOUN
ajlm-1296	58	56	patients	patient	NOUN
ajlm-1296	58	57	vs	vs	ADP
ajlm-1296	58	58	8.9	8.9	NUM
ajlm-1296	58	59	±	±	NUM
ajlm-1296	58	60	0.34	0.34	NUM
ajlm-1296	58	61	among	among	ADP
ajlm-1296	58	62	controls	control	NOUN
ajlm-1296	58	63	,	,	PUNCT
ajlm-1296	58	64	p	p	X
ajlm-1296	58	65	<	<	X
ajlm-1296	58	66	0.0001	0.0001	NUM
ajlm-1296	58	67	;	;	PUNCT
ajlm-1296	58	68	and	and	CCONJ
ajlm-1296	58	69	intermediate	intermediate	ADJ
ajlm-1296	58	70	monocytes	monocyte	NOUN
ajlm-1296	58	71	:	:	PUNCT
ajlm-1296	58	72	10.3	10.3	NUM
ajlm-1296	58	73	±	±	NUM
ajlm-1296	58	74	0.24	0.24	NUM
ajlm-1296	58	75	in	in	ADP
ajlm-1296	58	76	multiple	multiple	ADJ
ajlm-1296	58	77	myeloma	myeloma	NOUN
ajlm-1296	58	78	patients	patient	NOUN
ajlm-1296	58	79	vs	vs	ADP
ajlm-1296	58	80	7.4	7.4	NUM
ajlm-1296	58	81	±	±	NUM
ajlm-1296	58	82	0.29	0.29	NUM
ajlm-1296	58	83	among	among	ADP
ajlm-1296	58	84	controls	control	NOUN
ajlm-1296	58	85	,	,	PUNCT
ajlm-1296	58	86	p	p	X
ajlm-1296	58	87	<	<	X
ajlm-1296	58	88	0.0001	0.0001	NUM
ajlm-1296	58	89	)	)	PUNCT
ajlm-1296	58	90	.	.	PUNCT
ajlm-1296	59	1	statistical	statistical	ADJ
ajlm-1296	59	2	analysis	analysis	NOUN
ajlm-1296	59	3	we	we	PRON
ajlm-1296	59	4	used	use	VERB
ajlm-1296	59	5	statistical	statistical	ADJ
ajlm-1296	59	6	package	package	NOUN
ajlm-1296	59	7	for	for	ADP
ajlm-1296	59	8	the	the	DET
ajlm-1296	59	9	social	social	ADJ
ajlm-1296	59	10	sciences	sciences	PROPN
ajlm-1296	59	11	version	version	NOUN
ajlm-1296	59	12	21	21	NUM
ajlm-1296	59	13	(	(	PUNCT
ajlm-1296	59	14	ibm	ibm	PROPN
ajlm-1296	59	15	corporation	corporation	PROPN
ajlm-1296	59	16	,	,	PUNCT
ajlm-1296	59	17	armonk	armonk	PROPN
ajlm-1296	59	18	,	,	PUNCT
ajlm-1296	59	19	new	new	PROPN
ajlm-1296	59	20	york	york	PROPN
ajlm-1296	59	21	,	,	PUNCT
ajlm-1296	59	22	united	united	PROPN
ajlm-1296	59	23	states	states	PROPN
ajlm-1296	59	24	)	)	PUNCT
ajlm-1296	59	25	for	for	ADP
ajlm-1296	59	26	data	data	NOUN
ajlm-1296	59	27	analysis	analysis	NOUN
ajlm-1296	59	28	.	.	PUNCT
ajlm-1296	60	1	quantitative	quantitative	ADJ
ajlm-1296	60	2	data	datum	NOUN
ajlm-1296	60	3	are	be	AUX
ajlm-1296	60	4	presented	present	VERB
ajlm-1296	60	5	as	as	ADP
ajlm-1296	60	6	mean	mean	NOUN
ajlm-1296	60	7	±	±	NUM
ajlm-1296	60	8	standard	standard	NOUN
ajlm-1296	60	9	error	error	NOUN
ajlm-1296	60	10	while	while	SCONJ
ajlm-1296	60	11	qualitative	qualitative	ADJ
ajlm-1296	60	12	data	datum	NOUN
ajlm-1296	60	13	are	be	AUX
ajlm-1296	60	14	presented	present	VERB
ajlm-1296	60	15	as	as	ADP
ajlm-1296	60	16	frequencies	frequency	NOUN
ajlm-1296	60	17	and	and	CCONJ
ajlm-1296	60	18	percentages	percentage	NOUN
ajlm-1296	60	19	.	.	PUNCT
ajlm-1296	61	1	mann	mann	PROPN
ajlm-1296	61	2	-	-	PUNCT
ajlm-1296	61	3	whitney	whitney	PROPN
ajlm-1296	61	4	test	test	NOUN
ajlm-1296	61	5	analysis	analysis	NOUN
ajlm-1296	61	6	was	be	AUX
ajlm-1296	61	7	performed	perform	VERB
ajlm-1296	61	8	to	to	PART
ajlm-1296	61	9	determine	determine	VERB
ajlm-1296	61	10	the	the	DET
ajlm-1296	61	11	statistical	statistical	ADJ
ajlm-1296	61	12	significance	significance	NOUN
ajlm-1296	61	13	and	and	CCONJ
ajlm-1296	61	14	differences	difference	NOUN
ajlm-1296	61	15	between	between	ADP
ajlm-1296	61	16	the	the	DET
ajlm-1296	61	17	study	study	NOUN
ajlm-1296	61	18	groups	group	NOUN
ajlm-1296	61	19	.	.	PUNCT
ajlm-1296	62	1	spearman	spearman	NOUN
ajlm-1296	62	2	’s	’s	PART
ajlm-1296	62	3	correlation	correlation	NOUN
ajlm-1296	62	4	was	be	AUX
ajlm-1296	62	5	performed	perform	VERB
ajlm-1296	62	6	to	to	PART
ajlm-1296	62	7	determine	determine	VERB
ajlm-1296	62	8	the	the	DET
ajlm-1296	62	9	association	association	NOUN
ajlm-1296	62	10	between	between	ADP
ajlm-1296	62	11	monocytes	monocyte	VERB
ajlm-1296	62	12	subtypes	subtype	NOUN
ajlm-1296	62	13	and	and	CCONJ
ajlm-1296	62	14	laboratory	laboratory	NOUN
ajlm-1296	62	15	parameters	parameter	NOUN
ajlm-1296	62	16	.	.	PUNCT
ajlm-1296	63	1	results	result	NOUN
ajlm-1296	63	2	were	be	AUX
ajlm-1296	63	3	considered	consider	VERB
ajlm-1296	63	4	significant	significant	ADJ
ajlm-1296	63	5	if	if	SCONJ
ajlm-1296	63	6	p	p	PRON
ajlm-1296	63	7	was	be	AUX
ajlm-1296	63	8	0.05	0.05	NUM
ajlm-1296	63	9	or	or	CCONJ
ajlm-1296	63	10	less	less	ADJ
ajlm-1296	63	11	.	.	PUNCT
ajlm-1296	64	1	results	result	NOUN
ajlm-1296	64	2	baseline	baseline	VERB
ajlm-1296	64	3	characteristics	characteristic	NOUN
ajlm-1296	64	4	of	of	ADP
ajlm-1296	64	5	newly	newly	ADV
ajlm-1296	64	6	diagnosed	diagnose	VERB
ajlm-1296	64	7	multiple	multiple	ADJ
ajlm-1296	64	8	myeloma	myeloma	NOUN
ajlm-1296	64	9	patients	patient	NOUN
ajlm-1296	64	10	and	and	CCONJ
ajlm-1296	64	11	healthy	healthy	ADJ
ajlm-1296	64	12	controls	control	NOUN
ajlm-1296	64	13	the	the	DET
ajlm-1296	64	14	mean	mean	ADJ
ajlm-1296	64	15	age	age	NOUN
ajlm-1296	64	16	of	of	ADP
ajlm-1296	64	17	the	the	DET
ajlm-1296	64	18	mm	mm	PROPN
ajlm-1296	64	19	patients	patient	NOUN
ajlm-1296	64	20	was	be	AUX
ajlm-1296	64	21	6.35	6.35	NUM
ajlm-1296	64	22	±	±	NUM
ajlm-1296	64	23	4.07	4.07	NUM
ajlm-1296	64	24	years	year	NOUN
ajlm-1296	64	25	,	,	PUNCT
ajlm-1296	64	26	and	and	CCONJ
ajlm-1296	64	27	the	the	DET
ajlm-1296	64	28	number	number	NOUN
ajlm-1296	64	29	of	of	ADP
ajlm-1296	64	30	men	man	NOUN
ajlm-1296	64	31	(	(	PUNCT
ajlm-1296	64	32	13	13	NUM
ajlm-1296	64	33	)	)	PUNCT
ajlm-1296	64	34	was	be	AUX
ajlm-1296	64	35	double	double	ADJ
ajlm-1296	64	36	that	that	PRON
ajlm-1296	64	37	of	of	ADP
ajlm-1296	64	38	women	woman	NOUN
ajlm-1296	64	39	(	(	PUNCT
ajlm-1296	64	40	7	7	NUM
ajlm-1296	64	41	)	)	PUNCT
ajlm-1296	64	42	(	(	PUNCT
ajlm-1296	64	43	table	table	NOUN
ajlm-1296	64	44	1	1	NUM
ajlm-1296	64	45	)	)	PUNCT
ajlm-1296	64	46	.	.	PUNCT
ajlm-1296	65	1	the	the	DET
ajlm-1296	65	2	proportion	proportion	NOUN
ajlm-1296	65	3	of	of	ADP
ajlm-1296	65	4	plasma	plasma	NOUN
ajlm-1296	65	5	cells	cell	NOUN
ajlm-1296	65	6	in	in	ADP
ajlm-1296	65	7	bone	bone	NOUN
ajlm-1296	65	8	marrow	marrow	NOUN
ajlm-1296	65	9	was	be	AUX
ajlm-1296	65	10	39.7	39.7	NUM
ajlm-1296	65	11	±	±	NUM
ajlm-1296	65	12	3.7	3.7	NUM
ajlm-1296	65	13	%	%	NOUN
ajlm-1296	65	14	and	and	CCONJ
ajlm-1296	65	15	that	that	PRON
ajlm-1296	65	16	of	of	ADP
ajlm-1296	65	17	the	the	DET
ajlm-1296	65	18	monoclonal	monoclonal	NOUN
ajlm-1296	65	19	band	band	NOUN
ajlm-1296	65	20	(	(	PUNCT
ajlm-1296	65	21	m	m	NOUN
ajlm-1296	65	22	-	-	NOUN
ajlm-1296	65	23	protein	protein	NOUN
ajlm-1296	65	24	)	)	PUNCT
ajlm-1296	65	25	was	be	AUX
ajlm-1296	65	26	4.44	4.44	NUM
ajlm-1296	65	27	±	±	NUM
ajlm-1296	65	28	2.8	2.8	NUM
ajlm-1296	65	29	g	g	NOUN
ajlm-1296	65	30	/	/	SYM
ajlm-1296	65	31	dl	dl	PROPN
ajlm-1296	65	32	.	.	PROPN
ajlm-1296	65	33	table	table	NOUN
ajlm-1296	65	34	1	1	NUM
ajlm-1296	65	35	:	:	PUNCT
ajlm-1296	65	36	 	 	SPACE
ajlm-1296	65	37	baseline	baseline	PROPN
ajlm-1296	65	38	characteristics	characteristic	NOUN
ajlm-1296	65	39	of	of	ADP
ajlm-1296	65	40	studied	study	VERB
ajlm-1296	65	41	newly	newly	ADV
ajlm-1296	65	42	diagnosed	diagnose	VERB
ajlm-1296	65	43	multiple	multiple	ADJ
ajlm-1296	65	44	myeloma	myeloma	NOUN
ajlm-1296	65	45	patients	patient	NOUN
ajlm-1296	65	46	and	and	CCONJ
ajlm-1296	65	47	healthy	healthy	ADJ
ajlm-1296	65	48	controls	control	NOUN
ajlm-1296	65	49	,	,	PUNCT
ajlm-1296	65	50	assiut	assiut	PROPN
ajlm-1296	65	51	,	,	PUNCT
ajlm-1296	65	52	egypt	egypt	PROPN
ajlm-1296	65	53	,	,	PUNCT
ajlm-1296	65	54	october	october	PROPN
ajlm-1296	65	55	2018	2018	NUM
ajlm-1296	65	56	–	–	PUNCT
ajlm-1296	65	57	august	august	PROPN
ajlm-1296	65	58	2019	2019	NUM
ajlm-1296	65	59	.	.	PUNCT
ajlm-1296	66	1	laboratory	laboratory	NOUN
ajlm-1296	66	2	investigations	investigation	NOUN
ajlm-1296	66	3	showed	show	VERB
ajlm-1296	66	4	that	that	SCONJ
ajlm-1296	66	5	platelet	platelet	NOUN
ajlm-1296	66	6	counts	count	NOUN
ajlm-1296	66	7	,	,	PUNCT
ajlm-1296	66	8	total	total	ADJ
ajlm-1296	66	9	leukocytic	leukocytic	ADJ
ajlm-1296	66	10	counts	count	NOUN
ajlm-1296	66	11	,	,	PUNCT
ajlm-1296	66	12	serum	serum	NOUN
ajlm-1296	66	13	total	total	ADJ
ajlm-1296	66	14	protein	protein	NOUN
ajlm-1296	66	15	,	,	PUNCT
ajlm-1296	66	16	and	and	CCONJ
ajlm-1296	66	17	urea	urea	NOUN
ajlm-1296	66	18	levels	level	NOUN
ajlm-1296	66	19	were	be	AUX
ajlm-1296	66	20	comparable	comparable	ADJ
ajlm-1296	66	21	between	between	ADP
ajlm-1296	66	22	patients	patient	NOUN
ajlm-1296	66	23	and	and	CCONJ
ajlm-1296	66	24	healthy	healthy	ADJ
ajlm-1296	66	25	controls	control	NOUN
ajlm-1296	66	26	(	(	PUNCT
ajlm-1296	66	27	p	p	X
ajlm-1296	66	28	>	>	X
ajlm-1296	66	29	0.05	0.05	NUM
ajlm-1296	66	30	)	)	PUNCT
ajlm-1296	66	31	.	.	PUNCT
ajlm-1296	67	1	multiple	multiple	ADJ
ajlm-1296	67	2	myeloma	myeloma	PROPN
ajlm-1296	67	3	patients	patient	NOUN
ajlm-1296	67	4	had	have	AUX
ajlm-1296	67	5	significantly	significantly	ADV
ajlm-1296	67	6	reduced	reduce	VERB
ajlm-1296	67	7	haemoglobin	haemoglobin	NOUN
ajlm-1296	67	8	(	(	PUNCT
ajlm-1296	67	9	9.3	9.3	NUM
ajlm-1296	67	10	±	±	NUM
ajlm-1296	67	11	2.4	2.4	NUM
ajlm-1296	67	12	g	g	NOUN
ajlm-1296	67	13	/	/	SYM
ajlm-1296	67	14	dl	dl	PROPN
ajlm-1296	67	15	in	in	ADP
ajlm-1296	67	16	mm	mm	PROPN
ajlm-1296	67	17	vs	vs	ADP
ajlm-1296	67	18	12.8	12.8	NUM
ajlm-1296	67	19	±	±	NUM
ajlm-1296	67	20	1.97	1.97	NUM
ajlm-1296	67	21	g	g	NOUN
ajlm-1296	67	22	/	/	SYM
ajlm-1296	67	23	dl	dl	PROPN
ajlm-1296	67	24	in	in	ADP
ajlm-1296	67	25	healthy	healthy	ADJ
ajlm-1296	67	26	controls	control	NOUN
ajlm-1296	67	27	;	;	PUNCT
ajlm-1296	67	28	p	p	X
ajlm-1296	67	29	=	=	NOUN
ajlm-1296	67	30	0.045	0.045	NUM
ajlm-1296	67	31	)	)	PUNCT
ajlm-1296	67	32	and	and	CCONJ
ajlm-1296	67	33	serum	serum	NOUN
ajlm-1296	67	34	albumin	albumin	NOUN
ajlm-1296	67	35	(	(	PUNCT
ajlm-1296	67	36	2.46	2.46	NUM
ajlm-1296	67	37	±	±	NUM
ajlm-1296	67	38	0.9	0.9	NUM
ajlm-1296	67	39	g	g	NOUN
ajlm-1296	67	40	/	/	SYM
ajlm-1296	67	41	dl	dl	PROPN
ajlm-1296	67	42	in	in	ADP
ajlm-1296	67	43	mm	mm	PROPN
ajlm-1296	67	44	patients	patient	NOUN
ajlm-1296	67	45	vs	vs	ADP
ajlm-1296	67	46	4.63	4.63	NUM
ajlm-1296	67	47	±	±	NUM
ajlm-1296	67	48	1.1	1.1	NUM
ajlm-1296	67	49	g	g	NOUN
ajlm-1296	67	50	/	/	SYM
ajlm-1296	67	51	dl	dl	PROPN
ajlm-1296	67	52	in	in	ADP
ajlm-1296	67	53	healthy	healthy	ADJ
ajlm-1296	67	54	controls	control	NOUN
ajlm-1296	67	55	;	;	PUNCT
ajlm-1296	67	56	p	p	X
ajlm-1296	67	57	<	<	X
ajlm-1296	67	58	0.0001	0.0001	NUM
ajlm-1296	67	59	)	)	PUNCT
ajlm-1296	67	60	when	when	SCONJ
ajlm-1296	67	61	compared	compare	VERB
ajlm-1296	67	62	to	to	ADP
ajlm-1296	67	63	healthy	healthy	ADJ
ajlm-1296	67	64	controls	control	NOUN
ajlm-1296	67	65	.	.	PUNCT
ajlm-1296	68	1	on	on	ADP
ajlm-1296	68	2	the	the	DET
ajlm-1296	68	3	other	other	ADJ
ajlm-1296	68	4	hand	hand	NOUN
ajlm-1296	68	5	,	,	PUNCT
ajlm-1296	68	6	after	after	ADP
ajlm-1296	68	7	comparing	compare	VERB
ajlm-1296	68	8	the	the	DET
ajlm-1296	68	9	mean	mean	ADJ
ajlm-1296	68	10	levels	level	NOUN
ajlm-1296	68	11	of	of	ADP
ajlm-1296	68	12	serum	serum	NOUN
ajlm-1296	68	13	calcium	calcium	NOUN
ajlm-1296	68	14	,	,	PUNCT
ajlm-1296	68	15	ldh	ldh	NOUN
ajlm-1296	68	16	,	,	PUNCT
ajlm-1296	68	17	and	and	CCONJ
ajlm-1296	68	18	serum	serum	NOUN
ajlm-1296	68	19	creatinine	creatinine	NOUN
ajlm-1296	68	20	between	between	ADP
ajlm-1296	68	21	mm	mm	PROPN
ajlm-1296	68	22	patients	patient	NOUN
ajlm-1296	68	23	and	and	CCONJ
ajlm-1296	68	24	healthy	healthy	ADJ
ajlm-1296	68	25	controls	control	NOUN
ajlm-1296	68	26	,	,	PUNCT
ajlm-1296	68	27	we	we	PRON
ajlm-1296	68	28	found	find	VERB
ajlm-1296	68	29	statistically	statistically	ADV
ajlm-1296	68	30	significant	significant	ADJ
ajlm-1296	68	31	increased	increase	VERB
ajlm-1296	68	32	levels	level	NOUN
ajlm-1296	68	33	in	in	ADP
ajlm-1296	68	34	mm	mm	PROPN
ajlm-1296	68	35	patients	patient	NOUN
ajlm-1296	68	36	(	(	PUNCT
ajlm-1296	68	37	calcium	calcium	NOUN
ajlm-1296	68	38	:	:	PUNCT
ajlm-1296	68	39	11.75	11.75	NUM
ajlm-1296	68	40	±	±	NUM
ajlm-1296	68	41	0.4	0.4	NUM
ajlm-1296	68	42	mg	mg	PROPN
ajlm-1296	68	43	/	/	SYM
ajlm-1296	68	44	dl	dl	PROPN
ajlm-1296	68	45	in	in	ADP
ajlm-1296	68	46	mm	mm	PROPN
ajlm-1296	68	47	patients	patient	NOUN
ajlm-1296	68	48	vs	vs	ADP
ajlm-1296	68	49	8.8	8.8	NUM
ajlm-1296	68	50	±	±	NUM
ajlm-1296	68	51	0.1	0.1	NUM
ajlm-1296	68	52	mg	mg	PROPN
ajlm-1296	68	53	/	/	SYM
ajlm-1296	68	54	dl	dl	PROPN
ajlm-1296	68	55	in	in	ADP
ajlm-1296	68	56	healthy	healthy	ADJ
ajlm-1296	68	57	controls	control	NOUN
ajlm-1296	68	58	,	,	PUNCT
ajlm-1296	68	59	p	p	X
ajlm-1296	68	60	<	<	X
ajlm-1296	68	61	0.0001	0.0001	NUM
ajlm-1296	68	62	;	;	PUNCT
ajlm-1296	68	63	ldh	ldh	NOUN
ajlm-1296	68	64	:	:	PUNCT
ajlm-1296	68	65	886.86	886.86	NUM
ajlm-1296	68	66	±	±	NUM
ajlm-1296	68	67	92.6	92.6	NUM
ajlm-1296	68	68	units	unit	NOUN
ajlm-1296	68	69	per	per	ADP
ajlm-1296	68	70	litre	litre	NOUN
ajlm-1296	68	71	in	in	ADP
ajlm-1296	68	72	mm	mm	PROPN
ajlm-1296	68	73	vs	vs	ADP
ajlm-1296	68	74	155.8	155.8	NUM
ajlm-1296	68	75	±	±	NUM
ajlm-1296	68	76	8.23	8.23	NUM
ajlm-1296	68	77	units	unit	NOUN
ajlm-1296	68	78	per	per	ADP
ajlm-1296	68	79	litre	litre	NOUN
ajlm-1296	68	80	in	in	ADP
ajlm-1296	68	81	controls	control	NOUN
ajlm-1296	68	82	,	,	PUNCT
ajlm-1296	68	83	p	p	X
ajlm-1296	68	84	<	<	X
ajlm-1296	68	85	0.0001	0.0001	NUM
ajlm-1296	68	86	;	;	PUNCT
ajlm-1296	68	87	serum	serum	NOUN
ajlm-1296	68	88	creatinine	creatinine	NOUN
ajlm-1296	68	89	:	:	PUNCT
ajlm-1296	68	90	1.9	1.9	NUM
ajlm-1296	68	91	±	±	NUM
ajlm-1296	68	92	0.2	0.2	NUM
ajlm-1296	68	93	mg	mg	PROPN
ajlm-1296	68	94	/	/	SYM
ajlm-1296	68	95	dl	dl	PROPN
ajlm-1296	68	96	in	in	ADP
ajlm-1296	68	97	mm	mm	PROPN
ajlm-1296	68	98	patients	patient	NOUN
ajlm-1296	68	99	vs	vs	ADP
ajlm-1296	68	100	0.97	0.97	NUM
ajlm-1296	68	101	±	±	NUM
ajlm-1296	68	102	0.1	0.1	NUM
ajlm-1296	68	103	mg	mg	PROPN
ajlm-1296	68	104	/	/	SYM
ajlm-1296	68	105	dl	dl	PROPN
ajlm-1296	68	106	in	in	ADP
ajlm-1296	68	107	healthy	healthy	ADJ
ajlm-1296	68	108	controls	control	NOUN
ajlm-1296	68	109	,	,	PUNCT
ajlm-1296	68	110	p	p	X
ajlm-1296	68	111	<	<	X
ajlm-1296	68	112	0.0001	0.0001	NUM
ajlm-1296	68	113	)	)	PUNCT
ajlm-1296	68	114	.	.	PUNCT
ajlm-1296	69	1	based	base	VERB
ajlm-1296	69	2	on	on	ADP
ajlm-1296	69	3	the	the	DET
ajlm-1296	69	4	durie	durie	NOUN
ajlm-1296	69	5	-	-	PUNCT
ajlm-1296	69	6	salmon	salmon	NOUN
ajlm-1296	69	7	staging	staging	NOUN
ajlm-1296	69	8	system	system	NOUN
ajlm-1296	69	9	,	,	PUNCT
ajlm-1296	69	10	12	12	NUM
ajlm-1296	69	11	(	(	PUNCT
ajlm-1296	69	12	60	60	NUM
ajlm-1296	69	13	%	%	NOUN
ajlm-1296	69	14	)	)	PUNCT
ajlm-1296	69	15	of	of	ADP
ajlm-1296	69	16	the	the	DET
ajlm-1296	69	17	20	20	NUM
ajlm-1296	69	18	newly	newly	ADV
ajlm-1296	69	19	diagnosed	diagnose	VERB
ajlm-1296	69	20	untreated	untreated	ADJ
ajlm-1296	69	21	mm	mm	PROPN
ajlm-1296	69	22	patients	patient	NOUN
ajlm-1296	69	23	had	have	VERB
ajlm-1296	69	24	stage	stage	NOUN
ajlm-1296	69	25	i	i	PRON
ajlm-1296	69	26	disease	disease	VERB
ajlm-1296	69	27	,	,	PUNCT
ajlm-1296	69	28	6/20	6/20	NUM
ajlm-1296	69	29	patients	patient	NOUN
ajlm-1296	69	30	(	(	PUNCT
ajlm-1296	69	31	30	30	NUM
ajlm-1296	69	32	%	%	NOUN
ajlm-1296	69	33	)	)	PUNCT
ajlm-1296	69	34	had	have	VERB
ajlm-1296	69	35	stage	stage	NOUN
ajlm-1296	69	36	ii	ii	NOUN
ajlm-1296	69	37	disease	disease	NOUN
ajlm-1296	69	38	,	,	PUNCT
ajlm-1296	69	39	and	and	CCONJ
ajlm-1296	69	40	2/20	2/20	NUM
ajlm-1296	69	41	patients	patient	NOUN
ajlm-1296	69	42	(	(	PUNCT
ajlm-1296	69	43	10	10	NUM
ajlm-1296	69	44	%	%	NOUN
ajlm-1296	69	45	)	)	PUNCT
ajlm-1296	69	46	had	have	VERB
ajlm-1296	69	47	stage	stage	NOUN
ajlm-1296	69	48	iii	iii	NUM
ajlm-1296	69	49	disease	disease	NOUN
ajlm-1296	69	50	.	.	PUNCT
ajlm-1296	70	1	whereas	whereas	SCONJ
ajlm-1296	70	2	according	accord	VERB
ajlm-1296	70	3	to	to	ADP
ajlm-1296	70	4	the	the	DET
ajlm-1296	70	5	international	international	ADJ
ajlm-1296	70	6	staging	staging	NOUN
ajlm-1296	70	7	system	system	NOUN
ajlm-1296	70	8	,	,	PUNCT
ajlm-1296	70	9	70	70	NUM
ajlm-1296	70	10	%	%	NOUN
ajlm-1296	70	11	(	(	PUNCT
ajlm-1296	70	12	n	n	NOUN
ajlm-1296	70	13	=	=	SYM
ajlm-1296	70	14	14	14	NUM
ajlm-1296	70	15	)	)	PUNCT
ajlm-1296	70	16	of	of	ADP
ajlm-1296	70	17	mm	mm	PROPN
ajlm-1296	70	18	patients	patient	NOUN
ajlm-1296	70	19	had	have	VERB
ajlm-1296	70	20	stage	stage	NOUN
ajlm-1296	70	21	i	i	PRON
ajlm-1296	70	22	disease	disease	VERB
ajlm-1296	70	23	,	,	PUNCT
ajlm-1296	70	24	20	20	NUM
ajlm-1296	70	25	%	%	NOUN
ajlm-1296	70	26	(	(	PUNCT
ajlm-1296	70	27	n	n	NOUN
ajlm-1296	70	28	=	=	SYM
ajlm-1296	70	29	4	4	X
ajlm-1296	70	30	)	)	PUNCT
ajlm-1296	70	31	had	have	VERB
ajlm-1296	70	32	stage	stage	NOUN
ajlm-1296	70	33	ii	ii	PROPN
ajlm-1296	70	34	,	,	PUNCT
ajlm-1296	70	35	and	and	CCONJ
ajlm-1296	70	36	10	10	NUM
ajlm-1296	70	37	%	%	NOUN
ajlm-1296	70	38	(	(	PUNCT
ajlm-1296	70	39	n	n	NOUN
ajlm-1296	70	40	=	=	SYM
ajlm-1296	70	41	2	2	NUM
ajlm-1296	70	42	)	)	PUNCT
ajlm-1296	70	43	had	have	VERB
ajlm-1296	70	44	stage	stage	NOUN
ajlm-1296	70	45	iii	iii	PROPN
ajlm-1296	70	46	.	.	PUNCT
ajlm-1296	71	1	phenotypic	phenotypic	ADJ
ajlm-1296	71	2	characterisation	characterisation	NOUN
ajlm-1296	71	3	of	of	ADP
ajlm-1296	71	4	monocytes	monocyte	NOUN
ajlm-1296	71	5	in	in	ADP
ajlm-1296	71	6	multiple	multiple	ADJ
ajlm-1296	71	7	myeloma	myeloma	NOUN
ajlm-1296	71	8	patients	patient	NOUN
ajlm-1296	71	9	monocytes	monocyte	VERB
ajlm-1296	71	10	present	present	ADJ
ajlm-1296	71	11	in	in	ADP
ajlm-1296	71	12	the	the	DET
ajlm-1296	71	13	peripheral	peripheral	ADJ
ajlm-1296	71	14	blood	blood	NOUN
ajlm-1296	71	15	displayed	display	VERB
ajlm-1296	71	16	a	a	DET
ajlm-1296	71	17	range	range	NOUN
ajlm-1296	71	18	of	of	ADP
ajlm-1296	71	19	intensities	intensity	NOUN
ajlm-1296	71	20	of	of	ADP
ajlm-1296	71	21	cd16	cd16	PROPN
ajlm-1296	71	22	and	and	CCONJ
ajlm-1296	71	23	cd14	cd14	PROPN
ajlm-1296	71	24	expression	expression	NOUN
ajlm-1296	71	25	.	.	PUNCT
ajlm-1296	72	1	they	they	PRON
ajlm-1296	72	2	were	be	AUX
ajlm-1296	72	3	divided	divide	VERB
ajlm-1296	72	4	into	into	ADP
ajlm-1296	72	5	classical	classical	ADJ
ajlm-1296	72	6	(	(	PUNCT
ajlm-1296	72	7	cd16−cd14++	cd16−cd14++	PROPN
ajlm-1296	72	8	)	)	PUNCT
ajlm-1296	72	9	,	,	PUNCT
ajlm-1296	72	10	intermediate	intermediate	ADJ
ajlm-1296	72	11	(	(	PUNCT
ajlm-1296	72	12	cd16+cd14++	cd16+cd14++	PROPN
ajlm-1296	72	13	)	)	PUNCT
ajlm-1296	72	14	,	,	PUNCT
ajlm-1296	72	15	and	and	CCONJ
ajlm-1296	72	16	non	non	ADJ
ajlm-1296	72	17	-	-	ADJ
ajlm-1296	72	18	classical	classical	ADJ
ajlm-1296	72	19	(	(	PUNCT
ajlm-1296	72	20	cd16++cd14	cd16++cd14	NOUN
ajlm-1296	72	21	+	+	NOUN
ajlm-1296	72	22	)	)	PUNCT
ajlm-1296	72	23	based	base	VERB
ajlm-1296	72	24	on	on	ADP
ajlm-1296	72	25	these	these	DET
ajlm-1296	72	26	ranges	range	NOUN
ajlm-1296	72	27	.	.	PUNCT
ajlm-1296	73	1	in	in	ADP
ajlm-1296	73	2	healthy	healthy	ADJ
ajlm-1296	73	3	controls	control	NOUN
ajlm-1296	73	4	,	,	PUNCT
ajlm-1296	73	5	classical	classical	ADJ
ajlm-1296	73	6	monocytes	monocyte	NOUN
ajlm-1296	73	7	represented	represent	VERB
ajlm-1296	73	8	the	the	DET
ajlm-1296	73	9	major	major	ADJ
ajlm-1296	73	10	component	component	NOUN
ajlm-1296	73	11	among	among	ADP
ajlm-1296	73	12	total	total	ADJ
ajlm-1296	73	13	monocytes	monocyte	NOUN
ajlm-1296	73	14	(	(	PUNCT
ajlm-1296	73	15	83.8	83.8	NUM
ajlm-1296	73	16	%	%	NOUN
ajlm-1296	73	17	)	)	PUNCT
ajlm-1296	73	18	,	,	PUNCT
ajlm-1296	73	19	followed	follow	VERB
ajlm-1296	73	20	by	by	ADP
ajlm-1296	73	21	non	non	ADJ
ajlm-1296	73	22	-	-	ADJ
ajlm-1296	73	23	classical	classical	ADJ
ajlm-1296	73	24	monocytes	monocyte	NOUN
ajlm-1296	73	25	(	(	PUNCT
ajlm-1296	73	26	8.9	8.9	NUM
ajlm-1296	73	27	%	%	NOUN
ajlm-1296	73	28	)	)	PUNCT
ajlm-1296	73	29	and	and	CCONJ
ajlm-1296	73	30	intermediate	intermediate	ADJ
ajlm-1296	73	31	monocytes	monocyte	NOUN
ajlm-1296	73	32	(	(	PUNCT
ajlm-1296	73	33	7.4	7.4	NUM
ajlm-1296	73	34	%	%	NOUN
ajlm-1296	73	35	)	)	PUNCT
ajlm-1296	73	36	.	.	PUNCT
ajlm-1296	74	1	multiple	multiple	ADJ
ajlm-1296	74	2	myeloma	myeloma	PROPN
ajlm-1296	74	3	patients	patient	NOUN
ajlm-1296	74	4	had	have	VERB
ajlm-1296	74	5	statistically	statistically	ADV
ajlm-1296	74	6	significant	significant	ADJ
ajlm-1296	74	7	lower	low	ADJ
ajlm-1296	74	8	proportions	proportion	NOUN
ajlm-1296	74	9	of	of	ADP
ajlm-1296	74	10	classical	classical	ADJ
ajlm-1296	74	11	monocytes	monocyte	NOUN
ajlm-1296	74	12	(	(	PUNCT
ajlm-1296	74	13	77.24	77.24	NUM
ajlm-1296	74	14	%	%	NOUN
ajlm-1296	74	15	±	±	NUM
ajlm-1296	74	16	0.66	0.66	NUM
ajlm-1296	74	17	in	in	ADP
ajlm-1296	74	18	mm	mm	PROPN
ajlm-1296	74	19	patients	patient	NOUN
ajlm-1296	74	20	vs	vs	ADP
ajlm-1296	74	21	83.75	83.75	NUM
ajlm-1296	74	22	%	%	NOUN
ajlm-1296	74	23	±	±	NUM
ajlm-1296	74	24	0.5	0.5	NUM
ajlm-1296	74	25	in	in	ADP
ajlm-1296	74	26	controls	control	NOUN
ajlm-1296	74	27	)	)	PUNCT
ajlm-1296	74	28	,	,	PUNCT
ajlm-1296	74	29	and	and	CCONJ
ajlm-1296	74	30	higher	high	ADJ
ajlm-1296	74	31	proportions	proportion	NOUN
ajlm-1296	74	32	of	of	ADP
ajlm-1296	74	33	non	non	ADJ
ajlm-1296	74	34	-	-	ADJ
ajlm-1296	74	35	classical	classical	ADJ
ajlm-1296	74	36	(	(	PUNCT
ajlm-1296	74	37	12.44	12.44	NUM
ajlm-1296	74	38	%	%	NOUN
ajlm-1296	74	39	±	±	NUM
ajlm-1296	74	40	0.5	0.5	NUM
ajlm-1296	74	41	in	in	ADP
ajlm-1296	74	42	mm	mm	PROPN
ajlm-1296	74	43	patients	patient	NOUN
ajlm-1296	74	44	vs	vs	ADP
ajlm-1296	74	45	8.9	8.9	NUM
ajlm-1296	74	46	%	%	NOUN
ajlm-1296	74	47	±	±	NUM
ajlm-1296	74	48	0.34	0.34	NUM
ajlm-1296	74	49	in	in	ADP
ajlm-1296	74	50	controls	control	NOUN
ajlm-1296	74	51	)	)	PUNCT
ajlm-1296	74	52	and	and	CCONJ
ajlm-1296	74	53	intermediate	intermediate	ADJ
ajlm-1296	74	54	(	(	PUNCT
ajlm-1296	74	55	10.3	10.3	NUM
ajlm-1296	74	56	%	%	NOUN
ajlm-1296	74	57	±	±	NUM
ajlm-1296	74	58	0.24	0.24	NUM
ajlm-1296	74	59	in	in	ADP
ajlm-1296	74	60	mm	mm	PROPN
ajlm-1296	74	61	patients	patient	NOUN
ajlm-1296	74	62	vs	vs	ADP
ajlm-1296	74	63	7.4	7.4	NUM
ajlm-1296	74	64	%	%	NOUN
ajlm-1296	74	65	±	±	NUM
ajlm-1296	74	66	0.29	0.29	NUM
ajlm-1296	74	67	in	in	ADP
ajlm-1296	74	68	controls	control	NOUN
ajlm-1296	74	69	)	)	PUNCT
ajlm-1296	74	70	monocytes	monocyte	NOUN
ajlm-1296	74	71	compared	compare	VERB
ajlm-1296	74	72	to	to	ADP
ajlm-1296	74	73	healthy	healthy	ADJ
ajlm-1296	74	74	controls	control	NOUN
ajlm-1296	74	75	(	(	PUNCT
ajlm-1296	74	76	all	all	ADV
ajlm-1296	74	77	with	with	ADP
ajlm-1296	74	78	p	p	X
ajlm-1296	74	79	<	<	X
ajlm-1296	74	80	0.0001	0.0001	NUM
ajlm-1296	74	81	)	)	PUNCT
ajlm-1296	74	82	(	(	PUNCT
ajlm-1296	74	83	figure	figure	NOUN
ajlm-1296	74	84	1	1	NUM
ajlm-1296	74	85	)	)	PUNCT
ajlm-1296	74	86	.	.	PUNCT
ajlm-1296	75	1	correlation	correlation	NOUN
ajlm-1296	75	2	between	between	ADP
ajlm-1296	75	3	monocyte	monocyte	NOUN
ajlm-1296	75	4	subsets	subset	NOUN
ajlm-1296	75	5	and	and	CCONJ
ajlm-1296	75	6	laboratory	laboratory	NOUN
ajlm-1296	75	7	parameters	parameter	NOUN
ajlm-1296	75	8	in	in	ADP
ajlm-1296	75	9	newly	newly	ADV
ajlm-1296	75	10	diagnosed	diagnose	VERB
ajlm-1296	75	11	untreated	untreated	ADJ
ajlm-1296	75	12	multiple	multiple	ADJ
ajlm-1296	75	13	myeloma	myeloma	NOUN
ajlm-1296	75	14	patients	patient	NOUN
ajlm-1296	75	15	in	in	ADP
ajlm-1296	75	16	newly	newly	ADV
ajlm-1296	75	17	diagnosed	diagnose	VERB
ajlm-1296	75	18	untreated	untreated	ADJ
ajlm-1296	75	19	mm	mm	PROPN
ajlm-1296	75	20	patients	patient	NOUN
ajlm-1296	75	21	,	,	PUNCT
ajlm-1296	75	22	the	the	DET
ajlm-1296	75	23	proportion	proportion	NOUN
ajlm-1296	75	24	(	(	PUNCT
ajlm-1296	75	25	%	%	NOUN
ajlm-1296	75	26	)	)	PUNCT
ajlm-1296	75	27	of	of	ADP
ajlm-1296	75	28	classical	classical	ADJ
ajlm-1296	75	29	monocytes	monocyte	NOUN
ajlm-1296	75	30	correlated	correlate	VERB
ajlm-1296	75	31	positively	positively	ADV
ajlm-1296	75	32	with	with	ADP
ajlm-1296	75	33	the	the	DET
ajlm-1296	75	34	serum	serum	NOUN
ajlm-1296	75	35	albumin	albumin	ADJ
ajlm-1296	75	36	level	level	NOUN
ajlm-1296	75	37	(	(	PUNCT
ajlm-1296	75	38	r2	r2	NOUN
ajlm-1296	75	39	=	=	SYM
ajlm-1296	75	40	0.731	0.731	NUM
ajlm-1296	75	41	;	;	PUNCT
ajlm-1296	75	42	p	p	X
ajlm-1296	75	43	<	<	X
ajlm-1296	75	44	0.0001	0.0001	NUM
ajlm-1296	75	45	)	)	PUNCT
ajlm-1296	75	46	,	,	PUNCT
ajlm-1296	75	47	and	and	CCONJ
ajlm-1296	75	48	correlated	correlate	VERB
ajlm-1296	75	49	negatively	negatively	ADV
ajlm-1296	75	50	with	with	ADP
ajlm-1296	75	51	serum	serum	NOUN
ajlm-1296	75	52	levels	level	NOUN
ajlm-1296	75	53	of	of	ADP
ajlm-1296	75	54	serum	serum	NOUN
ajlm-1296	75	55	creatinine	creatinine	NOUN
ajlm-1296	75	56	(	(	PUNCT
ajlm-1296	75	57	r2	r2	NOUN
ajlm-1296	75	58	=	=	PUNCT
ajlm-1296	75	59	0.389	0.389	NUM
ajlm-1296	75	60	,	,	PUNCT
ajlm-1296	75	61	p	p	X
ajlm-1296	75	62	<	<	X
ajlm-1296	75	63	0.0001	0.0001	NUM
ajlm-1296	75	64	)	)	PUNCT
ajlm-1296	75	65	,	,	PUNCT
ajlm-1296	75	66	ldh	ldh	X
ajlm-1296	75	67	(	(	PUNCT
ajlm-1296	75	68	r2	r2	PROPN
ajlm-1296	75	69	=	=	PUNCT
ajlm-1296	75	70	0.545	0.545	NUM
ajlm-1296	75	71	,	,	PUNCT
ajlm-1296	75	72	p	p	X
ajlm-1296	75	73	<	<	X
ajlm-1296	75	74	0.0010	0.0010	NUM
ajlm-1296	75	75	)	)	PUNCT
ajlm-1296	75	76	,	,	PUNCT
ajlm-1296	75	77	calcium	calcium	NOUN
ajlm-1296	75	78	(	(	PUNCT
ajlm-1296	75	79	r2	r2	PROPN
ajlm-1296	75	80	=	=	PUNCT
ajlm-1296	75	81	0.582	0.582	NUM
ajlm-1296	75	82	,	,	PUNCT
ajlm-1296	75	83	p	p	X
ajlm-1296	75	84	<	<	X
ajlm-1296	75	85	0.0001	0.0001	NUM
ajlm-1296	75	86	)	)	PUNCT
ajlm-1296	75	87	,	,	PUNCT
ajlm-1296	75	88	m	m	NOUN
ajlm-1296	75	89	-	-	NOUN
ajlm-1296	75	90	protein	protein	NOUN
ajlm-1296	75	91	(	(	PUNCT
ajlm-1296	75	92	r2	r2	PROPN
ajlm-1296	75	93	=	=	SYM
ajlm-1296	75	94	0.222	0.222	NUM
ajlm-1296	75	95	,	,	PUNCT
ajlm-1296	75	96	p	p	NOUN
ajlm-1296	75	97	=	=	NOUN
ajlm-1296	75	98	0.005	0.005	NUM
ajlm-1296	75	99	)	)	PUNCT
ajlm-1296	75	100	,	,	PUNCT
ajlm-1296	75	101	and	and	CCONJ
ajlm-1296	75	102	with	with	ADP
ajlm-1296	75	103	the	the	DET
ajlm-1296	75	104	percentage	percentage	NOUN
ajlm-1296	75	105	of	of	ADP
ajlm-1296	75	106	bone	bone	NOUN
ajlm-1296	75	107	marrow	marrow	NOUN
ajlm-1296	75	108	plasma	plasma	NOUN
ajlm-1296	75	109	cells	cell	NOUN
ajlm-1296	75	110	(	(	PUNCT
ajlm-1296	75	111	r2	r2	PROPN
ajlm-1296	75	112	=	=	PUNCT
ajlm-1296	75	113	0.347	0.347	NUM
ajlm-1296	75	114	,	,	PUNCT
ajlm-1296	75	115	p	p	X
ajlm-1296	75	116	<	<	X
ajlm-1296	75	117	0.0001	0.0001	NUM
ajlm-1296	75	118	)	)	PUNCT
ajlm-1296	75	119	,	,	PUNCT
ajlm-1296	75	120	while	while	SCONJ
ajlm-1296	75	121	urea	urea	NOUN
ajlm-1296	75	122	and	and	CCONJ
ajlm-1296	75	123	total	total	ADJ
ajlm-1296	75	124	protein	protein	NOUN
ajlm-1296	75	125	did	do	AUX
ajlm-1296	75	126	not	not	PART
ajlm-1296	75	127	show	show	VERB
ajlm-1296	75	128	significant	significant	ADJ
ajlm-1296	75	129	correlation	correlation	NOUN
ajlm-1296	75	130	(	(	PUNCT
ajlm-1296	75	131	figure	figure	NOUN
ajlm-1296	75	132	2	2	NUM
ajlm-1296	75	133	)	)	PUNCT
ajlm-1296	75	134	.	.	PUNCT
ajlm-1296	76	1	figure	figure	VERB
ajlm-1296	76	2	2	2	NUM
ajlm-1296	76	3	:	:	PUNCT
ajlm-1296	76	4	correlation	correlation	NOUN
ajlm-1296	76	5	of	of	ADP
ajlm-1296	76	6	classical	classical	ADJ
ajlm-1296	76	7	monocytes	monocyte	NOUN
ajlm-1296	76	8	with	with	ADP
ajlm-1296	76	9	laboratory	laboratory	NOUN
ajlm-1296	76	10	parameters	parameter	NOUN
ajlm-1296	76	11	in	in	ADP
ajlm-1296	76	12	multiple	multiple	ADJ
ajlm-1296	76	13	myeloma	myeloma	NOUN
ajlm-1296	76	14	patients	patient	NOUN
ajlm-1296	76	15	and	and	CCONJ
ajlm-1296	76	16	healthy	healthy	ADJ
ajlm-1296	76	17	controls	control	NOUN
ajlm-1296	76	18	at	at	ADP
ajlm-1296	76	19	assiut	assiut	PROPN
ajlm-1296	76	20	university	university	PROPN
ajlm-1296	76	21	,	,	PUNCT
ajlm-1296	76	22	assiut	assiut	PROPN
ajlm-1296	76	23	,	,	PUNCT
ajlm-1296	76	24	egypt	egypt	PROPN
ajlm-1296	76	25	,	,	PUNCT
ajlm-1296	76	26	from	from	ADP
ajlm-1296	76	27	october	october	PROPN
ajlm-1296	76	28	2018	2018	NUM
ajlm-1296	76	29	to	to	ADP
ajlm-1296	76	30	august	august	PROPN
ajlm-1296	76	31	2019	2019	NUM
ajlm-1296	76	32	.	.	PUNCT
ajlm-1296	77	1	the	the	DET
ajlm-1296	77	2	percentage	percentage	NOUN
ajlm-1296	77	3	of	of	ADP
ajlm-1296	77	4	classical	classical	ADJ
ajlm-1296	77	5	monocytes	monocyte	NOUN
ajlm-1296	77	6	(	(	PUNCT
ajlm-1296	77	7	cd16−cd14++	cd16−cd14++	PROPN
ajlm-1296	77	8	)	)	PUNCT
ajlm-1296	77	9	and	and	CCONJ
ajlm-1296	77	10	(	(	PUNCT
ajlm-1296	77	11	a	a	PRON
ajlm-1296	77	12	)	)	PUNCT
ajlm-1296	77	13	creatinine	creatinine	NOUN
ajlm-1296	77	14	,	,	PUNCT
ajlm-1296	77	15	(	(	PUNCT
ajlm-1296	77	16	b	b	NOUN
ajlm-1296	77	17	)	)	PUNCT
ajlm-1296	77	18	urea	urea	NOUN
ajlm-1296	77	19	,	,	PUNCT
ajlm-1296	77	20	(	(	PUNCT
ajlm-1296	77	21	c	c	X
ajlm-1296	77	22	)	)	PUNCT
ajlm-1296	77	23	lactate	lactate	NOUN
ajlm-1296	77	24	dehydrogenase	dehydrogenase	NOUN
ajlm-1296	77	25	,	,	PUNCT
ajlm-1296	77	26	(	(	PUNCT
ajlm-1296	77	27	d	d	NOUN
ajlm-1296	77	28	)	)	PUNCT
ajlm-1296	77	29	calcium	calcium	NOUN
ajlm-1296	77	30	,	,	PUNCT
ajlm-1296	77	31	(	(	PUNCT
ajlm-1296	77	32	e	e	NOUN
ajlm-1296	77	33	)	)	PUNCT
ajlm-1296	77	34	total	total	ADJ
ajlm-1296	77	35	protein	protein	NOUN
ajlm-1296	77	36	,	,	PUNCT
ajlm-1296	77	37	(	(	PUNCT
ajlm-1296	77	38	f	f	X
ajlm-1296	77	39	)	)	PUNCT
ajlm-1296	77	40	albumin	albumin	NOUN
ajlm-1296	77	41	,	,	PUNCT
ajlm-1296	77	42	(	(	PUNCT
ajlm-1296	77	43	g	g	NOUN
ajlm-1296	77	44	)	)	PUNCT
ajlm-1296	77	45	m	m	NOUN
ajlm-1296	77	46	-	-	NOUN
ajlm-1296	77	47	protein	protein	NOUN
ajlm-1296	77	48	,	,	PUNCT
ajlm-1296	77	49	and	and	CCONJ
ajlm-1296	77	50	(	(	PUNCT
ajlm-1296	77	51	h	h	NOUN
ajlm-1296	77	52	)	)	PUNCT
ajlm-1296	77	53	bone	bone	NOUN
ajlm-1296	77	54	marrow	marrow	NOUN
ajlm-1296	77	55	plasma	plasma	NOUN
ajlm-1296	77	56	cells	cell	NOUN
ajlm-1296	77	57	%	%	NOUN
ajlm-1296	77	58	were	be	AUX
ajlm-1296	77	59	correlated	correlate	VERB
ajlm-1296	77	60	using	use	VERB
ajlm-1296	77	61	spearman	spearman	NOUN
ajlm-1296	77	62	’s	’s	PART
ajlm-1296	77	63	correlation	correlation	NOUN
ajlm-1296	77	64	test	test	NOUN
ajlm-1296	77	65	and	and	CCONJ
ajlm-1296	77	66	correlated	correlate	VERB
ajlm-1296	77	67	positively	positively	ADV
ajlm-1296	77	68	with	with	ADP
ajlm-1296	77	69	level	level	NOUN
ajlm-1296	77	70	of	of	ADP
ajlm-1296	77	71	serum	serum	NOUN
ajlm-1296	77	72	albumin	albumin	NOUN
ajlm-1296	77	73	(	(	PUNCT
ajlm-1296	77	74	r2	r2	PROPN
ajlm-1296	77	75	=	=	SYM
ajlm-1296	77	76	0.731	0.731	NUM
ajlm-1296	77	77	,	,	PUNCT
ajlm-1296	77	78	p	p	X
ajlm-1296	77	79	<	<	X
ajlm-1296	77	80	0.0001	0.0001	NUM
ajlm-1296	77	81	)	)	PUNCT
ajlm-1296	77	82	(	(	PUNCT
ajlm-1296	77	83	f	f	X
ajlm-1296	77	84	)	)	PUNCT
ajlm-1296	77	85	,	,	PUNCT
ajlm-1296	77	86	and	and	CCONJ
ajlm-1296	77	87	correlated	correlate	VERB
ajlm-1296	77	88	negatively	negatively	ADV
ajlm-1296	77	89	with	with	ADP
ajlm-1296	77	90	levels	level	NOUN
ajlm-1296	77	91	of	of	ADP
ajlm-1296	77	92	serum	serum	NOUN
ajlm-1296	77	93	creatinine	creatinine	NOUN
ajlm-1296	77	94	(	(	PUNCT
ajlm-1296	77	95	r2	r2	NOUN
ajlm-1296	77	96	=	=	PUNCT
ajlm-1296	77	97	0.389	0.389	NUM
ajlm-1296	77	98	,	,	PUNCT
ajlm-1296	77	99	p	p	X
ajlm-1296	77	100	<	<	X
ajlm-1296	77	101	0.0001	0.0001	NUM
ajlm-1296	77	102	)	)	PUNCT
ajlm-1296	77	103	(	(	PUNCT
ajlm-1296	77	104	a	a	X
ajlm-1296	77	105	)	)	PUNCT
ajlm-1296	77	106	,	,	PUNCT
ajlm-1296	77	107	lactate	lactate	NOUN
ajlm-1296	77	108	dehydrogenase	dehydrogenase	NOUN
ajlm-1296	77	109	(	(	PUNCT
ajlm-1296	77	110	r2	r2	NOUN
ajlm-1296	77	111	=	=	PUNCT
ajlm-1296	77	112	0.545	0.545	NUM
ajlm-1296	77	113	,	,	PUNCT
ajlm-1296	77	114	p	p	X
ajlm-1296	77	115	<	<	X
ajlm-1296	77	116	0.0001	0.0001	NUM
ajlm-1296	77	117	)	)	PUNCT
ajlm-1296	77	118	(	(	PUNCT
ajlm-1296	77	119	e	e	NOUN
ajlm-1296	77	120	)	)	PUNCT
ajlm-1296	77	121	,	,	PUNCT
ajlm-1296	77	122	calcium	calcium	NOUN
ajlm-1296	77	123	(	(	PUNCT
ajlm-1296	77	124	r2	r2	PROPN
ajlm-1296	77	125	=	=	PUNCT
ajlm-1296	77	126	0.582	0.582	NUM
ajlm-1296	77	127	,	,	PUNCT
ajlm-1296	77	128	p	p	X
ajlm-1296	77	129	<	<	X
ajlm-1296	77	130	0.0001	0.0001	NUM
ajlm-1296	77	131	)	)	PUNCT
ajlm-1296	77	132	(	(	PUNCT
ajlm-1296	77	133	d	d	NOUN
ajlm-1296	77	134	)	)	PUNCT
ajlm-1296	77	135	,	,	PUNCT
ajlm-1296	77	136	m	m	NOUN
ajlm-1296	77	137	-	-	NOUN
ajlm-1296	77	138	protein	protein	NOUN
ajlm-1296	77	139	(	(	PUNCT
ajlm-1296	77	140	r2	r2	PROPN
ajlm-1296	77	141	=	=	SYM
ajlm-1296	77	142	0.222	0.222	NUM
ajlm-1296	77	143	,	,	PUNCT
ajlm-1296	77	144	p	p	NOUN
ajlm-1296	77	145	=	=	NOUN
ajlm-1296	77	146	0.05	0.05	NUM
ajlm-1296	77	147	)	)	PUNCT
ajlm-1296	77	148	(	(	PUNCT
ajlm-1296	77	149	g	g	NOUN
ajlm-1296	77	150	)	)	PUNCT
ajlm-1296	77	151	,	,	PUNCT
ajlm-1296	77	152	and	and	CCONJ
ajlm-1296	77	153	the	the	DET
ajlm-1296	77	154	percentage	percentage	NOUN
ajlm-1296	77	155	of	of	ADP
ajlm-1296	77	156	bone	bone	NOUN
ajlm-1296	77	157	marrow	marrow	NOUN
ajlm-1296	77	158	plasma	plasma	NOUN
ajlm-1296	77	159	cells	cell	NOUN
ajlm-1296	77	160	(	(	PUNCT
ajlm-1296	77	161	r2	r2	PROPN
ajlm-1296	77	162	=	=	PUNCT
ajlm-1296	77	163	0.347	0.347	NUM
ajlm-1296	77	164	,	,	PUNCT
ajlm-1296	77	165	p	p	NOUN
ajlm-1296	77	166	=	=	NOUN
ajlm-1296	77	167	0.005	0.005	NUM
ajlm-1296	77	168	)	)	PUNCT
ajlm-1296	77	169	(	(	PUNCT
ajlm-1296	77	170	h	h	NOUN
ajlm-1296	77	171	)	)	PUNCT
ajlm-1296	77	172	.	.	PUNCT
ajlm-1296	78	1	in	in	ADP
ajlm-1296	78	2	contrast	contrast	NOUN
ajlm-1296	78	3	,	,	PUNCT
ajlm-1296	78	4	the	the	DET
ajlm-1296	78	5	proportion	proportion	NOUN
ajlm-1296	78	6	(	(	PUNCT
ajlm-1296	78	7	%	%	NOUN
ajlm-1296	78	8	)	)	PUNCT
ajlm-1296	78	9	of	of	ADP
ajlm-1296	78	10	non	non	ADJ
ajlm-1296	78	11	-	-	ADJ
ajlm-1296	78	12	classical	classical	ADJ
ajlm-1296	78	13	monocytes	monocyte	NOUN
ajlm-1296	78	14	in	in	ADP
ajlm-1296	78	15	newly	newly	ADV
ajlm-1296	78	16	diagnosed	diagnose	VERB
ajlm-1296	78	17	untreated	untreated	ADJ
ajlm-1296	78	18	mm	mm	PROPN
ajlm-1296	78	19	patients	patient	NOUN
ajlm-1296	78	20	correlated	correlate	VERB
ajlm-1296	78	21	negatively	negatively	ADV
ajlm-1296	78	22	with	with	ADP
ajlm-1296	78	23	the	the	DET
ajlm-1296	78	24	serum	serum	NOUN
ajlm-1296	78	25	albumin	albumin	ADJ
ajlm-1296	78	26	level	level	NOUN
ajlm-1296	78	27	(	(	PUNCT
ajlm-1296	78	28	r2	r2	NOUN
ajlm-1296	78	29	=	=	SYM
ajlm-1296	78	30	0.624	0.624	NUM
ajlm-1296	78	31	,	,	PUNCT
ajlm-1296	78	32	p	p	X
ajlm-1296	78	33	<	<	X
ajlm-1296	78	34	0.0001	0.0001	NUM
ajlm-1296	78	35	)	)	PUNCT
ajlm-1296	78	36	,	,	PUNCT
ajlm-1296	78	37	and	and	CCONJ
ajlm-1296	78	38	correlated	correlate	VERB
ajlm-1296	78	39	positively	positively	ADV
ajlm-1296	78	40	with	with	ADP
ajlm-1296	78	41	serum	serum	NOUN
ajlm-1296	78	42	levels	level	NOUN
ajlm-1296	78	43	of	of	ADP
ajlm-1296	78	44	creatinine	creatinine	NOUN
ajlm-1296	78	45	(	(	PUNCT
ajlm-1296	78	46	r2	r2	NOUN
ajlm-1296	78	47	=	=	PUNCT
ajlm-1296	78	48	0.413	0.413	NUM
ajlm-1296	78	49	,	,	PUNCT
ajlm-1296	78	50	p	p	X
ajlm-1296	78	51	<	<	X
ajlm-1296	78	52	0.0001	0.0001	NUM
ajlm-1296	78	53	)	)	PUNCT
ajlm-1296	78	54	,	,	PUNCT
ajlm-1296	78	55	ldh	ldh	X
ajlm-1296	78	56	(	(	PUNCT
ajlm-1296	78	57	r2	r2	PROPN
ajlm-1296	78	58	=	=	PUNCT
ajlm-1296	78	59	0.533	0.533	NUM
ajlm-1296	78	60	,	,	PUNCT
ajlm-1296	78	61	p	p	X
ajlm-1296	78	62	<	<	X
ajlm-1296	78	63	0.0001	0.0001	NUM
ajlm-1296	78	64	)	)	PUNCT
ajlm-1296	78	65	,	,	PUNCT
ajlm-1296	78	66	calcium	calcium	NOUN
ajlm-1296	78	67	(	(	PUNCT
ajlm-1296	78	68	r2	r2	NOUN
ajlm-1296	78	69	=	=	PUNCT
ajlm-1296	78	70	0.575	0.575	NUM
ajlm-1296	78	71	,	,	PUNCT
ajlm-1296	78	72	p	p	X
ajlm-1296	78	73	<	<	X
ajlm-1296	78	74	0.0001	0.0001	NUM
ajlm-1296	78	75	)	)	PUNCT
ajlm-1296	78	76	,	,	PUNCT
ajlm-1296	78	77	m	m	NOUN
ajlm-1296	78	78	-	-	NOUN
ajlm-1296	78	79	protein	protein	NOUN
ajlm-1296	78	80	(	(	PUNCT
ajlm-1296	78	81	r2	r2	PROPN
ajlm-1296	78	82	=	=	NOUN
ajlm-1296	78	83	0.28	0.28	NUM
ajlm-1296	78	84	,	,	PUNCT
ajlm-1296	78	85	p	p	NOUN
ajlm-1296	78	86	=	=	NOUN
ajlm-1296	78	87	0.024	0.024	NUM
ajlm-1296	78	88	)	)	PUNCT
ajlm-1296	78	89	,	,	PUNCT
ajlm-1296	78	90	and	and	CCONJ
ajlm-1296	78	91	with	with	ADP
ajlm-1296	78	92	the	the	DET
ajlm-1296	78	93	percentage	percentage	NOUN
ajlm-1296	78	94	of	of	ADP
ajlm-1296	78	95	bone	bone	NOUN
ajlm-1296	78	96	marrow	marrow	NOUN
ajlm-1296	78	97	plasma	plasma	NOUN
ajlm-1296	78	98	cells	cell	NOUN
ajlm-1296	78	99	(	(	PUNCT
ajlm-1296	78	100	r2	r2	PROPN
ajlm-1296	78	101	=	=	SYM
ajlm-1296	78	102	0.27	0.27	NUM
ajlm-1296	78	103	,	,	PUNCT
ajlm-1296	78	104	p	p	NOUN
ajlm-1296	78	105	=	=	NOUN
ajlm-1296	78	106	0.018	0.018	NUM
ajlm-1296	78	107	)	)	PUNCT
ajlm-1296	78	108	,	,	PUNCT
ajlm-1296	78	109	while	while	SCONJ
ajlm-1296	78	110	urea	urea	NOUN
ajlm-1296	78	111	and	and	CCONJ
ajlm-1296	78	112	total	total	ADJ
ajlm-1296	78	113	protein	protein	NOUN
ajlm-1296	78	114	did	do	AUX
ajlm-1296	78	115	not	not	PART
ajlm-1296	78	116	show	show	VERB
ajlm-1296	78	117	significant	significant	ADJ
ajlm-1296	78	118	correlation	correlation	NOUN
ajlm-1296	78	119	(	(	PUNCT
ajlm-1296	78	120	figure	figure	NOUN
ajlm-1296	78	121	3	3	NUM
ajlm-1296	78	122	)	)	PUNCT
ajlm-1296	78	123	.	.	PUNCT
ajlm-1296	79	1	figure	figure	VERB
ajlm-1296	79	2	3	3	NUM
ajlm-1296	79	3	:	:	PUNCT
ajlm-1296	79	4	correlation	correlation	NOUN
ajlm-1296	79	5	of	of	ADP
ajlm-1296	79	6	non	non	ADJ
ajlm-1296	79	7	-	-	ADJ
ajlm-1296	79	8	classical	classical	ADJ
ajlm-1296	79	9	monocytes	monocyte	NOUN
ajlm-1296	79	10	with	with	ADP
ajlm-1296	79	11	laboratory	laboratory	NOUN
ajlm-1296	79	12	parameters	parameter	NOUN
ajlm-1296	79	13	in	in	ADP
ajlm-1296	79	14	multiple	multiple	ADJ
ajlm-1296	79	15	myeloma	myeloma	NOUN
ajlm-1296	79	16	patients	patient	NOUN
ajlm-1296	79	17	and	and	CCONJ
ajlm-1296	79	18	healthy	healthy	ADJ
ajlm-1296	79	19	controls	control	NOUN
ajlm-1296	79	20	at	at	ADP
ajlm-1296	79	21	assiut	assiut	PROPN
ajlm-1296	79	22	university	university	PROPN
ajlm-1296	79	23	,	,	PUNCT
ajlm-1296	79	24	assiut	assiut	PROPN
ajlm-1296	79	25	,	,	PUNCT
ajlm-1296	79	26	egypt	egypt	PROPN
ajlm-1296	79	27	,	,	PUNCT
ajlm-1296	79	28	from	from	ADP
ajlm-1296	79	29	october	october	PROPN
ajlm-1296	79	30	2018	2018	NUM
ajlm-1296	79	31	to	to	ADP
ajlm-1296	79	32	august	august	PROPN
ajlm-1296	79	33	2019	2019	NUM
ajlm-1296	79	34	.	.	PUNCT
ajlm-1296	80	1	the	the	DET
ajlm-1296	80	2	percentage	percentage	NOUN
ajlm-1296	80	3	of	of	ADP
ajlm-1296	80	4	non	non	ADJ
ajlm-1296	80	5	-	-	ADJ
ajlm-1296	80	6	classical	classical	ADJ
ajlm-1296	80	7	monocytes	monocyte	NOUN
ajlm-1296	80	8	(	(	PUNCT
ajlm-1296	80	9	cd16++cd14	cd16++cd14	NOUN
ajlm-1296	80	10	+	+	NOUN
ajlm-1296	80	11	)	)	PUNCT
ajlm-1296	80	12	and	and	CCONJ
ajlm-1296	80	13	(	(	PUNCT
ajlm-1296	80	14	a	a	PRON
ajlm-1296	80	15	)	)	PUNCT
ajlm-1296	80	16	creatinine	creatinine	NOUN
ajlm-1296	80	17	,	,	PUNCT
ajlm-1296	80	18	(	(	PUNCT
ajlm-1296	80	19	b	b	NOUN
ajlm-1296	80	20	)	)	PUNCT
ajlm-1296	80	21	urea	urea	NOUN
ajlm-1296	80	22	,	,	PUNCT
ajlm-1296	80	23	(	(	PUNCT
ajlm-1296	80	24	c	c	X
ajlm-1296	80	25	)	)	PUNCT
ajlm-1296	80	26	lactate	lactate	NOUN
ajlm-1296	80	27	dehydrogenase	dehydrogenase	NOUN
ajlm-1296	80	28	,	,	PUNCT
ajlm-1296	80	29	(	(	PUNCT
ajlm-1296	80	30	d	d	NOUN
ajlm-1296	80	31	)	)	PUNCT
ajlm-1296	80	32	calcium	calcium	NOUN
ajlm-1296	80	33	,	,	PUNCT
ajlm-1296	80	34	(	(	PUNCT
ajlm-1296	80	35	e	e	NOUN
ajlm-1296	80	36	)	)	PUNCT
ajlm-1296	80	37	total	total	ADJ
ajlm-1296	80	38	protein	protein	NOUN
ajlm-1296	80	39	,	,	PUNCT
ajlm-1296	80	40	(	(	PUNCT
ajlm-1296	80	41	f	f	X
ajlm-1296	80	42	)	)	PUNCT
ajlm-1296	80	43	albumin	albumin	NOUN
ajlm-1296	80	44	,	,	PUNCT
ajlm-1296	80	45	(	(	PUNCT
ajlm-1296	80	46	g	g	NOUN
ajlm-1296	80	47	)	)	PUNCT
ajlm-1296	80	48	m	m	NOUN
ajlm-1296	80	49	-	-	NOUN
ajlm-1296	80	50	protein	protein	NOUN
ajlm-1296	80	51	,	,	PUNCT
ajlm-1296	80	52	and	and	CCONJ
ajlm-1296	80	53	(	(	PUNCT
ajlm-1296	80	54	h	h	NOUN
ajlm-1296	80	55	)	)	PUNCT
ajlm-1296	80	56	bone	bone	NOUN
ajlm-1296	80	57	marrow	marrow	NOUN
ajlm-1296	80	58	plasma	plasma	NOUN
ajlm-1296	80	59	cells	cell	NOUN
ajlm-1296	80	60	%	%	NOUN
ajlm-1296	80	61	were	be	AUX
ajlm-1296	80	62	correlated	correlate	VERB
ajlm-1296	80	63	using	use	VERB
ajlm-1296	80	64	spearman	spearman	NOUN
ajlm-1296	80	65	’s	’s	PART
ajlm-1296	80	66	correlation	correlation	NOUN
ajlm-1296	80	67	test	test	NOUN
ajlm-1296	80	68	and	and	CCONJ
ajlm-1296	80	69	correlated	correlate	VERB
ajlm-1296	80	70	negatively	negatively	ADV
ajlm-1296	80	71	with	with	ADP
ajlm-1296	80	72	level	level	NOUN
ajlm-1296	80	73	of	of	ADP
ajlm-1296	80	74	serum	serum	NOUN
ajlm-1296	80	75	albumin	albumin	NOUN
ajlm-1296	80	76	(	(	PUNCT
ajlm-1296	80	77	r2	r2	PROPN
ajlm-1296	80	78	=	=	PUNCT
ajlm-1296	80	79	0.624	0.624	NUM
ajlm-1296	80	80	,	,	PUNCT
ajlm-1296	80	81	p	p	X
ajlm-1296	80	82	<	<	X
ajlm-1296	80	83	0.0001	0.0001	NUM
ajlm-1296	80	84	)	)	PUNCT
ajlm-1296	80	85	(	(	PUNCT
ajlm-1296	80	86	f	f	X
ajlm-1296	80	87	)	)	PUNCT
ajlm-1296	80	88	,	,	PUNCT
ajlm-1296	80	89	and	and	CCONJ
ajlm-1296	80	90	correlated	correlate	VERB
ajlm-1296	80	91	positively	positively	ADV
ajlm-1296	80	92	with	with	ADP
ajlm-1296	80	93	higher	high	ADJ
ajlm-1296	80	94	levels	level	NOUN
ajlm-1296	80	95	of	of	ADP
ajlm-1296	80	96	creatinine	creatinine	NOUN
ajlm-1296	80	97	(	(	PUNCT
ajlm-1296	80	98	r2	r2	NOUN
ajlm-1296	80	99	=	=	PUNCT
ajlm-1296	80	100	0.413	0.413	NUM
ajlm-1296	80	101	,	,	PUNCT
ajlm-1296	80	102	p	p	X
ajlm-1296	80	103	<	<	X
ajlm-1296	80	104	0.0001	0.0001	NUM
ajlm-1296	80	105	)	)	PUNCT
ajlm-1296	80	106	(	(	PUNCT
ajlm-1296	80	107	a	a	X
ajlm-1296	80	108	)	)	PUNCT
ajlm-1296	80	109	,	,	PUNCT
ajlm-1296	81	1	lactate	lactate	NOUN
ajlm-1296	81	2	dehydrogenase	dehydrogenase	NOUN
ajlm-1296	81	3	(	(	PUNCT
ajlm-1296	81	4	r2	r2	PROPN
ajlm-1296	81	5	=	=	PUNCT
ajlm-1296	81	6	0.533	0.533	NUM
ajlm-1296	81	7	,	,	PUNCT
ajlm-1296	81	8	p	p	X
ajlm-1296	81	9	<	<	X
ajlm-1296	81	10	0.0001	0.0001	NUM
ajlm-1296	81	11	)	)	PUNCT
ajlm-1296	81	12	(	(	PUNCT
ajlm-1296	81	13	c	c	NOUN
ajlm-1296	81	14	)	)	PUNCT
ajlm-1296	81	15	,	,	PUNCT
ajlm-1296	81	16	serum	serum	NOUN
ajlm-1296	81	17	calcium	calcium	NOUN
ajlm-1296	81	18	(	(	PUNCT
ajlm-1296	81	19	r2	r2	NOUN
ajlm-1296	81	20	=	=	PUNCT
ajlm-1296	81	21	0.575	0.575	NUM
ajlm-1296	81	22	,	,	PUNCT
ajlm-1296	81	23	p	p	X
ajlm-1296	81	24	<	<	X
ajlm-1296	81	25	0.0001	0.0001	NUM
ajlm-1296	81	26	)	)	PUNCT
ajlm-1296	81	27	(	(	PUNCT
ajlm-1296	81	28	d	d	NOUN
ajlm-1296	81	29	)	)	PUNCT
ajlm-1296	81	30	,	,	PUNCT
ajlm-1296	81	31	m	m	NOUN
ajlm-1296	81	32	-	-	NOUN
ajlm-1296	81	33	protein	protein	NOUN
ajlm-1296	81	34	(	(	PUNCT
ajlm-1296	81	35	r2	r2	PROPN
ajlm-1296	81	36	=	=	NOUN
ajlm-1296	81	37	0.28	0.28	NUM
ajlm-1296	81	38	,	,	PUNCT
ajlm-1296	81	39	p	p	NOUN
ajlm-1296	81	40	=	=	NOUN
ajlm-1296	81	41	0.024	0.024	NUM
ajlm-1296	81	42	)	)	PUNCT
ajlm-1296	81	43	(	(	PUNCT
ajlm-1296	81	44	g	g	NOUN
ajlm-1296	81	45	)	)	PUNCT
ajlm-1296	81	46	,	,	PUNCT
ajlm-1296	81	47	and	and	CCONJ
ajlm-1296	81	48	the	the	DET
ajlm-1296	81	49	percentage	percentage	NOUN
ajlm-1296	81	50	of	of	ADP
ajlm-1296	81	51	bone	bone	NOUN
ajlm-1296	81	52	marrow	marrow	NOUN
ajlm-1296	81	53	plasma	plasma	NOUN
ajlm-1296	81	54	cells	cell	NOUN
ajlm-1296	81	55	(	(	PUNCT
ajlm-1296	81	56	r2	r2	PROPN
ajlm-1296	81	57	=	=	SYM
ajlm-1296	81	58	0.27	0.27	NUM
ajlm-1296	81	59	,	,	PUNCT
ajlm-1296	81	60	p	p	NOUN
ajlm-1296	81	61	=	=	NOUN
ajlm-1296	81	62	0.018	0.018	NUM
ajlm-1296	81	63	)	)	PUNCT
ajlm-1296	81	64	(	(	PUNCT
ajlm-1296	81	65	h	h	NOUN
ajlm-1296	81	66	)	)	PUNCT
ajlm-1296	81	67	.	.	PUNCT
ajlm-1296	82	1	similarly	similarly	ADV
ajlm-1296	82	2	,	,	PUNCT
ajlm-1296	82	3	the	the	DET
ajlm-1296	82	4	proportion	proportion	NOUN
ajlm-1296	82	5	(	(	PUNCT
ajlm-1296	82	6	%	%	NOUN
ajlm-1296	82	7	)	)	PUNCT
ajlm-1296	82	8	of	of	ADP
ajlm-1296	82	9	intermediate	intermediate	ADJ
ajlm-1296	82	10	monocytes	monocyte	NOUN
ajlm-1296	82	11	in	in	ADP
ajlm-1296	82	12	newly	newly	ADV
ajlm-1296	82	13	diagnosed	diagnose	VERB
ajlm-1296	82	14	untreated	untreated	ADJ
ajlm-1296	82	15	mm	mm	PROPN
ajlm-1296	82	16	patients	patient	NOUN
ajlm-1296	82	17	correlated	correlate	VERB
ajlm-1296	82	18	negatively	negatively	ADV
ajlm-1296	82	19	with	with	ADP
ajlm-1296	82	20	serum	serum	NOUN
ajlm-1296	82	21	albumin	albumin	ADJ
ajlm-1296	82	22	level	level	NOUN
ajlm-1296	82	23	(	(	PUNCT
ajlm-1296	82	24	r2	r2	PROPN
ajlm-1296	82	25	=	=	PUNCT
ajlm-1296	82	26	0.649	0.649	NUM
ajlm-1296	82	27	,	,	PUNCT
ajlm-1296	82	28	p	p	X
ajlm-1296	82	29	<	<	X
ajlm-1296	82	30	0.0001	0.0001	NUM
ajlm-1296	82	31	)	)	PUNCT
ajlm-1296	82	32	and	and	CCONJ
ajlm-1296	82	33	correlated	correlate	VERB
ajlm-1296	82	34	positively	positively	ADV
ajlm-1296	82	35	with	with	ADP
ajlm-1296	82	36	the	the	DET
ajlm-1296	82	37	serum	serum	NOUN
ajlm-1296	82	38	levels	level	NOUN
ajlm-1296	82	39	of	of	ADP
ajlm-1296	82	40	creatinine	creatinine	NOUN
ajlm-1296	82	41	(	(	PUNCT
ajlm-1296	82	42	r2	r2	PROPN
ajlm-1296	82	43	=	=	SYM
ajlm-1296	82	44	0.222	0.222	NUM
ajlm-1296	82	45	,	,	PUNCT
ajlm-1296	82	46	p	p	NOUN
ajlm-1296	82	47	=	=	NOUN
ajlm-1296	82	48	0.002	0.002	NUM
ajlm-1296	82	49	)	)	PUNCT
ajlm-1296	82	50	,	,	PUNCT
ajlm-1296	82	51	ldh	ldh	X
ajlm-1296	82	52	(	(	PUNCT
ajlm-1296	82	53	r2	r2	PROPN
ajlm-1296	82	54	=	=	PUNCT
ajlm-1296	82	55	0.338	0.338	NUM
ajlm-1296	82	56	,	,	PUNCT
ajlm-1296	82	57	p	p	X
ajlm-1296	82	58	<	<	X
ajlm-1296	82	59	0.0001	0.0001	NUM
ajlm-1296	82	60	)	)	PUNCT
ajlm-1296	82	61	,	,	PUNCT
ajlm-1296	82	62	calcium	calcium	NOUN
ajlm-1296	82	63	(	(	PUNCT
ajlm-1296	82	64	r2	r2	PROPN
ajlm-1296	82	65	=	=	SYM
ajlm-1296	82	66	0.398	0.398	NUM
ajlm-1296	82	67	,	,	PUNCT
ajlm-1296	82	68	p	p	X
ajlm-1296	82	69	<	<	X
ajlm-1296	82	70	0.0001	0.0001	NUM
ajlm-1296	82	71	)	)	PUNCT
ajlm-1296	82	72	,	,	PUNCT
ajlm-1296	82	73	and	and	CCONJ
ajlm-1296	82	74	with	with	ADP
ajlm-1296	82	75	the	the	DET
ajlm-1296	82	76	percentage	percentage	NOUN
ajlm-1296	82	77	of	of	ADP
ajlm-1296	82	78	bone	bone	NOUN
ajlm-1296	82	79	marrow	marrow	NOUN
ajlm-1296	82	80	plasma	plasma	NOUN
ajlm-1296	82	81	cells	cell	NOUN
ajlm-1296	82	82	(	(	PUNCT
ajlm-1296	82	83	r2	r2	PROPN
ajlm-1296	82	84	=	=	PUNCT
ajlm-1296	82	85	0.301	0.301	NUM
ajlm-1296	82	86	,	,	PUNCT
ajlm-1296	82	87	p	p	X
ajlm-1296	82	88	=	=	NOUN
ajlm-1296	82	89	0.016	0.016	NUM
ajlm-1296	82	90	)	)	PUNCT
ajlm-1296	82	91	,	,	PUNCT
ajlm-1296	82	92	while	while	SCONJ
ajlm-1296	82	93	urea	urea	NOUN
ajlm-1296	82	94	,	,	PUNCT
ajlm-1296	82	95	total	total	ADJ
ajlm-1296	82	96	protein	protein	NOUN
ajlm-1296	82	97	,	,	PUNCT
ajlm-1296	82	98	and	and	CCONJ
ajlm-1296	82	99	m	m	NOUN
ajlm-1296	82	100	-	-	ADJ
ajlm-1296	82	101	protein	protein	NOUN
ajlm-1296	82	102	did	do	AUX
ajlm-1296	82	103	not	not	PART
ajlm-1296	82	104	show	show	VERB
ajlm-1296	82	105	significant	significant	ADJ
ajlm-1296	82	106	correlation	correlation	NOUN
ajlm-1296	82	107	(	(	PUNCT
ajlm-1296	82	108	figure	figure	NOUN
ajlm-1296	82	109	4	4	NUM
ajlm-1296	82	110	)	)	PUNCT
ajlm-1296	82	111	.	.	PUNCT
ajlm-1296	83	1	figure	figure	VERB
ajlm-1296	83	2	4	4	NUM
ajlm-1296	83	3	:	:	PUNCT
ajlm-1296	83	4	correlation	correlation	NOUN
ajlm-1296	83	5	of	of	ADP
ajlm-1296	83	6	intermediate	intermediate	ADJ
ajlm-1296	83	7	monocytes	monocyte	NOUN
ajlm-1296	83	8	with	with	ADP
ajlm-1296	83	9	laboratory	laboratory	NOUN
ajlm-1296	83	10	parameters	parameter	NOUN
ajlm-1296	83	11	in	in	ADP
ajlm-1296	83	12	multiple	multiple	ADJ
ajlm-1296	83	13	myeloma	myeloma	NOUN
ajlm-1296	83	14	patients	patient	NOUN
ajlm-1296	83	15	and	and	CCONJ
ajlm-1296	83	16	healthy	healthy	ADJ
ajlm-1296	83	17	controls	control	NOUN
ajlm-1296	83	18	at	at	ADP
ajlm-1296	83	19	assiut	assiut	PROPN
ajlm-1296	83	20	university	university	PROPN
ajlm-1296	83	21	,	,	PUNCT
ajlm-1296	83	22	assiut	assiut	PROPN
ajlm-1296	83	23	,	,	PUNCT
ajlm-1296	83	24	egypt	egypt	PROPN
ajlm-1296	83	25	,	,	PUNCT
ajlm-1296	83	26	from	from	ADP
ajlm-1296	83	27	october	october	PROPN
ajlm-1296	83	28	2018	2018	NUM
ajlm-1296	83	29	to	to	ADP
ajlm-1296	83	30	august	august	PROPN
ajlm-1296	83	31	2019	2019	NUM
ajlm-1296	83	32	.	.	PUNCT
ajlm-1296	84	1	the	the	DET
ajlm-1296	84	2	percentage	percentage	NOUN
ajlm-1296	84	3	of	of	ADP
ajlm-1296	84	4	intermediate	intermediate	ADJ
ajlm-1296	84	5	monocytes	monocyte	NOUN
ajlm-1296	84	6	(	(	PUNCT
ajlm-1296	84	7	cd16+cd14++	cd16+cd14++	PROPN
ajlm-1296	84	8	)	)	PUNCT
ajlm-1296	84	9	and	and	CCONJ
ajlm-1296	84	10	(	(	PUNCT
ajlm-1296	84	11	a	a	PRON
ajlm-1296	84	12	)	)	PUNCT
ajlm-1296	84	13	creatinine	creatinine	NOUN
ajlm-1296	84	14	,	,	PUNCT
ajlm-1296	84	15	(	(	PUNCT
ajlm-1296	84	16	b	b	NOUN
ajlm-1296	84	17	)	)	PUNCT
ajlm-1296	84	18	urea	urea	NOUN
ajlm-1296	84	19	,	,	PUNCT
ajlm-1296	84	20	(	(	PUNCT
ajlm-1296	84	21	c	c	X
ajlm-1296	84	22	)	)	PUNCT
ajlm-1296	84	23	lactate	lactate	NOUN
ajlm-1296	84	24	dehydrogenase	dehydrogenase	NOUN
ajlm-1296	84	25	,	,	PUNCT
ajlm-1296	84	26	(	(	PUNCT
ajlm-1296	84	27	d	d	NOUN
ajlm-1296	84	28	)	)	PUNCT
ajlm-1296	84	29	calcium	calcium	NOUN
ajlm-1296	84	30	,	,	PUNCT
ajlm-1296	84	31	(	(	PUNCT
ajlm-1296	84	32	e	e	NOUN
ajlm-1296	84	33	)	)	PUNCT
ajlm-1296	84	34	total	total	ADJ
ajlm-1296	84	35	protein	protein	NOUN
ajlm-1296	84	36	,	,	PUNCT
ajlm-1296	84	37	(	(	PUNCT
ajlm-1296	84	38	f	f	X
ajlm-1296	84	39	)	)	PUNCT
ajlm-1296	84	40	albumin	albumin	NOUN
ajlm-1296	84	41	,	,	PUNCT
ajlm-1296	84	42	(	(	PUNCT
ajlm-1296	84	43	g	g	NOUN
ajlm-1296	84	44	)	)	PUNCT
ajlm-1296	84	45	m	m	NOUN
ajlm-1296	84	46	-	-	NOUN
ajlm-1296	84	47	protein	protein	NOUN
ajlm-1296	84	48	,	,	PUNCT
ajlm-1296	84	49	and	and	CCONJ
ajlm-1296	84	50	(	(	PUNCT
ajlm-1296	84	51	h	h	NOUN
ajlm-1296	84	52	)	)	PUNCT
ajlm-1296	84	53	bone	bone	NOUN
ajlm-1296	84	54	marrow	marrow	NOUN
ajlm-1296	84	55	plasma	plasma	NOUN
ajlm-1296	84	56	cells	cell	NOUN
ajlm-1296	84	57	%	%	NOUN
ajlm-1296	84	58	were	be	AUX
ajlm-1296	84	59	correlated	correlate	VERB
ajlm-1296	84	60	using	use	VERB
ajlm-1296	84	61	spearman	spearman	NOUN
ajlm-1296	84	62	’s	’s	PART
ajlm-1296	84	63	correlation	correlation	NOUN
ajlm-1296	84	64	test	test	NOUN
ajlm-1296	84	65	and	and	CCONJ
ajlm-1296	84	66	correlated	correlate	VERB
ajlm-1296	84	67	negatively	negatively	ADV
ajlm-1296	84	68	with	with	ADP
ajlm-1296	84	69	level	level	NOUN
ajlm-1296	84	70	of	of	ADP
ajlm-1296	84	71	serum	serum	NOUN
ajlm-1296	84	72	albumin	albumin	NOUN
ajlm-1296	84	73	(	(	PUNCT
ajlm-1296	84	74	r2	r2	PROPN
ajlm-1296	84	75	=	=	PUNCT
ajlm-1296	84	76	0.649	0.649	NUM
ajlm-1296	84	77	,	,	PUNCT
ajlm-1296	84	78	p	p	X
ajlm-1296	84	79	<	<	X
ajlm-1296	84	80	0.0001	0.0001	NUM
ajlm-1296	84	81	)	)	PUNCT
ajlm-1296	84	82	(	(	PUNCT
ajlm-1296	84	83	f	f	X
ajlm-1296	84	84	)	)	PUNCT
ajlm-1296	84	85	,	,	PUNCT
ajlm-1296	84	86	and	and	CCONJ
ajlm-1296	84	87	correlated	correlate	VERB
ajlm-1296	84	88	positively	positively	ADV
ajlm-1296	84	89	with	with	ADP
ajlm-1296	84	90	levels	level	NOUN
ajlm-1296	84	91	of	of	ADP
ajlm-1296	84	92	serum	serum	NOUN
ajlm-1296	84	93	creatinine	creatinine	NOUN
ajlm-1296	84	94	(	(	PUNCT
ajlm-1296	84	95	r2	r2	PROPN
ajlm-1296	84	96	=	=	SYM
ajlm-1296	84	97	0.222	0.222	NUM
ajlm-1296	84	98	,	,	PUNCT
ajlm-1296	84	99	p	p	NOUN
ajlm-1296	84	100	=	=	NOUN
ajlm-1296	84	101	0.002	0.002	NUM
ajlm-1296	84	102	)	)	PUNCT
ajlm-1296	84	103	(	(	PUNCT
ajlm-1296	84	104	a	a	X
ajlm-1296	84	105	)	)	PUNCT
ajlm-1296	84	106	,	,	PUNCT
ajlm-1296	84	107	lactate	lactate	NOUN
ajlm-1296	84	108	dehydrogenase	dehydrogenase	NOUN
ajlm-1296	84	109	(	(	PUNCT
ajlm-1296	84	110	r2	r2	PROPN
ajlm-1296	84	111	=	=	PUNCT
ajlm-1296	84	112	0.338	0.338	NUM
ajlm-1296	84	113	,	,	PUNCT
ajlm-1296	84	114	p	p	X
ajlm-1296	84	115	<	<	X
ajlm-1296	84	116	0.0001	0.0001	NUM
ajlm-1296	84	117	)	)	PUNCT
ajlm-1296	84	118	(	(	PUNCT
ajlm-1296	84	119	c	c	NOUN
ajlm-1296	84	120	)	)	PUNCT
ajlm-1296	84	121	,	,	PUNCT
ajlm-1296	84	122	calcium	calcium	NOUN
ajlm-1296	84	123	(	(	PUNCT
ajlm-1296	84	124	r2	r2	PROPN
ajlm-1296	84	125	=	=	SYM
ajlm-1296	84	126	0.398	0.398	NUM
ajlm-1296	84	127	,	,	PUNCT
ajlm-1296	84	128	p	p	X
ajlm-1296	84	129	<	<	X
ajlm-1296	84	130	0.0001	0.0001	NUM
ajlm-1296	84	131	)	)	PUNCT
ajlm-1296	84	132	(	(	PUNCT
ajlm-1296	84	133	d	d	NOUN
ajlm-1296	84	134	)	)	PUNCT
ajlm-1296	84	135	,	,	PUNCT
ajlm-1296	84	136	and	and	CCONJ
ajlm-1296	84	137	the	the	DET
ajlm-1296	84	138	percentage	percentage	NOUN
ajlm-1296	84	139	of	of	ADP
ajlm-1296	84	140	bone	bone	NOUN
ajlm-1296	84	141	marrow	marrow	NOUN
ajlm-1296	84	142	plasma	plasma	NOUN
ajlm-1296	84	143	cells	cell	NOUN
ajlm-1296	84	144	(	(	PUNCT
ajlm-1296	84	145	r2	r2	PROPN
ajlm-1296	84	146	=	=	PUNCT
ajlm-1296	84	147	0.301	0.301	NUM
ajlm-1296	84	148	,	,	PUNCT
ajlm-1296	84	149	p	p	X
ajlm-1296	84	150	=	=	NOUN
ajlm-1296	84	151	0.016	0.016	NUM
ajlm-1296	84	152	)	)	PUNCT
ajlm-1296	84	153	(	(	PUNCT
ajlm-1296	84	154	h	h	NOUN
ajlm-1296	84	155	)	)	PUNCT
ajlm-1296	84	156	.	.	PUNCT
ajlm-1296	85	1	discussion	discussion	NOUN
ajlm-1296	85	2	this	this	DET
ajlm-1296	85	3	study	study	NOUN
ajlm-1296	85	4	found	find	VERB
ajlm-1296	85	5	that	that	SCONJ
ajlm-1296	85	6	the	the	DET
ajlm-1296	85	7	percentage	percentage	NOUN
ajlm-1296	85	8	of	of	ADP
ajlm-1296	85	9	classical	classical	ADJ
ajlm-1296	85	10	monocytes	monocyte	NOUN
ajlm-1296	85	11	was	be	AUX
ajlm-1296	85	12	significantly	significantly	ADV
ajlm-1296	85	13	lower	low	ADJ
ajlm-1296	85	14	in	in	ADP
ajlm-1296	85	15	patients	patient	NOUN
ajlm-1296	85	16	with	with	ADP
ajlm-1296	85	17	mm	mm	PROPN
ajlm-1296	85	18	compared	compare	VERB
ajlm-1296	85	19	to	to	ADP
ajlm-1296	85	20	controls	control	NOUN
ajlm-1296	85	21	,	,	PUNCT
ajlm-1296	85	22	while	while	SCONJ
ajlm-1296	85	23	the	the	DET
ajlm-1296	85	24	percentages	percentage	NOUN
ajlm-1296	85	25	of	of	ADP
ajlm-1296	85	26	non	non	ADJ
ajlm-1296	85	27	-	-	ADJ
ajlm-1296	85	28	classical	classical	ADJ
ajlm-1296	85	29	and	and	CCONJ
ajlm-1296	85	30	intermediate	intermediate	ADJ
ajlm-1296	85	31	monocytes	monocyte	NOUN
ajlm-1296	85	32	were	be	AUX
ajlm-1296	85	33	significantly	significantly	ADV
ajlm-1296	85	34	higher	high	ADJ
ajlm-1296	85	35	.	.	PUNCT
ajlm-1296	86	1	moreover	moreover	ADV
ajlm-1296	86	2	,	,	PUNCT
ajlm-1296	86	3	the	the	DET
ajlm-1296	86	4	proportions	proportion	NOUN
ajlm-1296	86	5	of	of	ADP
ajlm-1296	86	6	non	non	ADJ
ajlm-1296	86	7	-	-	ADJ
ajlm-1296	86	8	classical	classical	ADJ
ajlm-1296	86	9	and	and	CCONJ
ajlm-1296	86	10	intermediate	intermediate	ADJ
ajlm-1296	86	11	monocytes	monocyte	NOUN
ajlm-1296	86	12	were	be	AUX
ajlm-1296	86	13	positively	positively	ADV
ajlm-1296	86	14	correlated	correlate	VERB
ajlm-1296	86	15	with	with	ADP
ajlm-1296	86	16	serum	serum	NOUN
ajlm-1296	86	17	levels	level	NOUN
ajlm-1296	86	18	of	of	ADP
ajlm-1296	86	19	plasma	plasma	NOUN
ajlm-1296	86	20	cells	cell	NOUN
ajlm-1296	86	21	,	,	PUNCT
ajlm-1296	86	22	m	m	NOUN
ajlm-1296	86	23	-	-	NOUN
ajlm-1296	86	24	protein	protein	NOUN
ajlm-1296	86	25	,	,	PUNCT
ajlm-1296	86	26	calcium	calcium	NOUN
ajlm-1296	86	27	,	,	PUNCT
ajlm-1296	86	28	creatinine	creatinine	NOUN
ajlm-1296	86	29	,	,	PUNCT
ajlm-1296	86	30	and	and	CCONJ
ajlm-1296	86	31	lactate	lactate	NOUN
ajlm-1296	86	32	dehydrogenase	dehydrogenase	NOUN
ajlm-1296	86	33	,	,	PUNCT
ajlm-1296	86	34	and	and	CCONJ
ajlm-1296	86	35	correlated	correlate	VERB
ajlm-1296	86	36	negatively	negatively	ADV
ajlm-1296	86	37	with	with	ADP
ajlm-1296	86	38	the	the	DET
ajlm-1296	86	39	serum	serum	NOUN
ajlm-1296	86	40	albumin	albumin	ADJ
ajlm-1296	86	41	level	level	NOUN
ajlm-1296	86	42	.	.	PUNCT
ajlm-1296	87	1	proportions	proportion	NOUN
ajlm-1296	87	2	of	of	ADP
ajlm-1296	87	3	classical	classical	ADJ
ajlm-1296	87	4	monocytes	monocyte	NOUN
ajlm-1296	87	5	correlated	correlate	VERB
ajlm-1296	87	6	positively	positively	ADV
ajlm-1296	87	7	with	with	ADP
ajlm-1296	87	8	albumin	albumin	ADJ
ajlm-1296	87	9	level	level	NOUN
ajlm-1296	87	10	and	and	CCONJ
ajlm-1296	87	11	correlated	correlate	VERB
ajlm-1296	87	12	negatively	negatively	ADV
ajlm-1296	87	13	with	with	ADP
ajlm-1296	87	14	serum	serum	NOUN
ajlm-1296	87	15	levels	level	NOUN
ajlm-1296	87	16	of	of	ADP
ajlm-1296	87	17	m	m	NOUN
ajlm-1296	87	18	-	-	NOUN
ajlm-1296	87	19	protein	protein	NOUN
ajlm-1296	87	20	,	,	PUNCT
ajlm-1296	87	21	plasma	plasma	NOUN
ajlm-1296	87	22	cells	cell	NOUN
ajlm-1296	87	23	,	,	PUNCT
ajlm-1296	87	24	calcium	calcium	NOUN
ajlm-1296	87	25	,	,	PUNCT
ajlm-1296	87	26	creatinine	creatinine	NOUN
ajlm-1296	87	27	,	,	PUNCT
ajlm-1296	87	28	and	and	CCONJ
ajlm-1296	87	29	lactate	lactate	PROPN
ajlm-1296	87	30	dehydrogenase	dehydrogenase	NOUN
ajlm-1296	87	31	.	.	PUNCT
ajlm-1296	88	1	multiple	multiple	ADJ
ajlm-1296	88	2	myeloma	myeloma	PROPN
ajlm-1296	88	3	is	be	AUX
ajlm-1296	88	4	a	a	DET
ajlm-1296	88	5	plasma	plasma	NOUN
ajlm-1296	88	6	cell	cell	NOUN
ajlm-1296	88	7	cancer	cancer	NOUN
ajlm-1296	88	8	that	that	PRON
ajlm-1296	88	9	exploits	exploit	VERB
ajlm-1296	88	10	monocytes	monocyte	NOUN
ajlm-1296	88	11	and	and	CCONJ
ajlm-1296	88	12	macrophages	macrophage	NOUN
ajlm-1296	88	13	for	for	ADP
ajlm-1296	88	14	growth	growth	NOUN
ajlm-1296	88	15	and	and	CCONJ
ajlm-1296	88	16	expansion16	expansion16	NOUN
ajlm-1296	88	17	through	through	ADP
ajlm-1296	88	18	the	the	DET
ajlm-1296	88	19	production	production	NOUN
ajlm-1296	88	20	of	of	ADP
ajlm-1296	88	21	inflammatory	inflammatory	ADJ
ajlm-1296	88	22	interleukins	interleukin	NOUN
ajlm-1296	88	23	such	such	ADJ
ajlm-1296	88	24	as	as	ADP
ajlm-1296	88	25	il-6	il-6	NOUN
ajlm-1296	88	26	that	that	PRON
ajlm-1296	88	27	promote	promote	VERB
ajlm-1296	88	28	persistence	persistence	NOUN
ajlm-1296	88	29	of	of	ADP
ajlm-1296	88	30	malignant	malignant	ADJ
ajlm-1296	88	31	plasma	plasma	NOUN
ajlm-1296	88	32	cells4,16	cells4,16	PUNCT
ajlm-1296	88	33	and	and	CCONJ
ajlm-1296	88	34	enhance	enhance	VERB
ajlm-1296	88	35	tumour	tumour	NOUN
ajlm-1296	88	36	progression.5	progression.5	PROPN
ajlm-1296	88	37	monocytes,20	monocytes,20	NOUN
ajlm-1296	88	38	especially	especially	ADV
ajlm-1296	88	39	non	non	ADJ
ajlm-1296	88	40	-	-	ADJ
ajlm-1296	88	41	classical	classical	ADJ
ajlm-1296	88	42	monocytes,16	monocytes,16	ADJ
ajlm-1296	88	43	increase	increase	NOUN
ajlm-1296	88	44	in	in	ADP
ajlm-1296	88	45	mm	mm	PROPN
ajlm-1296	88	46	patients	patient	NOUN
ajlm-1296	88	47	.	.	PUNCT
ajlm-1296	89	1	in	in	ADP
ajlm-1296	89	2	this	this	DET
ajlm-1296	89	3	study	study	NOUN
ajlm-1296	89	4	,	,	PUNCT
ajlm-1296	89	5	we	we	PRON
ajlm-1296	89	6	analysed	analyse	VERB
ajlm-1296	89	7	circulating	circulate	VERB
ajlm-1296	89	8	monocytes	monocyte	NOUN
ajlm-1296	89	9	in	in	ADP
ajlm-1296	89	10	20	20	NUM
ajlm-1296	89	11	newly	newly	ADV
ajlm-1296	89	12	identified	identify	VERB
ajlm-1296	89	13	untreated	untreated	ADJ
ajlm-1296	89	14	mm	mm	PROPN
ajlm-1296	89	15	patients	patient	NOUN
ajlm-1296	89	16	to	to	PART
ajlm-1296	89	17	discover	discover	VERB
ajlm-1296	89	18	their	their	PRON
ajlm-1296	89	19	role	role	NOUN
ajlm-1296	89	20	in	in	ADP
ajlm-1296	89	21	disease	disease	NOUN
ajlm-1296	89	22	progression	progression	NOUN
ajlm-1296	89	23	and	and	CCONJ
ajlm-1296	89	24	postulate	postulate	VERB
ajlm-1296	89	25	their	their	PRON
ajlm-1296	89	26	possible	possible	ADJ
ajlm-1296	89	27	use	use	NOUN
ajlm-1296	89	28	as	as	ADP
ajlm-1296	89	29	a	a	DET
ajlm-1296	89	30	prognostic	prognostic	ADJ
ajlm-1296	89	31	factor	factor	NOUN
ajlm-1296	89	32	during	during	ADP
ajlm-1296	89	33	patient	patient	ADJ
ajlm-1296	89	34	follow	follow	NOUN
ajlm-1296	89	35	-	-	PUNCT
ajlm-1296	89	36	up	up	NOUN
ajlm-1296	89	37	.	.	PUNCT
ajlm-1296	90	1	we	we	PRON
ajlm-1296	90	2	found	find	VERB
ajlm-1296	90	3	significantly	significantly	ADV
ajlm-1296	90	4	increased	increase	VERB
ajlm-1296	90	5	proportions	proportion	NOUN
ajlm-1296	90	6	of	of	ADP
ajlm-1296	90	7	non	non	ADJ
ajlm-1296	90	8	-	-	ADJ
ajlm-1296	90	9	classical	classical	ADJ
ajlm-1296	90	10	(	(	PUNCT
ajlm-1296	90	11	cd16++	cd16++	ADJ
ajlm-1296	90	12	cd14	cd14	PROPN
ajlm-1296	90	13	+	+	PROPN
ajlm-1296	90	14	)	)	PUNCT
ajlm-1296	90	15	and	and	CCONJ
ajlm-1296	90	16	intermediate	intermediate	ADJ
ajlm-1296	90	17	(	(	PUNCT
ajlm-1296	90	18	cd16	cd16	PROPN
ajlm-1296	90	19	+	+	NOUN
ajlm-1296	90	20	cd14++	cd14++	NOUN
ajlm-1296	90	21	)	)	PUNCT
ajlm-1296	90	22	circulating	circulate	VERB
ajlm-1296	90	23	monocytes	monocyte	NOUN
ajlm-1296	90	24	in	in	ADP
ajlm-1296	90	25	newly	newly	ADV
ajlm-1296	90	26	diagnosed	diagnose	VERB
ajlm-1296	90	27	untreated	untreated	ADJ
ajlm-1296	90	28	mm	mm	PROPN
ajlm-1296	90	29	patients	patient	NOUN
ajlm-1296	90	30	compared	compare	VERB
ajlm-1296	90	31	to	to	ADP
ajlm-1296	90	32	healthy	healthy	ADJ
ajlm-1296	90	33	controls	control	NOUN
ajlm-1296	90	34	.	.	PUNCT
ajlm-1296	91	1	our	our	PRON
ajlm-1296	91	2	results	result	NOUN
ajlm-1296	91	3	are	be	AUX
ajlm-1296	91	4	similar	similar	ADJ
ajlm-1296	91	5	to	to	ADP
ajlm-1296	91	6	those	those	PRON
ajlm-1296	91	7	of	of	ADP
ajlm-1296	91	8	a	a	DET
ajlm-1296	91	9	study	study	NOUN
ajlm-1296	91	10	in	in	ADP
ajlm-1296	91	11	2015	2015	NUM
ajlm-1296	91	12	in	in	ADP
ajlm-1296	91	13	france	france	PROPN
ajlm-1296	91	14	that	that	PRON
ajlm-1296	91	15	found	find	VERB
ajlm-1296	91	16	an	an	DET
ajlm-1296	91	17	increased	increase	VERB
ajlm-1296	91	18	frequency	frequency	NOUN
ajlm-1296	91	19	of	of	ADP
ajlm-1296	91	20	cd14+/++	cd14+/++	PROPN
ajlm-1296	91	21	cd16	cd16	PROPN
ajlm-1296	91	22	+	+	PROPN
ajlm-1296	91	23	monocytes	monocyte	VERB
ajlm-1296	91	24	in	in	ADP
ajlm-1296	91	25	20	20	NUM
ajlm-1296	91	26	mm	mm	NOUN
ajlm-1296	91	27	patients	patient	NOUN
ajlm-1296	91	28	compared	compare	VERB
ajlm-1296	91	29	to	to	ADP
ajlm-1296	91	30	healthy	healthy	ADJ
ajlm-1296	91	31	volunteers	volunteer	NOUN
ajlm-1296	91	32	;	;	PUNCT
ajlm-1296	91	33	however	however	ADV
ajlm-1296	91	34	,	,	PUNCT
ajlm-1296	91	35	they	they	PRON
ajlm-1296	91	36	did	do	AUX
ajlm-1296	91	37	not	not	PART
ajlm-1296	91	38	find	find	VERB
ajlm-1296	91	39	a	a	DET
ajlm-1296	91	40	correlation	correlation	NOUN
ajlm-1296	91	41	between	between	ADP
ajlm-1296	91	42	the	the	DET
ajlm-1296	91	43	monocyte	monocyte	NOUN
ajlm-1296	91	44	subsets	subset	NOUN
ajlm-1296	91	45	and	and	CCONJ
ajlm-1296	91	46	circulating	circulate	VERB
ajlm-1296	91	47	or	or	CCONJ
ajlm-1296	91	48	bone	bone	NOUN
ajlm-1296	91	49	marrow	marrow	NOUN
ajlm-1296	91	50	plasma	plasma	NOUN
ajlm-1296	91	51	cell	cell	NOUN
ajlm-1296	91	52	counts.15	counts.15	NOUN
ajlm-1296	91	53	similarly	similarly	ADV
ajlm-1296	91	54	,	,	PUNCT
ajlm-1296	91	55	a	a	DET
ajlm-1296	91	56	study	study	NOUN
ajlm-1296	91	57	in	in	ADP
ajlm-1296	91	58	norway	norway	PROPN
ajlm-1296	91	59	in	in	ADP
ajlm-1296	91	60	2015	2015	NUM
ajlm-1296	91	61	found	find	VERB
ajlm-1296	91	62	that	that	SCONJ
ajlm-1296	91	63	the	the	DET
ajlm-1296	91	64	proportion	proportion	NOUN
ajlm-1296	91	65	of	of	ADP
ajlm-1296	91	66	non	non	ADJ
ajlm-1296	91	67	-	-	ADJ
ajlm-1296	91	68	classical	classical	ADJ
ajlm-1296	91	69	monocytes	monocyte	NOUN
ajlm-1296	91	70	increased	increase	VERB
ajlm-1296	91	71	with	with	ADP
ajlm-1296	91	72	tumour	tumour	NOUN
ajlm-1296	91	73	load	load	NOUN
ajlm-1296	91	74	in	in	ADP
ajlm-1296	91	75	mm	mm	PROPN
ajlm-1296	91	76	patients	patient	NOUN
ajlm-1296	91	77	(	(	PUNCT
ajlm-1296	91	78	n	n	NOUN
ajlm-1296	91	79	=	=	NUM
ajlm-1296	91	80	12	12	NUM
ajlm-1296	91	81	)	)	PUNCT
ajlm-1296	91	82	and	and	CCONJ
ajlm-1296	91	83	suggested	suggest	VERB
ajlm-1296	91	84	that	that	SCONJ
ajlm-1296	91	85	non	non	ADJ
ajlm-1296	91	86	-	-	ADJ
ajlm-1296	91	87	classical	classical	ADJ
ajlm-1296	91	88	monocytes	monocyte	NOUN
ajlm-1296	91	89	could	could	AUX
ajlm-1296	91	90	maintain	maintain	VERB
ajlm-1296	91	91	the	the	DET
ajlm-1296	91	92	development	development	NOUN
ajlm-1296	91	93	of	of	ADP
ajlm-1296	91	94	myeloma	myeloma	PROPN
ajlm-1296	91	95	cells.16	cells.16	PROPN
ajlm-1296	91	96	however	however	ADV
ajlm-1296	91	97	,	,	PUNCT
ajlm-1296	91	98	the	the	DET
ajlm-1296	91	99	study	study	NOUN
ajlm-1296	91	100	noted	note	VERB
ajlm-1296	91	101	that	that	SCONJ
ajlm-1296	91	102	the	the	DET
ajlm-1296	91	103	increased	increase	VERB
ajlm-1296	91	104	proportion	proportion	NOUN
ajlm-1296	91	105	of	of	ADP
ajlm-1296	91	106	non	non	ADJ
ajlm-1296	91	107	-	-	ADJ
ajlm-1296	91	108	classical	classical	ADJ
ajlm-1296	91	109	monocytes	monocyte	NOUN
ajlm-1296	91	110	might	might	AUX
ajlm-1296	91	111	be	be	AUX
ajlm-1296	91	112	caused	cause	VERB
ajlm-1296	91	113	by	by	ADP
ajlm-1296	91	114	numerous	numerous	ADJ
ajlm-1296	91	115	mechanisms	mechanism	NOUN
ajlm-1296	91	116	.	.	PUNCT
ajlm-1296	92	1	by	by	ADP
ajlm-1296	92	2	the	the	DET
ajlm-1296	92	3	end	end	NOUN
ajlm-1296	92	4	of	of	ADP
ajlm-1296	92	5	the	the	DET
ajlm-1296	92	6	study	study	NOUN
ajlm-1296	92	7	,	,	PUNCT
ajlm-1296	92	8	the	the	DET
ajlm-1296	92	9	investigators	investigator	NOUN
ajlm-1296	92	10	concluded	conclude	VERB
ajlm-1296	92	11	that	that	SCONJ
ajlm-1296	92	12	the	the	DET
ajlm-1296	92	13	non	non	ADJ
ajlm-1296	92	14	-	-	ADJ
ajlm-1296	92	15	classical	classical	ADJ
ajlm-1296	92	16	subset	subset	NOUN
ajlm-1296	92	17	of	of	ADP
ajlm-1296	92	18	monocytes	monocyte	NOUN
ajlm-1296	92	19	in	in	ADP
ajlm-1296	92	20	patients	patient	NOUN
ajlm-1296	92	21	with	with	ADP
ajlm-1296	92	22	mm	mm	PROPN
ajlm-1296	92	23	are	be	AUX
ajlm-1296	92	24	functional	functional	ADJ
ajlm-1296	92	25	monocytes	monocyte	NOUN
ajlm-1296	92	26	that	that	PRON
ajlm-1296	92	27	could	could	AUX
ajlm-1296	92	28	be	be	AUX
ajlm-1296	92	29	stimulated	stimulate	VERB
ajlm-1296	92	30	to	to	PART
ajlm-1296	92	31	produce	produce	VERB
ajlm-1296	92	32	cytokines	cytokine	NOUN
ajlm-1296	92	33	,	,	PUNCT
ajlm-1296	92	34	and	and	CCONJ
ajlm-1296	92	35	may	may	AUX
ajlm-1296	92	36	enhance	enhance	VERB
ajlm-1296	92	37	myeloma	myeloma	NOUN
ajlm-1296	92	38	expansion	expansion	NOUN
ajlm-1296	92	39	,	,	PUNCT
ajlm-1296	92	40	contributing	contribute	VERB
ajlm-1296	92	41	to	to	ADP
ajlm-1296	92	42	the	the	DET
ajlm-1296	92	43	disease	disease	NOUN
ajlm-1296	92	44	process	process	NOUN
ajlm-1296	92	45	.	.	PUNCT
ajlm-1296	93	1	furthermore	furthermore	ADV
ajlm-1296	93	2	,	,	PUNCT
ajlm-1296	93	3	malignant	malignant	ADJ
ajlm-1296	93	4	plasma	plasma	NOUN
ajlm-1296	93	5	cells	cell	NOUN
ajlm-1296	93	6	yield	yield	VERB
ajlm-1296	93	7	increased	increase	VERB
ajlm-1296	93	8	levels	level	NOUN
ajlm-1296	93	9	of	of	ADP
ajlm-1296	93	10	transforming	transform	VERB
ajlm-1296	93	11	growth	growth	NOUN
ajlm-1296	93	12	factor	factor	NOUN
ajlm-1296	93	13	beta	beta	NOUN
ajlm-1296	93	14	1,21	1,21	NUM
ajlm-1296	93	15	which	which	PRON
ajlm-1296	93	16	hypothetically	hypothetically	ADV
ajlm-1296	93	17	increases	increase	VERB
ajlm-1296	93	18	cd16	cd16	PROPN
ajlm-1296	93	19	expression	expression	NOUN
ajlm-1296	93	20	.	.	PUNCT
ajlm-1296	94	1	therefore	therefore	ADV
ajlm-1296	94	2	,	,	PUNCT
ajlm-1296	94	3	it	it	PRON
ajlm-1296	94	4	is	be	AUX
ajlm-1296	94	5	probable	probable	ADJ
ajlm-1296	94	6	that	that	SCONJ
ajlm-1296	94	7	in	in	ADP
ajlm-1296	94	8	patients	patient	NOUN
ajlm-1296	94	9	with	with	ADP
ajlm-1296	94	10	high	high	ADJ
ajlm-1296	94	11	plasma	plasma	NOUN
ajlm-1296	94	12	cell	cell	NOUN
ajlm-1296	94	13	levels	level	NOUN
ajlm-1296	94	14	,	,	PUNCT
ajlm-1296	94	15	cd14	cd14	PROPN
ajlm-1296	94	16	-	-	PUNCT
ajlm-1296	94	17	high	high	ADJ
ajlm-1296	94	18	cells	cell	NOUN
ajlm-1296	94	19	under	under	ADP
ajlm-1296	94	20	the	the	DET
ajlm-1296	94	21	effect	effect	NOUN
ajlm-1296	94	22	of	of	ADP
ajlm-1296	94	23	transforming	transform	VERB
ajlm-1296	94	24	growth	growth	NOUN
ajlm-1296	94	25	factor	factor	NOUN
ajlm-1296	94	26	beta	beta	NOUN
ajlm-1296	94	27	1	1	NUM
ajlm-1296	94	28	settle	settle	VERB
ajlm-1296	94	29	into	into	ADP
ajlm-1296	94	30	the	the	DET
ajlm-1296	94	31	cd16+cd14dim	cd16+cd14dim	PROPN
ajlm-1296	94	32	cell	cell	NOUN
ajlm-1296	94	33	regions	region	NOUN
ajlm-1296	94	34	.	.	PUNCT
ajlm-1296	95	1	the	the	DET
ajlm-1296	95	2	different	different	ADJ
ajlm-1296	95	3	monocyte	monocyte	NOUN
ajlm-1296	95	4	subset	subset	NOUN
ajlm-1296	95	5	proportions	proportion	NOUN
ajlm-1296	95	6	between	between	ADP
ajlm-1296	95	7	mm	mm	PROPN
ajlm-1296	95	8	patients	patient	NOUN
ajlm-1296	95	9	and	and	CCONJ
ajlm-1296	95	10	healthy	healthy	ADJ
ajlm-1296	95	11	controls	control	NOUN
ajlm-1296	95	12	could	could	AUX
ajlm-1296	95	13	be	be	AUX
ajlm-1296	95	14	explained	explain	VERB
ajlm-1296	95	15	by	by	ADP
ajlm-1296	95	16	several	several	ADJ
ajlm-1296	95	17	mechanisms	mechanism	NOUN
ajlm-1296	95	18	.	.	PUNCT
ajlm-1296	96	1	nucleic	nucleic	ADJ
ajlm-1296	96	2	acids	acid	NOUN
ajlm-1296	96	3	and	and	CCONJ
ajlm-1296	96	4	immune	immune	ADJ
ajlm-1296	96	5	complexes	complex	NOUN
ajlm-1296	96	6	produced	produce	VERB
ajlm-1296	96	7	during	during	ADP
ajlm-1296	96	8	disease	disease	NOUN
ajlm-1296	96	9	mainly	mainly	ADV
ajlm-1296	96	10	encourage	encourage	VERB
ajlm-1296	96	11	the	the	DET
ajlm-1296	96	12	production	production	NOUN
ajlm-1296	96	13	of	of	ADP
ajlm-1296	96	14	intermediate	intermediate	ADJ
ajlm-1296	96	15	and	and	CCONJ
ajlm-1296	96	16	non	non	ADJ
ajlm-1296	96	17	-	-	ADJ
ajlm-1296	96	18	classical	classical	ADJ
ajlm-1296	96	19	monocyte	monocyte	NOUN
ajlm-1296	96	20	subsets	subset	NOUN
ajlm-1296	96	21	,	,	PUNCT
ajlm-1296	96	22	and	and	CCONJ
ajlm-1296	96	23	these	these	DET
ajlm-1296	96	24	yield	yield	NOUN
ajlm-1296	96	25	interleukins	interleukin	VERB
ajlm-1296	96	26	to	to	PART
ajlm-1296	96	27	maintain	maintain	VERB
ajlm-1296	96	28	myeloma	myeloma	NOUN
ajlm-1296	96	29	growth	growth	NOUN
ajlm-1296	96	30	in	in	ADP
ajlm-1296	96	31	mm	mm	PROPN
ajlm-1296	96	32	patients.14	patients.14	PROPN
ajlm-1296	96	33	also	also	ADV
ajlm-1296	96	34	,	,	PUNCT
ajlm-1296	96	35	higher	high	ADJ
ajlm-1296	96	36	proportions	proportion	NOUN
ajlm-1296	96	37	of	of	ADP
ajlm-1296	96	38	the	the	DET
ajlm-1296	96	39	non	non	ADJ
ajlm-1296	96	40	-	-	ADJ
ajlm-1296	96	41	classical	classical	ADJ
ajlm-1296	96	42	subset	subset	NOUN
ajlm-1296	96	43	of	of	ADP
ajlm-1296	96	44	monocytes	monocyte	NOUN
ajlm-1296	96	45	could	could	AUX
ajlm-1296	96	46	be	be	AUX
ajlm-1296	96	47	produced	produce	VERB
ajlm-1296	96	48	by	by	ADP
ajlm-1296	96	49	numerous	numerous	ADJ
ajlm-1296	96	50	mechanisms	mechanism	NOUN
ajlm-1296	96	51	such	such	ADJ
ajlm-1296	96	52	as	as	ADP
ajlm-1296	96	53	stimulation	stimulation	NOUN
ajlm-1296	96	54	by	by	ADP
ajlm-1296	96	55	m	m	NOUN
ajlm-1296	96	56	-	-	NOUN
ajlm-1296	96	57	protein	protein	NOUN
ajlm-1296	96	58	,	,	PUNCT
ajlm-1296	96	59	which	which	PRON
ajlm-1296	96	60	is	be	AUX
ajlm-1296	96	61	produced	produce	VERB
ajlm-1296	96	62	by	by	ADP
ajlm-1296	96	63	the	the	DET
ajlm-1296	96	64	malignant	malignant	ADJ
ajlm-1296	96	65	plasma	plasma	NOUN
ajlm-1296	96	66	cells,16	cells,16	VERB
ajlm-1296	96	67	as	as	SCONJ
ajlm-1296	96	68	myeloma	myeloma	NOUN
ajlm-1296	96	69	cells	cell	NOUN
ajlm-1296	96	70	secrete	secrete	VERB
ajlm-1296	96	71	higher	high	ADJ
ajlm-1296	96	72	quantities	quantity	NOUN
ajlm-1296	96	73	of	of	ADP
ajlm-1296	96	74	immunoglobulins.9	immunoglobulins.9	PROPN
ajlm-1296	96	75	further	further	ADJ
ajlm-1296	96	76	studies	study	NOUN
ajlm-1296	96	77	are	be	AUX
ajlm-1296	96	78	necessary	necessary	ADJ
ajlm-1296	96	79	to	to	PART
ajlm-1296	96	80	understand	understand	VERB
ajlm-1296	96	81	the	the	DET
ajlm-1296	96	82	mechanisms	mechanism	NOUN
ajlm-1296	96	83	behind	behind	ADP
ajlm-1296	96	84	these	these	DET
ajlm-1296	96	85	skewed	skewed	ADJ
ajlm-1296	96	86	monocyte	monocyte	NOUN
ajlm-1296	96	87	subpopulation	subpopulation	NOUN
ajlm-1296	96	88	frequencies	frequency	NOUN
ajlm-1296	96	89	and	and	CCONJ
ajlm-1296	96	90	whether	whether	SCONJ
ajlm-1296	96	91	it	it	PRON
ajlm-1296	96	92	is	be	AUX
ajlm-1296	96	93	a	a	DET
ajlm-1296	96	94	cause	cause	NOUN
ajlm-1296	96	95	of	of	ADP
ajlm-1296	96	96	disease	disease	NOUN
ajlm-1296	96	97	severity	severity	NOUN
ajlm-1296	96	98	.	.	PUNCT
ajlm-1296	97	1	multiple	multiple	ADJ
ajlm-1296	97	2	myeloma	myeloma	NOUN
ajlm-1296	97	3	patients	patient	NOUN
ajlm-1296	97	4	had	have	VERB
ajlm-1296	97	5	lower	low	ADJ
ajlm-1296	97	6	levels	level	NOUN
ajlm-1296	97	7	of	of	ADP
ajlm-1296	97	8	haemoglobin	haemoglobin	NOUN
ajlm-1296	97	9	,	,	PUNCT
ajlm-1296	97	10	albumin	albumin	NOUN
ajlm-1296	97	11	,	,	PUNCT
ajlm-1296	97	12	and	and	CCONJ
ajlm-1296	97	13	calcium	calcium	NOUN
ajlm-1296	97	14	when	when	SCONJ
ajlm-1296	97	15	compared	compare	VERB
ajlm-1296	97	16	to	to	ADP
ajlm-1296	97	17	healthy	healthy	ADJ
ajlm-1296	97	18	control	control	NOUN
ajlm-1296	97	19	volunteers	volunteer	NOUN
ajlm-1296	97	20	(	(	PUNCT
ajlm-1296	97	21	p	p	X
ajlm-1296	97	22	=	=	PUNCT
ajlm-1296	97	23	0.045	0.045	NUM
ajlm-1296	97	24	,	,	PUNCT
ajlm-1296	97	25	p	p	X
ajlm-1296	97	26	<	<	X
ajlm-1296	97	27	0.0001	0.0001	NUM
ajlm-1296	97	28	,	,	PUNCT
ajlm-1296	97	29	and	and	CCONJ
ajlm-1296	97	30	p	p	X
ajlm-1296	97	31	<	<	X
ajlm-1296	97	32	0.0001	0.0001	NUM
ajlm-1296	97	33	)	)	PUNCT
ajlm-1296	97	34	.	.	PUNCT
ajlm-1296	98	1	parts	part	NOUN
ajlm-1296	98	2	of	of	ADP
ajlm-1296	98	3	these	these	DET
ajlm-1296	98	4	findings	finding	NOUN
ajlm-1296	98	5	are	be	AUX
ajlm-1296	98	6	in	in	ADP
ajlm-1296	98	7	agreement	agreement	NOUN
ajlm-1296	98	8	with	with	ADP
ajlm-1296	98	9	a	a	DET
ajlm-1296	98	10	study	study	NOUN
ajlm-1296	98	11	conducted	conduct	VERB
ajlm-1296	98	12	in	in	ADP
ajlm-1296	98	13	austria	austria	PROPN
ajlm-1296	98	14	in	in	ADP
ajlm-1296	98	15	2010	2010	NUM
ajlm-1296	98	16	which	which	PRON
ajlm-1296	98	17	reported	report	VERB
ajlm-1296	98	18	that	that	SCONJ
ajlm-1296	98	19	most	most	ADJ
ajlm-1296	98	20	mm	mm	NUM
ajlm-1296	98	21	cases	case	NOUN
ajlm-1296	98	22	had	have	VERB
ajlm-1296	98	23	anaemia	anaemia	NOUN
ajlm-1296	98	24	of	of	ADP
ajlm-1296	98	25	variable	variable	ADJ
ajlm-1296	98	26	severity.22	severity.22	NOUN
ajlm-1296	98	27	similarly	similarly	ADV
ajlm-1296	98	28	,	,	PUNCT
ajlm-1296	98	29	in	in	ADP
ajlm-1296	98	30	a	a	DET
ajlm-1296	98	31	study	study	NOUN
ajlm-1296	98	32	conducted	conduct	VERB
ajlm-1296	98	33	in	in	ADP
ajlm-1296	98	34	the	the	DET
ajlm-1296	98	35	united	united	PROPN
ajlm-1296	98	36	states	states	PROPN
ajlm-1296	98	37	in	in	ADP
ajlm-1296	98	38	1982,23	1982,23	NUM
ajlm-1296	98	39	we	we	PRON
ajlm-1296	98	40	found	find	VERB
ajlm-1296	98	41	no	no	DET
ajlm-1296	98	42	differences	difference	NOUN
ajlm-1296	98	43	between	between	ADP
ajlm-1296	98	44	the	the	DET
ajlm-1296	98	45	platelet	platelet	NOUN
ajlm-1296	98	46	count	count	NOUN
ajlm-1296	98	47	and	and	CCONJ
ajlm-1296	98	48	total	total	ADJ
ajlm-1296	98	49	leukocytic	leukocytic	ADJ
ajlm-1296	98	50	count	count	NOUN
ajlm-1296	98	51	in	in	ADP
ajlm-1296	98	52	mm	mm	NOUN
ajlm-1296	98	53	cases	case	NOUN
ajlm-1296	98	54	and	and	CCONJ
ajlm-1296	98	55	healthy	healthy	ADJ
ajlm-1296	98	56	controls	control	NOUN
ajlm-1296	98	57	.	.	PUNCT
ajlm-1296	99	1	the	the	DET
ajlm-1296	99	2	urea	urea	NOUN
ajlm-1296	99	3	levels	level	NOUN
ajlm-1296	99	4	were	be	AUX
ajlm-1296	99	5	comparable	comparable	ADJ
ajlm-1296	99	6	among	among	ADP
ajlm-1296	99	7	mm	mm	PROPN
ajlm-1296	99	8	patients	patient	NOUN
ajlm-1296	99	9	and	and	CCONJ
ajlm-1296	99	10	controls	control	NOUN
ajlm-1296	99	11	,	,	PUNCT
ajlm-1296	99	12	while	while	SCONJ
ajlm-1296	99	13	the	the	DET
ajlm-1296	99	14	serum	serum	NOUN
ajlm-1296	99	15	creatinine	creatinine	NOUN
ajlm-1296	99	16	levels	level	NOUN
ajlm-1296	99	17	were	be	AUX
ajlm-1296	99	18	significantly	significantly	ADV
ajlm-1296	99	19	higher	high	ADJ
ajlm-1296	99	20	in	in	ADP
ajlm-1296	99	21	mm	mm	PROPN
ajlm-1296	99	22	patients	patient	NOUN
ajlm-1296	99	23	compared	compare	VERB
ajlm-1296	99	24	to	to	ADP
ajlm-1296	99	25	controls	control	NOUN
ajlm-1296	99	26	(	(	PUNCT
ajlm-1296	99	27	p	p	X
ajlm-1296	99	28	<	<	X
ajlm-1296	99	29	0.0001	0.0001	NUM
ajlm-1296	99	30	)	)	PUNCT
ajlm-1296	99	31	;	;	PUNCT
ajlm-1296	99	32	this	this	PRON
ajlm-1296	99	33	is	be	AUX
ajlm-1296	99	34	in	in	ADP
ajlm-1296	99	35	contrast	contrast	NOUN
ajlm-1296	99	36	to	to	ADP
ajlm-1296	99	37	previous	previous	ADJ
ajlm-1296	99	38	reports	report	NOUN
ajlm-1296	99	39	that	that	PRON
ajlm-1296	99	40	found	find	VERB
ajlm-1296	99	41	variable	variable	ADJ
ajlm-1296	99	42	degrees	degree	NOUN
ajlm-1296	99	43	of	of	ADP
ajlm-1296	99	44	renal	renal	ADJ
ajlm-1296	99	45	impairment	impairment	NOUN
ajlm-1296	99	46	in	in	ADP
ajlm-1296	99	47	patients	patient	NOUN
ajlm-1296	99	48	with	with	ADP
ajlm-1296	99	49	mm.24,25	mm.24,25	PROPN
ajlm-1296	99	50	lactate	lactate	PROPN
ajlm-1296	99	51	dehydrogenase	dehydrogenase	NOUN
ajlm-1296	99	52	was	be	AUX
ajlm-1296	99	53	significantly	significantly	ADV
ajlm-1296	99	54	increased	increase	VERB
ajlm-1296	99	55	in	in	ADP
ajlm-1296	99	56	mm	mm	PROPN
ajlm-1296	99	57	patients	patient	NOUN
ajlm-1296	99	58	versus	versus	ADP
ajlm-1296	99	59	controls	control	NOUN
ajlm-1296	99	60	(	(	PUNCT
ajlm-1296	99	61	p	p	X
ajlm-1296	99	62	<	<	X
ajlm-1296	99	63	0.0001	0.0001	NUM
ajlm-1296	99	64	)	)	PUNCT
ajlm-1296	99	65	,	,	PUNCT
ajlm-1296	99	66	as	as	SCONJ
ajlm-1296	99	67	previously	previously	ADV
ajlm-1296	99	68	reported.26	reported.26	VERB
ajlm-1296	99	69	the	the	DET
ajlm-1296	99	70	proportion	proportion	NOUN
ajlm-1296	99	71	of	of	ADP
ajlm-1296	99	72	plasma	plasma	NOUN
ajlm-1296	99	73	cells	cell	NOUN
ajlm-1296	99	74	in	in	ADP
ajlm-1296	99	75	bone	bone	NOUN
ajlm-1296	99	76	marrow	marrow	NOUN
ajlm-1296	99	77	was	be	AUX
ajlm-1296	99	78	39.7	39.7	NUM
ajlm-1296	99	79	±	±	NUM
ajlm-1296	99	80	3.7	3.7	NUM
ajlm-1296	99	81	%	%	NOUN
ajlm-1296	99	82	and	and	CCONJ
ajlm-1296	99	83	that	that	PRON
ajlm-1296	99	84	of	of	ADP
ajlm-1296	99	85	the	the	DET
ajlm-1296	99	86	monoclonal	monoclonal	NOUN
ajlm-1296	99	87	band	band	NOUN
ajlm-1296	99	88	(	(	PUNCT
ajlm-1296	99	89	m	m	NOUN
ajlm-1296	99	90	-	-	NOUN
ajlm-1296	99	91	protein	protein	NOUN
ajlm-1296	99	92	)	)	PUNCT
ajlm-1296	99	93	was	be	AUX
ajlm-1296	99	94	44.4	44.4	NUM
ajlm-1296	99	95	±	±	NUM
ajlm-1296	99	96	2.8	2.8	NUM
ajlm-1296	99	97	g	g	NOUN
ajlm-1296	99	98	/	/	SYM
ajlm-1296	99	99	l	l	NOUN
ajlm-1296	99	100	,	,	PUNCT
ajlm-1296	99	101	comparable	comparable	ADJ
ajlm-1296	99	102	with	with	ADP
ajlm-1296	99	103	that	that	PRON
ajlm-1296	99	104	of	of	ADP
ajlm-1296	99	105	previous	previous	ADJ
ajlm-1296	99	106	reports.16	reports.16	PROPN
ajlm-1296	99	107	limitations	limitation	NOUN
ajlm-1296	99	108	one	one	NUM
ajlm-1296	99	109	limitation	limitation	NOUN
ajlm-1296	99	110	of	of	ADP
ajlm-1296	99	111	this	this	DET
ajlm-1296	99	112	study	study	NOUN
ajlm-1296	99	113	was	be	AUX
ajlm-1296	99	114	the	the	DET
ajlm-1296	99	115	small	small	ADJ
ajlm-1296	99	116	sample	sample	NOUN
ajlm-1296	99	117	size	size	NOUN
ajlm-1296	99	118	,	,	PUNCT
ajlm-1296	99	119	but	but	CCONJ
ajlm-1296	99	120	these	these	DET
ajlm-1296	99	121	initial	initial	ADJ
ajlm-1296	99	122	results	result	NOUN
ajlm-1296	99	123	provide	provide	VERB
ajlm-1296	99	124	new	new	ADJ
ajlm-1296	99	125	perspectives	perspective	NOUN
ajlm-1296	99	126	on	on	ADP
ajlm-1296	99	127	the	the	DET
ajlm-1296	99	128	diagnosis	diagnosis	NOUN
ajlm-1296	99	129	and	and	CCONJ
ajlm-1296	99	130	monitoring	monitoring	NOUN
ajlm-1296	99	131	of	of	ADP
ajlm-1296	99	132	mm	mm	PROPN
ajlm-1296	99	133	.	.	PUNCT
ajlm-1296	100	1	conclusion	conclusion	NOUN
ajlm-1296	100	2	the	the	DET
ajlm-1296	100	3	higher	high	ADJ
ajlm-1296	100	4	frequencies	frequency	NOUN
ajlm-1296	100	5	of	of	ADP
ajlm-1296	100	6	non	non	ADJ
ajlm-1296	100	7	-	-	ADJ
ajlm-1296	100	8	classical	classical	ADJ
ajlm-1296	100	9	and	and	CCONJ
ajlm-1296	100	10	intermediate	intermediate	ADJ
ajlm-1296	100	11	monocytes	monocyte	NOUN
ajlm-1296	100	12	in	in	ADP
ajlm-1296	100	13	newly	newly	ADV
ajlm-1296	100	14	diagnosed	diagnose	VERB
ajlm-1296	100	15	untreated	untreated	ADJ
ajlm-1296	100	16	mm	mm	PROPN
ajlm-1296	100	17	patients	patient	NOUN
ajlm-1296	100	18	suggest	suggest	VERB
ajlm-1296	100	19	a	a	DET
ajlm-1296	100	20	possible	possible	ADJ
ajlm-1296	100	21	role	role	NOUN
ajlm-1296	100	22	of	of	ADP
ajlm-1296	100	23	these	these	DET
ajlm-1296	100	24	cells	cell	NOUN
ajlm-1296	100	25	rather	rather	ADV
ajlm-1296	100	26	than	than	ADP
ajlm-1296	100	27	classical	classical	ADJ
ajlm-1296	100	28	monocytes	monocyte	NOUN
ajlm-1296	100	29	in	in	ADP
ajlm-1296	100	30	the	the	DET
ajlm-1296	100	31	disease	disease	NOUN
ajlm-1296	100	32	process	process	NOUN
ajlm-1296	100	33	.	.	PUNCT
ajlm-1296	101	1	the	the	DET
ajlm-1296	101	2	participation	participation	NOUN
ajlm-1296	101	3	of	of	ADP
ajlm-1296	101	4	these	these	DET
ajlm-1296	101	5	monocyte	monocyte	NOUN
ajlm-1296	101	6	subsets	subset	NOUN
ajlm-1296	101	7	in	in	ADP
ajlm-1296	101	8	mm	mm	PROPN
ajlm-1296	101	9	pathogenesis	pathogenesis	NOUN
ajlm-1296	101	10	should	should	AUX
ajlm-1296	101	11	thus	thus	ADV
ajlm-1296	101	12	be	be	AUX
ajlm-1296	101	13	part	part	NOUN
ajlm-1296	101	14	of	of	ADP
ajlm-1296	101	15	future	future	ADJ
ajlm-1296	101	16	investigations	investigation	NOUN
ajlm-1296	101	17	as	as	SCONJ
ajlm-1296	101	18	they	they	PRON
ajlm-1296	101	19	may	may	AUX
ajlm-1296	101	20	provide	provide	VERB
ajlm-1296	101	21	important	important	ADJ
ajlm-1296	101	22	information	information	NOUN
ajlm-1296	101	23	for	for	ADP
ajlm-1296	101	24	the	the	DET
ajlm-1296	101	25	diagnosis	diagnosis	NOUN
ajlm-1296	101	26	and	and	CCONJ
ajlm-1296	101	27	follow	follow	VERB
ajlm-1296	101	28	-	-	PUNCT
ajlm-1296	101	29	up	up	NOUN
ajlm-1296	101	30	of	of	ADP
ajlm-1296	101	31	mm	mm	PROPN
ajlm-1296	101	32	patients	patient	NOUN
ajlm-1296	101	33	.	.	PUNCT
ajlm-1296	102	1	more	more	ADJ
ajlm-1296	102	2	studies	study	NOUN
ajlm-1296	102	3	are	be	AUX
ajlm-1296	102	4	needed	need	VERB
ajlm-1296	102	5	to	to	PART
ajlm-1296	102	6	address	address	VERB
ajlm-1296	102	7	the	the	DET
ajlm-1296	102	8	possibility	possibility	NOUN
ajlm-1296	102	9	of	of	ADP
ajlm-1296	102	10	using	use	VERB
ajlm-1296	102	11	flow	flow	NOUN
ajlm-1296	102	12	cytometry	cytometry	NOUN
ajlm-1296	102	13	results	result	NOUN
ajlm-1296	102	14	as	as	ADP
ajlm-1296	102	15	a	a	DET
ajlm-1296	102	16	primary	primary	ADJ
ajlm-1296	102	17	staging	staging	NOUN
ajlm-1296	102	18	criterion	criterion	NOUN
ajlm-1296	102	19	.	.	PUNCT
ajlm-1296	103	1	acknowledgements	acknowledgement	NOUN
ajlm-1296	103	2	competing	compete	VERB
ajlm-1296	103	3	interests	interest	NOUN
ajlm-1296	103	4	the	the	DET
ajlm-1296	103	5	authors	author	NOUN
ajlm-1296	103	6	declare	declare	VERB
ajlm-1296	103	7	that	that	SCONJ
ajlm-1296	103	8	they	they	PRON
ajlm-1296	103	9	have	have	VERB
ajlm-1296	103	10	no	no	DET
ajlm-1296	103	11	financial	financial	ADJ
ajlm-1296	103	12	or	or	CCONJ
ajlm-1296	103	13	personal	personal	ADJ
ajlm-1296	103	14	relationships	relationship	NOUN
ajlm-1296	103	15	that	that	PRON
ajlm-1296	103	16	may	may	AUX
ajlm-1296	103	17	have	have	AUX
ajlm-1296	103	18	inappropriately	inappropriately	ADV
ajlm-1296	103	19	influenced	influence	VERB
ajlm-1296	103	20	them	they	PRON
ajlm-1296	103	21	in	in	ADP
ajlm-1296	103	22	writing	write	VERB
ajlm-1296	103	23	this	this	DET
ajlm-1296	103	24	article	article	NOUN
ajlm-1296	103	25	.	.	PUNCT
ajlm-1296	104	1	authors	author	NOUN
ajlm-1296	104	2	’	’	PART
ajlm-1296	104	3	contributions	contribution	NOUN
ajlm-1296	104	4	s.m.m	s.m.m	VERB
ajlm-1296	104	5	.	.	PUNCT
ajlm-1296	104	6	,	,	PUNCT
ajlm-1296	104	7	h.n.-h	h.n.-h	PROPN
ajlm-1296	104	8	.	.	PROPN
ajlm-1296	104	9	,	,	PUNCT
ajlm-1296	104	10	h.a.e	h.a.e	ADP
ajlm-1296	104	11	.	.	PUNCT
ajlm-1296	104	12	,	,	PUNCT
ajlm-1296	104	13	m.m.w	m.m.w	NOUN
ajlm-1296	104	14	.	.	PUNCT
ajlm-1296	104	15	and	and	CCONJ
ajlm-1296	104	16	a.m.z	a.m.z	NOUN
ajlm-1296	104	17	.	.	PUNCT
ajlm-1296	105	1	performed	perform	VERB
ajlm-1296	105	2	the	the	DET
ajlm-1296	105	3	research	research	NOUN
ajlm-1296	105	4	,	,	PUNCT
ajlm-1296	105	5	designed	design	VERB
ajlm-1296	105	6	the	the	DET
ajlm-1296	105	7	study	study	NOUN
ajlm-1296	105	8	,	,	PUNCT
ajlm-1296	105	9	analysed	analyse	VERB
ajlm-1296	105	10	the	the	DET
ajlm-1296	105	11	data	datum	NOUN
ajlm-1296	105	12	,	,	PUNCT
ajlm-1296	105	13	and	and	CCONJ
ajlm-1296	105	14	wrote	write	VERB
ajlm-1296	105	15	the	the	DET
ajlm-1296	105	16	manuscript	manuscript	NOUN
ajlm-1296	105	17	.	.	PUNCT
ajlm-1296	106	1	a.m.z	a.m.z	NOUN
ajlm-1296	106	2	.	.	PUNCT
ajlm-1296	107	1	and	and	CCONJ
ajlm-1296	107	2	a.n	a.n	PROPN
ajlm-1296	107	3	.	.	PROPN
ajlm-1296	107	4	performed	perform	VERB
ajlm-1296	107	5	the	the	DET
ajlm-1296	107	6	flowcytometric	flowcytometric	ADJ
ajlm-1296	107	7	study	study	NOUN
ajlm-1296	107	8	design	design	NOUN
ajlm-1296	107	9	and	and	CCONJ
ajlm-1296	107	10	analysis	analysis	NOUN
ajlm-1296	107	11	.	.	PUNCT
ajlm-1296	108	1	s.m.m	s.m.m	PROPN
ajlm-1296	108	2	.	.	PUNCT
ajlm-1296	108	3	,	,	PUNCT
ajlm-1296	108	4	a.n	a.n	PROPN
ajlm-1296	108	5	,	,	PUNCT
ajlm-1296	108	6	h.n.-h	h.n.-h	PROPN
ajlm-1296	108	7	.	.	PROPN
ajlm-1296	108	8	m.m.w	m.m.w	PROPN
ajlm-1296	108	9	.	.	PUNCT
ajlm-1296	108	10	and	and	CCONJ
ajlm-1296	108	11	a.m.z	a.m.z	NOUN
ajlm-1296	108	12	.	.	PUNCT
ajlm-1296	109	1	revised	revise	VERB
ajlm-1296	109	2	the	the	DET
ajlm-1296	109	3	article	article	NOUN
ajlm-1296	109	4	and	and	CCONJ
ajlm-1296	109	5	approved	approve	VERB
ajlm-1296	109	6	the	the	DET
ajlm-1296	109	7	final	final	ADJ
ajlm-1296	109	8	manuscript	manuscript	NOUN
ajlm-1296	109	9	.	.	PUNCT
ajlm-1296	110	1	sources	source	NOUN
ajlm-1296	110	2	of	of	ADP
ajlm-1296	110	3	support	support	NOUN
ajlm-1296	110	4	this	this	DET
ajlm-1296	110	5	research	research	NOUN
ajlm-1296	110	6	received	receive	VERB
ajlm-1296	110	7	no	no	DET
ajlm-1296	110	8	specific	specific	ADJ
ajlm-1296	110	9	grants	grant	NOUN
ajlm-1296	110	10	from	from	ADP
ajlm-1296	110	11	any	any	DET
ajlm-1296	110	12	funding	funding	NOUN
ajlm-1296	110	13	agency	agency	NOUN
ajlm-1296	110	14	in	in	ADP
ajlm-1296	110	15	the	the	DET
ajlm-1296	110	16	public	public	ADJ
ajlm-1296	110	17	,	,	PUNCT
ajlm-1296	110	18	commercial	commercial	ADJ
ajlm-1296	110	19	,	,	PUNCT
ajlm-1296	110	20	or	or	CCONJ
ajlm-1296	110	21	not	not	PART
ajlm-1296	110	22	-	-	PUNCT
ajlm-1296	110	23	for	for	ADP
ajlm-1296	110	24	-	-	PUNCT
ajlm-1296	110	25	profit	profit	NOUN
ajlm-1296	110	26	sectors	sector	NOUN
ajlm-1296	110	27	.	.	PUNCT
ajlm-1296	111	1	data	datum	NOUN
ajlm-1296	111	2	availability	availability	NOUN
ajlm-1296	111	3	data	datum	NOUN
ajlm-1296	111	4	are	be	AUX
ajlm-1296	111	5	available	available	ADJ
ajlm-1296	111	6	from	from	ADP
ajlm-1296	111	7	the	the	DET
ajlm-1296	111	8	corresponding	corresponding	ADJ
ajlm-1296	111	9	author	author	NOUN
ajlm-1296	111	10	upon	upon	SCONJ
ajlm-1296	111	11	request	request	NOUN
ajlm-1296	111	12	after	after	ADP
ajlm-1296	111	13	approval	approval	NOUN
ajlm-1296	111	14	of	of	ADP
ajlm-1296	111	15	the	the	DET
ajlm-1296	111	16	authors	author	NOUN
ajlm-1296	111	17	’	’	PART
ajlm-1296	111	18	governmental	governmental	ADJ
ajlm-1296	111	19	university	university	NOUN
ajlm-1296	111	20	leaders	leader	NOUN
ajlm-1296	111	21	.	.	PUNCT
ajlm-1296	112	1	disclaimer	disclaimer	VERB
ajlm-1296	112	2	the	the	DET
ajlm-1296	112	3	views	view	NOUN
ajlm-1296	112	4	and	and	CCONJ
ajlm-1296	112	5	opinions	opinion	NOUN
ajlm-1296	112	6	expressed	express	VERB
ajlm-1296	112	7	in	in	ADP
ajlm-1296	112	8	this	this	DET
ajlm-1296	112	9	article	article	NOUN
ajlm-1296	112	10	are	be	AUX
ajlm-1296	112	11	those	those	PRON
ajlm-1296	112	12	of	of	ADP
ajlm-1296	112	13	the	the	DET
ajlm-1296	112	14	authors	author	NOUN
ajlm-1296	112	15	and	and	CCONJ
ajlm-1296	112	16	do	do	AUX
ajlm-1296	112	17	not	not	PART
ajlm-1296	112	18	necessarily	necessarily	ADV
ajlm-1296	112	19	reflect	reflect	VERB
ajlm-1296	112	20	the	the	DET
ajlm-1296	112	21	official	official	ADJ
ajlm-1296	112	22	policy	policy	NOUN
ajlm-1296	112	23	or	or	CCONJ
ajlm-1296	112	24	position	position	NOUN
ajlm-1296	112	25	of	of	ADP
ajlm-1296	112	26	any	any	DET
ajlm-1296	112	27	affiliated	affiliated	ADJ
ajlm-1296	112	28	agency	agency	NOUN
ajlm-1296	112	29	of	of	ADP
ajlm-1296	112	30	the	the	DET
ajlm-1296	112	31	authors	author	NOUN
ajlm-1296	112	32	.	.	PUNCT
ajlm-1296	113	1	references	reference	NOUN
ajlm-1296	113	2	landgren	landgren	PROPN
ajlm-1296	113	3	o	o	PROPN
ajlm-1296	113	4	,	,	PUNCT
ajlm-1296	113	5	kyle	kyle	PROPN
ajlm-1296	113	6	ra	ra	PROPN
ajlm-1296	113	7	.	.	PUNCT
ajlm-1296	114	1	multiple	multiple	ADJ
ajlm-1296	114	2	myeloma	myeloma	NOUN
ajlm-1296	114	3	,	,	PUNCT
ajlm-1296	114	4	chronic	chronic	ADJ
ajlm-1296	114	5	lymphocytic	lymphocytic	ADJ
ajlm-1296	114	6	leukaemia	leukaemia	NOUN
ajlm-1296	114	7	and	and	CCONJ
ajlm-1296	114	8	associated	associated	ADJ
ajlm-1296	114	9	precursor	precursor	NOUN
ajlm-1296	114	10	diseases	disease	NOUN
ajlm-1296	114	11	.	.	PUNCT
ajlm-1296	115	1	br	br	PROPN
ajlm-1296	115	2	j	j	PROPN
ajlm-1296	115	3	haematol	haematol	NOUN
ajlm-1296	115	4	.	.	PUNCT
ajlm-1296	116	1	2007;139(5):717–723	2007;139(5):717–723	X
ajlm-1296	116	2	.	.	PUNCT
ajlm-1296	116	3	https://doi.org/10.1111/j.1365-2141.2007.06866.x	https://doi.org/10.1111/j.1365-2141.2007.06866.x	X
ajlm-1296	116	4	pessoa	pessoa	PROPN
ajlm-1296	116	5	de	de	PROPN
ajlm-1296	116	6	magalhaes	magalhaes	PROPN
ajlm-1296	116	7	rj	rj	PROPN
ajlm-1296	116	8	,	,	PUNCT
ajlm-1296	116	9	vidriales	vidriale	NOUN
ajlm-1296	116	10	mb	mb	PROPN
ajlm-1296	116	11	,	,	PUNCT
ajlm-1296	116	12	paiva	paiva	PROPN
ajlm-1296	116	13	b	b	PROPN
ajlm-1296	116	14	,	,	PUNCT
ajlm-1296	116	15	et	et	PROPN
ajlm-1296	116	16	al	al	PROPN
ajlm-1296	116	17	.	.	PUNCT
ajlm-1296	117	1	analysis	analysis	NOUN
ajlm-1296	117	2	of	of	ADP
ajlm-1296	117	3	the	the	DET
ajlm-1296	117	4	immune	immune	ADJ
ajlm-1296	117	5	system	system	NOUN
ajlm-1296	117	6	of	of	ADP
ajlm-1296	117	7	multiple	multiple	ADJ
ajlm-1296	117	8	myeloma	myeloma	NOUN
ajlm-1296	117	9	patients	patient	NOUN
ajlm-1296	117	10	achieving	achieve	VERB
ajlm-1296	117	11	long	long	ADJ
ajlm-1296	117	12	-	-	PUNCT
ajlm-1296	117	13	term	term	NOUN
ajlm-1296	117	14	disease	disease	NOUN
ajlm-1296	117	15	control	control	NOUN
ajlm-1296	117	16	by	by	ADP
ajlm-1296	117	17	multidimensional	multidimensional	ADJ
ajlm-1296	117	18	flow	flow	NOUN
ajlm-1296	117	19	cytometry	cytometry	NOUN
ajlm-1296	117	20	.	.	PUNCT
ajlm-1296	118	1	haematologica	haematologica	PROPN
ajlm-1296	118	2	.	.	PUNCT
ajlm-1296	119	1	2013;98(1):79–86	2013;98(1):79–86	NUM
ajlm-1296	119	2	.	.	PUNCT
ajlm-1296	120	1	https://doi.org/10.3324/haematol.2012.067272	https://doi.org/10.3324/haematol.2012.067272	PROPN
ajlm-1296	120	2	suyani	suyani	PROPN
ajlm-1296	120	3	e	e	PROPN
ajlm-1296	120	4	,	,	PUNCT
ajlm-1296	120	5	sucak	sucak	PROPN
ajlm-1296	120	6	gt	gt	PROPN
ajlm-1296	120	7	,	,	PUNCT
ajlm-1296	120	8	akyurek	akyurek	NOUN
ajlm-1296	120	9	n	n	CCONJ
ajlm-1296	120	10	,	,	PUNCT
ajlm-1296	120	11	et	et	PROPN
ajlm-1296	120	12	al	al	PROPN
ajlm-1296	120	13	.	.	PUNCT
ajlm-1296	120	14	tumor	tumor	NOUN
ajlm-1296	120	15	-	-	PUNCT
ajlm-1296	120	16	associated	associate	VERB
ajlm-1296	120	17	macrophages	macrophage	NOUN
ajlm-1296	120	18	as	as	ADP
ajlm-1296	120	19	a	a	DET
ajlm-1296	120	20	prognostic	prognostic	ADJ
ajlm-1296	120	21	parameter	parameter	NOUN
ajlm-1296	120	22	in	in	ADP
ajlm-1296	120	23	multiple	multiple	ADJ
ajlm-1296	120	24	myeloma	myeloma	NOUN
ajlm-1296	120	25	.	.	PUNCT
ajlm-1296	121	1	ann	ann	PROPN
ajlm-1296	121	2	hematol	hematol	NOUN
ajlm-1296	121	3	.	.	PUNCT
ajlm-1296	122	1	2013;92(5):669–677	2013;92(5):669–677	X
ajlm-1296	122	2	.	.	X
ajlm-1296	122	3	https://doi.org/10.1007/s00277-012-1652-6	https://doi.org/10.1007/s00277-012-1652-6	PROPN
ajlm-1296	123	1	kim	kim	PROPN
ajlm-1296	123	2	j	j	PROPN
ajlm-1296	123	3	,	,	PUNCT
ajlm-1296	123	4	denu	denu	PROPN
ajlm-1296	123	5	ra	ra	PROPN
ajlm-1296	123	6	,	,	PUNCT
ajlm-1296	123	7	dollar	dollar	PROPN
ajlm-1296	123	8	ba	ba	PROPN
ajlm-1296	123	9	,	,	PUNCT
ajlm-1296	123	10	et	et	PROPN
ajlm-1296	123	11	al	al	PROPN
ajlm-1296	123	12	.	.	PUNCT
ajlm-1296	123	13	macrophages	macrophage	NOUN
ajlm-1296	123	14	and	and	CCONJ
ajlm-1296	123	15	mesenchymal	mesenchymal	ADJ
ajlm-1296	123	16	stromal	stromal	ADJ
ajlm-1296	123	17	cells	cell	NOUN
ajlm-1296	123	18	support	support	VERB
ajlm-1296	123	19	survival	survival	NOUN
ajlm-1296	123	20	and	and	CCONJ
ajlm-1296	123	21	proliferation	proliferation	NOUN
ajlm-1296	123	22	of	of	ADP
ajlm-1296	123	23	multiple	multiple	ADJ
ajlm-1296	123	24	myeloma	myeloma	NOUN
ajlm-1296	123	25	cells	cell	NOUN
ajlm-1296	123	26	.	.	PUNCT
ajlm-1296	124	1	br	br	PROPN
ajlm-1296	124	2	j	j	PROPN
ajlm-1296	124	3	haematol	haematol	NOUN
ajlm-1296	124	4	.	.	PUNCT
ajlm-1296	125	1	2012;158(3):336–346	2012;158(3):336–346	NUM
ajlm-1296	125	2	.	.	PUNCT
ajlm-1296	125	3	https://doi.org/10.1111/j.1365-2141.2012.09154.x	https://doi.org/10.1111/j.1365-2141.2012.09154.x	PROPN
ajlm-1296	125	4	vacca	vacca	VERB
ajlm-1296	125	5	a	a	PRON
ajlm-1296	125	6	,	,	PUNCT
ajlm-1296	125	7	ria	ria	PROPN
ajlm-1296	125	8	r	r	PROPN
ajlm-1296	125	9	,	,	PUNCT
ajlm-1296	125	10	reale	reale	NOUN
ajlm-1296	125	11	a	a	X
ajlm-1296	125	12	,	,	PUNCT
ajlm-1296	125	13	et	et	PROPN
ajlm-1296	125	14	al	al	PROPN
ajlm-1296	125	15	.	.	PROPN
ajlm-1296	125	16	angiogenesis	angiogenesis	NOUN
ajlm-1296	125	17	in	in	ADP
ajlm-1296	125	18	multiple	multiple	ADJ
ajlm-1296	125	19	myeloma	myeloma	NOUN
ajlm-1296	125	20	.	.	PUNCT
ajlm-1296	126	1	chem	chem	PROPN
ajlm-1296	126	2	immunol	immunol	NOUN
ajlm-1296	126	3	allergy	allergy	NOUN
ajlm-1296	126	4	.	.	PUNCT
ajlm-1296	127	1	2014;99:180–196	2014;99:180–196	ADJ
ajlm-1296	127	2	.	.	PUNCT
ajlm-1296	128	1	https://doi.org/10.1159/000353312	https://doi.org/10.1159/000353312	X
ajlm-1296	128	2	zheng	zheng	PROPN
ajlm-1296	128	3	y	y	PROPN
ajlm-1296	128	4	,	,	PUNCT
ajlm-1296	128	5	cai	cai	PROPN
ajlm-1296	129	1	z	z	PROPN
ajlm-1296	129	2	,	,	PUNCT
ajlm-1296	129	3	wang	wang	PROPN
ajlm-1296	129	4	s	s	PROPN
ajlm-1296	129	5	,	,	PUNCT
ajlm-1296	129	6	et	et	PROPN
ajlm-1296	129	7	al	al	PROPN
ajlm-1296	129	8	.	.	PUNCT
ajlm-1296	130	1	macrophages	macrophage	NOUN
ajlm-1296	130	2	are	be	AUX
ajlm-1296	130	3	an	an	DET
ajlm-1296	130	4	abundant	abundant	ADJ
ajlm-1296	130	5	component	component	NOUN
ajlm-1296	130	6	of	of	ADP
ajlm-1296	130	7	myeloma	myeloma	NOUN
ajlm-1296	130	8	microenvironment	microenvironment	NOUN
ajlm-1296	130	9	and	and	CCONJ
ajlm-1296	130	10	protect	protect	VERB
ajlm-1296	130	11	myeloma	myeloma	NOUN
ajlm-1296	130	12	cells	cell	NOUN
ajlm-1296	130	13	from	from	ADP
ajlm-1296	130	14	chemotherapy	chemotherapy	NOUN
ajlm-1296	130	15	drug	drug	NOUN
ajlm-1296	130	16	-	-	PUNCT
ajlm-1296	130	17	induced	induce	VERB
ajlm-1296	130	18	apoptosis	apoptosis	NOUN
ajlm-1296	130	19	.	.	PUNCT
ajlm-1296	131	1	blood	blood	NOUN
ajlm-1296	131	2	.	.	PUNCT
ajlm-1296	132	1	2009;114(17):3625–3628	2009;114(17):3625–3628	NUM
ajlm-1296	132	2	.	.	PUNCT
ajlm-1296	133	1	https://doi.org/10.1182/blood-2009-05-220285	https://doi.org/10.1182/blood-2009-05-220285	PROPN
ajlm-1296	133	2	chauhan	chauhan	PROPN
ajlm-1296	133	3	d	d	PROPN
ajlm-1296	133	4	,	,	PUNCT
ajlm-1296	133	5	singh	singh	PROPN
ajlm-1296	133	6	av	av	PROPN
ajlm-1296	133	7	,	,	PUNCT
ajlm-1296	133	8	brahmandam	brahmandam	PROPN
ajlm-1296	133	9	m	m	PRON
ajlm-1296	133	10	,	,	PUNCT
ajlm-1296	133	11	et	et	PROPN
ajlm-1296	133	12	al	al	PROPN
ajlm-1296	133	13	.	.	PUNCT
ajlm-1296	134	1	functional	functional	ADJ
ajlm-1296	134	2	interaction	interaction	NOUN
ajlm-1296	134	3	of	of	ADP
ajlm-1296	134	4	plasmacytoid	plasmacytoid	NOUN
ajlm-1296	134	5	dendritic	dendritic	ADJ
ajlm-1296	134	6	cells	cell	NOUN
ajlm-1296	134	7	with	with	ADP
ajlm-1296	134	8	multiple	multiple	ADJ
ajlm-1296	134	9	myeloma	myeloma	NOUN
ajlm-1296	134	10	cells	cell	NOUN
ajlm-1296	134	11	:	:	PUNCT
ajlm-1296	134	12	a	a	DET
ajlm-1296	134	13	therapeutic	therapeutic	ADJ
ajlm-1296	134	14	target	target	NOUN
ajlm-1296	134	15	.	.	PUNCT
ajlm-1296	135	1	cancer	cancer	NOUN
ajlm-1296	135	2	cell	cell	NOUN
ajlm-1296	135	3	.	.	PUNCT
ajlm-1296	136	1	2009;16(4):309–323	2009;16(4):309–323	X
ajlm-1296	136	2	.	.	PUNCT
ajlm-1296	136	3	https://doi.org/10.1016/j.ccr.2009.08.019	https://doi.org/10.1016/j.ccr.2009.08.019	PROPN
ajlm-1296	136	4	grage	grage	NOUN
ajlm-1296	136	5	-	-	PUNCT
ajlm-1296	136	6	griebenow	griebenow	ADJ
ajlm-1296	136	7	e	e	NOUN
ajlm-1296	136	8	,	,	PUNCT
ajlm-1296	136	9	flad	flad	ADJ
ajlm-1296	136	10	hd	hd	PROPN
ajlm-1296	136	11	,	,	PUNCT
ajlm-1296	136	12	ernst	ernst	PROPN
ajlm-1296	136	13	m.	m.	PROPN
ajlm-1296	136	14	heterogeneity	heterogeneity	PROPN
ajlm-1296	136	15	of	of	ADP
ajlm-1296	136	16	human	human	ADJ
ajlm-1296	136	17	peripheral	peripheral	ADJ
ajlm-1296	136	18	blood	blood	NOUN
ajlm-1296	136	19	monocyte	monocyte	NOUN
ajlm-1296	136	20	subsets	subset	NOUN
ajlm-1296	136	21	.	.	PUNCT
ajlm-1296	137	1	j	j	PROPN
ajlm-1296	137	2	leukoc	leukoc	VERB
ajlm-1296	137	3	biol	biol	PROPN
ajlm-1296	137	4	.	.	PUNCT
ajlm-1296	138	1	2001;69(1):11–20	2001;69(1):11–20	X
ajlm-1296	138	2	.	.	PUNCT
ajlm-1296	139	1	ziegler	ziegler	NOUN
ajlm-1296	139	2	-	-	PROPN
ajlm-1296	139	3	heitbrock	heitbrock	PROPN
ajlm-1296	139	4	l.	l.	PROPN
ajlm-1296	139	5	the	the	DET
ajlm-1296	139	6	cd14	cd14	PROPN
ajlm-1296	139	7	+	+	CCONJ
ajlm-1296	139	8	cd16	cd16	PROPN
ajlm-1296	139	9	+	+	CCONJ
ajlm-1296	139	10	blood	blood	NOUN
ajlm-1296	139	11	monocytes	monocyte	VERB
ajlm-1296	139	12	:	:	PUNCT
ajlm-1296	139	13	their	their	PRON
ajlm-1296	139	14	role	role	NOUN
ajlm-1296	139	15	in	in	ADP
ajlm-1296	139	16	infection	infection	NOUN
ajlm-1296	139	17	and	and	CCONJ
ajlm-1296	139	18	inflammation	inflammation	NOUN
ajlm-1296	139	19	.	.	PUNCT
ajlm-1296	140	1	j	j	PROPN
ajlm-1296	140	2	leukoc	leukoc	VERB
ajlm-1296	140	3	biol	biol	PROPN
ajlm-1296	140	4	.	.	PUNCT
ajlm-1296	141	1	2007;81(3):584–592	2007;81(3):584–592	X
ajlm-1296	141	2	.	.	PUNCT
ajlm-1296	142	1	https://doi.org/10.1189/jlb.0806510	https://doi.org/10.1189/jlb.0806510	PROPN
ajlm-1296	142	2	cros	cros	PROPN
ajlm-1296	142	3	j	j	PROPN
ajlm-1296	142	4	,	,	PUNCT
ajlm-1296	142	5	cagnard	cagnard	NOUN
ajlm-1296	142	6	n	n	CCONJ
ajlm-1296	142	7	,	,	PUNCT
ajlm-1296	142	8	woollard	woollard	PROPN
ajlm-1296	142	9	k	k	PROPN
ajlm-1296	142	10	,	,	PUNCT
ajlm-1296	142	11	et	et	PROPN
ajlm-1296	142	12	al	al	PROPN
ajlm-1296	142	13	.	.	PUNCT
ajlm-1296	143	1	human	human	PROPN
ajlm-1296	143	2	cd14dim	cd14dim	PROPN
ajlm-1296	143	3	monocytes	monocyte	VERB
ajlm-1296	143	4	patrol	patrol	NOUN
ajlm-1296	143	5	and	and	CCONJ
ajlm-1296	143	6	sense	sense	VERB
ajlm-1296	143	7	nucleic	nucleic	ADJ
ajlm-1296	143	8	acids	acid	NOUN
ajlm-1296	143	9	and	and	CCONJ
ajlm-1296	143	10	viruses	virus	NOUN
ajlm-1296	143	11	via	via	ADP
ajlm-1296	143	12	tlr7	tlr7	NOUN
ajlm-1296	143	13	and	and	CCONJ
ajlm-1296	143	14	tlr8	tlr8	NOUN
ajlm-1296	143	15	receptors	receptor	NOUN
ajlm-1296	143	16	.	.	PUNCT
ajlm-1296	144	1	immunity	immunity	NOUN
ajlm-1296	144	2	.	.	PUNCT
ajlm-1296	145	1	2010;33(3):375–386	2010;33(3):375–386	NUM
ajlm-1296	145	2	.	.	X
ajlm-1296	145	3	https://doi.org/10.1016/j.immuni.2010.08.012	https://doi.org/10.1016/j.immuni.2010.08.012	PROPN
ajlm-1296	145	4	cooper	cooper	PROPN
ajlm-1296	145	5	dl	dl	PROPN
ajlm-1296	145	6	,	,	PUNCT
ajlm-1296	145	7	martin	martin	PROPN
ajlm-1296	145	8	sg	sg	PROPN
ajlm-1296	145	9	,	,	PUNCT
ajlm-1296	145	10	robinson	robinson	PROPN
ajlm-1296	145	11	ji	ji	PROPN
ajlm-1296	145	12	,	,	PUNCT
ajlm-1296	145	13	et	et	PROPN
ajlm-1296	145	14	al	al	PROPN
ajlm-1296	145	15	.	.	PROPN
ajlm-1296	145	16	fcgammariiia	fcgammariiia	VERB
ajlm-1296	145	17	expression	expression	NOUN
ajlm-1296	145	18	on	on	ADP
ajlm-1296	145	19	monocytes	monocyte	NOUN
ajlm-1296	145	20	in	in	ADP
ajlm-1296	145	21	rheumatoid	rheumatoid	ADJ
ajlm-1296	145	22	arthritis	arthritis	NOUN
ajlm-1296	145	23	:	:	PUNCT
ajlm-1296	145	24	role	role	NOUN
ajlm-1296	145	25	in	in	ADP
ajlm-1296	145	26	immune	immune	NOUN
ajlm-1296	145	27	-	-	PUNCT
ajlm-1296	145	28	complex	complex	NOUN
ajlm-1296	145	29	stimulated	stimulate	VERB
ajlm-1296	145	30	tnf	tnf	PROPN
ajlm-1296	145	31	production	production	NOUN
ajlm-1296	145	32	and	and	CCONJ
ajlm-1296	145	33	non	non	NOUN
ajlm-1296	145	34	-	-	NOUN
ajlm-1296	145	35	response	response	NOUN
ajlm-1296	145	36	to	to	PART
ajlm-1296	145	37	methotrexate	methotrexate	VERB
ajlm-1296	145	38	therapy	therapy	NOUN
ajlm-1296	145	39	.	.	PUNCT
ajlm-1296	146	1	plos	plos	PROPN
ajlm-1296	146	2	one	one	NUM
ajlm-1296	146	3	.	.	PUNCT
ajlm-1296	147	1	2012;7(1):e28918	2012;7(1):e28918	PROPN
ajlm-1296	147	2	.	.	PUNCT
ajlm-1296	148	1	https://doi.org/10.1371/journal.pone.0028918	https://doi.org/10.1371/journal.pone.0028918	PROPN
ajlm-1296	148	2	chiu	chiu	PROPN
ajlm-1296	148	3	yg	yg	PROPN
ajlm-1296	148	4	,	,	PUNCT
ajlm-1296	148	5	shao	shao	PROPN
ajlm-1296	148	6	t	t	PROPN
ajlm-1296	148	7	,	,	PUNCT
ajlm-1296	148	8	feng	feng	PROPN
ajlm-1296	148	9	c	c	AUX
ajlm-1296	148	10	,	,	PUNCT
ajlm-1296	148	11	et	et	PROPN
ajlm-1296	148	12	al	al	PROPN
ajlm-1296	148	13	.	.	PUNCT
ajlm-1296	149	1	cd16	cd16	PROPN
ajlm-1296	149	2	(	(	PUNCT
ajlm-1296	149	3	fcrgammaiii	fcrgammaiii	NOUN
ajlm-1296	149	4	)	)	PUNCT
ajlm-1296	149	5	as	as	ADP
ajlm-1296	149	6	a	a	DET
ajlm-1296	149	7	potential	potential	ADJ
ajlm-1296	149	8	marker	marker	NOUN
ajlm-1296	149	9	of	of	ADP
ajlm-1296	149	10	osteoclast	osteoclast	ADJ
ajlm-1296	149	11	precursors	precursor	NOUN
ajlm-1296	149	12	in	in	ADP
ajlm-1296	149	13	psoriatic	psoriatic	ADJ
ajlm-1296	149	14	arthritis	arthritis	NOUN
ajlm-1296	149	15	.	.	PUNCT
ajlm-1296	150	1	arthritis	arthritis	NOUN
ajlm-1296	150	2	res	re	NOUN
ajlm-1296	150	3	ther	ther	ADV
ajlm-1296	150	4	.	.	PUNCT
ajlm-1296	151	1	2010;12(1):r14	2010;12(1):r14	NUM
ajlm-1296	151	2	.	.	PUNCT
ajlm-1296	152	1	https://doi.org/10.1186/ar2915	https://doi.org/10.1186/ar2915	X
ajlm-1296	152	2	belge	belge	PROPN
ajlm-1296	152	3	ku	ku	PROPN
ajlm-1296	152	4	,	,	PUNCT
ajlm-1296	152	5	dayyani	dayyani	PROPN
ajlm-1296	152	6	f	f	PROPN
ajlm-1296	152	7	,	,	PUNCT
ajlm-1296	152	8	horelt	horelt	ADJ
ajlm-1296	152	9	a	a	PRON
ajlm-1296	152	10	,	,	PUNCT
ajlm-1296	152	11	et	et	PROPN
ajlm-1296	152	12	al	al	PROPN
ajlm-1296	152	13	.	.	PUNCT
ajlm-1296	153	1	the	the	DET
ajlm-1296	153	2	proinflammatory	proinflammatory	ADJ
ajlm-1296	153	3	cd14+cd16+dr++	cd14+cd16+dr++	NOUN
ajlm-1296	153	4	monocytes	monocyte	NOUN
ajlm-1296	153	5	are	be	AUX
ajlm-1296	153	6	a	a	DET
ajlm-1296	153	7	major	major	ADJ
ajlm-1296	153	8	source	source	NOUN
ajlm-1296	153	9	of	of	ADP
ajlm-1296	153	10	tnf	tnf	PROPN
ajlm-1296	153	11	.	.	PUNCT
ajlm-1296	154	1	j	j	PROPN
ajlm-1296	154	2	immunol	immunol	NOUN
ajlm-1296	154	3	.	.	PUNCT
ajlm-1296	155	1	2002;168(7):3536–3542	2002;168(7):3536–3542	NUM
ajlm-1296	155	2	.	.	PUNCT
ajlm-1296	156	1	https://doi.org/10.4049/jimmunol.168.7.3536	https://doi.org/10.4049/jimmunol.168.7.3536	NOUN
ajlm-1296	156	2	sponaas	sponaas	NOUN
ajlm-1296	156	3	am	am	NOUN
ajlm-1296	156	4	,	,	PUNCT
ajlm-1296	156	5	moen	moen	PROPN
ajlm-1296	156	6	sh	sh	PROPN
ajlm-1296	156	7	,	,	PUNCT
ajlm-1296	156	8	liabakk	liabakk	PROPN
ajlm-1296	156	9	nb	nb	PROPN
ajlm-1296	156	10	,	,	PUNCT
ajlm-1296	156	11	et	et	PROPN
ajlm-1296	156	12	al	al	PROPN
ajlm-1296	156	13	.	.	PUNCT
ajlm-1296	157	1	the	the	DET
ajlm-1296	157	2	proportion	proportion	NOUN
ajlm-1296	157	3	of	of	ADP
ajlm-1296	157	4	cd16(+)cd14(dim	cd16(+)cd14(dim	NOUN
ajlm-1296	157	5	)	)	PUNCT
ajlm-1296	157	6	monocytes	monocyte	VERB
ajlm-1296	157	7	increases	increase	NOUN
ajlm-1296	157	8	with	with	ADP
ajlm-1296	157	9	tumor	tumor	NOUN
ajlm-1296	157	10	cell	cell	NOUN
ajlm-1296	157	11	load	load	NOUN
ajlm-1296	157	12	in	in	ADP
ajlm-1296	157	13	bone	bone	NOUN
ajlm-1296	157	14	marrow	marrow	NOUN
ajlm-1296	157	15	of	of	ADP
ajlm-1296	157	16	patients	patient	NOUN
ajlm-1296	157	17	with	with	ADP
ajlm-1296	157	18	multiple	multiple	ADJ
ajlm-1296	157	19	myeloma	myeloma	NOUN
ajlm-1296	157	20	.	.	PUNCT
ajlm-1296	158	1	immun	immun	PROPN
ajlm-1296	158	2	inflamm	inflamm	PROPN
ajlm-1296	158	3	dis	dis	PROPN
ajlm-1296	158	4	.	.	PUNCT
ajlm-1296	159	1	2015;3(2):94–102	2015;3(2):94–102	NUM
ajlm-1296	159	2	.	.	PUNCT
ajlm-1296	160	1	https://doi.org/10.1002/iid3.53	https://doi.org/10.1002/iid3.53	PROPN
ajlm-1296	160	2	petitprez	petitprez	PROPN
ajlm-1296	160	3	v	v	PROPN
ajlm-1296	160	4	,	,	PUNCT
ajlm-1296	160	5	royer	royer	PROPN
ajlm-1296	160	6	b	b	PROPN
ajlm-1296	160	7	,	,	PUNCT
ajlm-1296	160	8	desoutter	desoutter	PROPN
ajlm-1296	160	9	jp	jp	PROPN
ajlm-1296	160	10	,	,	PUNCT
ajlm-1296	160	11	et	et	PROPN
ajlm-1296	160	12	al	al	PROPN
ajlm-1296	160	13	.	.	PUNCT
ajlm-1296	161	1	cd14	cd14	PROPN
ajlm-1296	161	2	+	+	CCONJ
ajlm-1296	161	3	cd16	cd16	PROPN
ajlm-1296	161	4	+	+	CCONJ
ajlm-1296	161	5	monocytes	monocyte	VERB
ajlm-1296	161	6	rather	rather	ADV
ajlm-1296	161	7	than	than	ADP
ajlm-1296	161	8	cd14	cd14	PROPN
ajlm-1296	161	9	+	+	CCONJ
ajlm-1296	161	10	cd51/61	cd51/61	NOUN
ajlm-1296	161	11	+	+	NUM
ajlm-1296	161	12	monocytes	monocyte	NOUN
ajlm-1296	161	13	are	be	AUX
ajlm-1296	161	14	a	a	DET
ajlm-1296	161	15	potential	potential	ADJ
ajlm-1296	161	16	cytological	cytological	ADJ
ajlm-1296	161	17	marker	marker	NOUN
ajlm-1296	161	18	of	of	ADP
ajlm-1296	161	19	circulating	circulate	VERB
ajlm-1296	161	20	osteoclast	osteoclast	ADJ
ajlm-1296	161	21	precursors	precursor	NOUN
ajlm-1296	161	22	in	in	ADP
ajlm-1296	161	23	multiple	multiple	ADJ
ajlm-1296	161	24	myeloma	myeloma	NOUN
ajlm-1296	161	25	.	.	PUNCT
ajlm-1296	162	1	a	a	DET
ajlm-1296	162	2	preliminary	preliminary	ADJ
ajlm-1296	162	3	study	study	NOUN
ajlm-1296	162	4	.	.	PUNCT
ajlm-1296	163	1	int	int	NOUN
ajlm-1296	163	2	j	j	PROPN
ajlm-1296	163	3	lab	lab	NOUN
ajlm-1296	163	4	hematol	hematol	NOUN
ajlm-1296	163	5	.	.	PUNCT
ajlm-1296	164	1	2015;37(1):29–35	2015;37(1):29–35	NUM
ajlm-1296	164	2	.	.	PROPN
ajlm-1296	164	3	https://doi.org/10.1111/ijlh.12216	https://doi.org/10.1111/ijlh.12216	VERB
ajlm-1296	164	4	balakumaran	balakumaran	NOUN
ajlm-1296	164	5	a	a	PRON
ajlm-1296	164	6	,	,	PUNCT
ajlm-1296	164	7	robey	robey	PROPN
ajlm-1296	164	8	pg	pg	PROPN
ajlm-1296	164	9	,	,	PUNCT
ajlm-1296	164	10	fedarko	fedarko	PROPN
ajlm-1296	164	11	n	n	CCONJ
ajlm-1296	164	12	,	,	PUNCT
ajlm-1296	164	13	et	et	PROPN
ajlm-1296	164	14	al	al	PROPN
ajlm-1296	164	15	.	.	PUNCT
ajlm-1296	164	16	bone	bone	PROPN
ajlm-1296	164	17	marrow	marrow	PROPN
ajlm-1296	164	18	microenvironment	microenvironment	NOUN
ajlm-1296	164	19	in	in	ADP
ajlm-1296	164	20	myelomagenesis	myelomagenesis	NOUN
ajlm-1296	164	21	:	:	PUNCT
ajlm-1296	164	22	its	its	PRON
ajlm-1296	164	23	potential	potential	ADJ
ajlm-1296	164	24	role	role	NOUN
ajlm-1296	164	25	in	in	ADP
ajlm-1296	164	26	early	early	ADJ
ajlm-1296	164	27	diagnosis	diagnosis	NOUN
ajlm-1296	164	28	.	.	PUNCT
ajlm-1296	165	1	expert	expert	NOUN
ajlm-1296	165	2	rev	rev	VERB
ajlm-1296	165	3	mol	mol	ADP
ajlm-1296	165	4	diagn	diagn	NOUN
ajlm-1296	165	5	.	.	PUNCT
ajlm-1296	166	1	2010;10(4):465–480	2010;10(4):465–480	NOUN
ajlm-1296	166	2	.	.	PUNCT
ajlm-1296	166	3	https://doi.org/10.1586/erm.10.31	https://doi.org/10.1586/erm.10.31	PROPN
ajlm-1296	166	4	tshabalala	tshabalala	PROPN
ajlm-1296	166	5	ws	ws	PROPN
ajlm-1296	166	6	,	,	PUNCT
ajlm-1296	166	7	pillay	pillay	PROPN
ajlm-1296	166	8	s	s	PROPN
ajlm-1296	166	9	,	,	PUNCT
ajlm-1296	166	10	wilson	wilson	PROPN
ajlm-1296	166	11	dpk	dpk	PROPN
ajlm-1296	166	12	.	.	PUNCT
ajlm-1296	167	1	diagnostic	diagnostic	ADJ
ajlm-1296	167	2	outcomes	outcome	NOUN
ajlm-1296	167	3	of	of	ADP
ajlm-1296	167	4	bone	bone	NOUN
ajlm-1296	167	5	marrow	marrow	NOUN
ajlm-1296	167	6	aspirate	aspirate	NOUN
ajlm-1296	167	7	and	and	CCONJ
ajlm-1296	167	8	trephine	trephine	NOUN
ajlm-1296	167	9	biopsies	biopsy	NOUN
ajlm-1296	167	10	performed	perform	VERB
ajlm-1296	167	11	at	at	ADP
ajlm-1296	167	12	a	a	DET
ajlm-1296	167	13	hospital	hospital	NOUN
ajlm-1296	167	14	in	in	ADP
ajlm-1296	167	15	kwazulu	kwazulu	NOUN
ajlm-1296	167	16	-	-	PUNCT
ajlm-1296	167	17	natal	natal	ADJ
ajlm-1296	167	18	,	,	PUNCT
ajlm-1296	167	19	south	south	PROPN
ajlm-1296	167	20	africa	africa	PROPN
ajlm-1296	167	21	.	.	PUNCT
ajlm-1296	168	1	afr	afr	PROPN
ajlm-1296	168	2	j	j	PROPN
ajlm-1296	168	3	lab	lab	PROPN
ajlm-1296	168	4	med	med	PROPN
ajlm-1296	168	5	.	.	PUNCT
ajlm-1296	169	1	2020;9(1):1028	2020;9(1):1028	NUM
ajlm-1296	169	2	.	.	PUNCT
ajlm-1296	169	3	https://doi.org/10.4102/ajlm.v9i1.1028	https://doi.org/10.4102/ajlm.v9i1.1028	PROPN
ajlm-1296	169	4	durie	durie	PROPN
ajlm-1296	169	5	bg	bg	PROPN
ajlm-1296	169	6	,	,	PUNCT
ajlm-1296	169	7	salmon	salmon	NOUN
ajlm-1296	169	8	se	se	PROPN
ajlm-1296	169	9	.	.	PUNCT
ajlm-1296	170	1	a	a	DET
ajlm-1296	170	2	clinical	clinical	ADJ
ajlm-1296	170	3	staging	staging	NOUN
ajlm-1296	170	4	system	system	NOUN
ajlm-1296	170	5	for	for	ADP
ajlm-1296	170	6	multiple	multiple	ADJ
ajlm-1296	170	7	myeloma	myeloma	NOUN
ajlm-1296	170	8	.	.	PUNCT
ajlm-1296	171	1	correlation	correlation	NOUN
ajlm-1296	171	2	of	of	ADP
ajlm-1296	171	3	measured	measure	VERB
ajlm-1296	171	4	myeloma	myeloma	NOUN
ajlm-1296	171	5	cell	cell	NOUN
ajlm-1296	171	6	mass	mass	NOUN
ajlm-1296	171	7	with	with	ADP
ajlm-1296	171	8	presenting	present	VERB
ajlm-1296	171	9	clinical	clinical	ADJ
ajlm-1296	171	10	features	feature	NOUN
ajlm-1296	171	11	,	,	PUNCT
ajlm-1296	171	12	response	response	NOUN
ajlm-1296	171	13	to	to	ADP
ajlm-1296	171	14	treatment	treatment	NOUN
ajlm-1296	171	15	,	,	PUNCT
ajlm-1296	171	16	and	and	CCONJ
ajlm-1296	171	17	survival	survival	NOUN
ajlm-1296	171	18	.	.	PUNCT
ajlm-1296	172	1	cancer	cancer	NOUN
ajlm-1296	172	2	.	.	PUNCT
ajlm-1296	173	1	1975;36(3):842–854	1975;36(3):842–854	X
ajlm-1296	173	2	.	.	PUNCT
ajlm-1296	174	1	https://doi.org/10.1002/1097-0142(197509)36:3%3c842::aid-cncr2820360303%3e3.0.co;2-u	https://doi.org/10.1002/1097-0142(197509)36:3%3c842::aid-cncr2820360303%3e3.0.co;2-u	NOUN
ajlm-1296	174	2	greipp	greipp	NOUN
ajlm-1296	174	3	pr	pr	NOUN
ajlm-1296	174	4	,	,	PUNCT
ajlm-1296	174	5	san	san	PROPN
ajlm-1296	174	6	miguel	miguel	PROPN
ajlm-1296	174	7	j	j	PROPN
ajlm-1296	174	8	,	,	PUNCT
ajlm-1296	174	9	durie	durie	VERB
ajlm-1296	174	10	bg	bg	PROPN
ajlm-1296	174	11	,	,	PUNCT
ajlm-1296	174	12	et	et	PROPN
ajlm-1296	174	13	al	al	PROPN
ajlm-1296	174	14	.	.	PUNCT
ajlm-1296	175	1	international	international	ADJ
ajlm-1296	175	2	staging	staging	NOUN
ajlm-1296	175	3	system	system	NOUN
ajlm-1296	175	4	for	for	ADP
ajlm-1296	175	5	multiple	multiple	ADJ
ajlm-1296	175	6	myeloma	myeloma	NOUN
ajlm-1296	175	7	.	.	PUNCT
ajlm-1296	176	1	j	j	PROPN
ajlm-1296	176	2	clin	clin	PROPN
ajlm-1296	176	3	oncol	oncol	PROPN
ajlm-1296	176	4	.	.	PUNCT
ajlm-1296	177	1	2005;23(15):3412–3420	2005;23(15):3412–3420	NUM
ajlm-1296	177	2	.	.	PUNCT
ajlm-1296	178	1	https://doi.org/10.1200/jco.2005.04.242	https://doi.org/10.1200/jco.2005.04.242	PROPN
ajlm-1296	179	1	tucci	tucci	PROPN
ajlm-1296	179	2	m	m	PRON
ajlm-1296	179	3	,	,	PUNCT
ajlm-1296	179	4	stucci	stucci	PROPN
ajlm-1296	179	5	s	s	PROPN
ajlm-1296	179	6	,	,	PUNCT
ajlm-1296	179	7	savonarola	savonarola	PROPN
ajlm-1296	179	8	a	a	NOUN
ajlm-1296	179	9	,	,	PUNCT
ajlm-1296	179	10	et	et	PROPN
ajlm-1296	179	11	al	al	PROPN
ajlm-1296	179	12	.	.	PUNCT
ajlm-1296	179	13	immature	immature	ADJ
ajlm-1296	179	14	dendritic	dendritic	ADJ
ajlm-1296	179	15	cells	cell	NOUN
ajlm-1296	179	16	in	in	ADP
ajlm-1296	179	17	multiple	multiple	ADJ
ajlm-1296	179	18	myeloma	myeloma	NOUN
ajlm-1296	179	19	are	be	AUX
ajlm-1296	179	20	prone	prone	ADJ
ajlm-1296	179	21	to	to	ADP
ajlm-1296	179	22	osteoclast	osteoclast	ADJ
ajlm-1296	179	23	-	-	PUNCT
ajlm-1296	179	24	like	like	ADJ
ajlm-1296	179	25	differentiation	differentiation	NOUN
ajlm-1296	179	26	through	through	ADP
ajlm-1296	179	27	interleukin-17a	interleukin-17a	PROPN
ajlm-1296	179	28	stimulation	stimulation	NOUN
ajlm-1296	179	29	.	.	PUNCT
ajlm-1296	180	1	br	br	X
ajlm-1296	180	2	j	j	PROPN
ajlm-1296	180	3	haematol	haematol	NOUN
ajlm-1296	180	4	.	.	PUNCT
ajlm-1296	181	1	2013;161(6):821–831	2013;161(6):821–831	X
ajlm-1296	181	2	.	.	PUNCT
ajlm-1296	182	1	https://doi.org/10.1111/bjh.12333	https://doi.org/10.1111/bjh.12333	PROPN
ajlm-1296	182	2	holien	holien	PROPN
ajlm-1296	182	3	t	t	PROPN
ajlm-1296	182	4	,	,	PUNCT
ajlm-1296	182	5	sundan	sundan	PROPN
ajlm-1296	182	6	a.	a.	PROPN
ajlm-1296	182	7	the	the	DET
ajlm-1296	182	8	role	role	NOUN
ajlm-1296	182	9	of	of	ADP
ajlm-1296	182	10	bone	bone	NOUN
ajlm-1296	182	11	morphogenetic	morphogenetic	ADJ
ajlm-1296	182	12	proteins	protein	NOUN
ajlm-1296	182	13	in	in	ADP
ajlm-1296	182	14	myeloma	myeloma	PROPN
ajlm-1296	182	15	cell	cell	NOUN
ajlm-1296	182	16	survival	survival	NOUN
ajlm-1296	182	17	.	.	PUNCT
ajlm-1296	183	1	cytokine	cytokine	ADJ
ajlm-1296	183	2	growth	growth	NOUN
ajlm-1296	183	3	factor	factor	NOUN
ajlm-1296	183	4	rev	rev	VERB
ajlm-1296	183	5	.	.	PUNCT
ajlm-1296	184	1	2014;25(3):343–350	2014;25(3):343–350	NUM
ajlm-1296	184	2	.	.	PUNCT
ajlm-1296	185	1	https://doi.org/10.1016/j.cytogfr.2014.04.009	https://doi.org/10.1016/j.cytogfr.2014.04.009	PROPN
ajlm-1296	185	2	ludwig	ludwig	PROPN
ajlm-1296	185	3	h	h	PROPN
ajlm-1296	185	4	,	,	PUNCT
ajlm-1296	185	5	beksac	beksac	NOUN
ajlm-1296	185	6	m	m	NOUN
ajlm-1296	185	7	,	,	PUNCT
ajlm-1296	185	8	bladé	bladé	PROPN
ajlm-1296	185	9	j	j	PROPN
ajlm-1296	185	10	,	,	PUNCT
ajlm-1296	185	11	et	et	PROPN
ajlm-1296	185	12	al	al	PROPN
ajlm-1296	185	13	.	.	PUNCT
ajlm-1296	186	1	current	current	ADJ
ajlm-1296	186	2	multiple	multiple	ADJ
ajlm-1296	186	3	myeloma	myeloma	NOUN
ajlm-1296	186	4	treatment	treatment	NOUN
ajlm-1296	186	5	strategies	strategy	NOUN
ajlm-1296	186	6	with	with	ADP
ajlm-1296	186	7	novel	novel	ADJ
ajlm-1296	186	8	agents	agent	NOUN
ajlm-1296	186	9	:	:	PUNCT
ajlm-1296	186	10	a	a	DET
ajlm-1296	186	11	european	european	PROPN
ajlm-1296	186	12	perspective	perspective	NOUN
ajlm-1296	186	13	.	.	PUNCT
ajlm-1296	187	1	oncologist	oncologist	NOUN
ajlm-1296	187	2	.	.	PUNCT
ajlm-1296	188	1	2010;15(1):6–25	2010;15(1):6–25	NUM
ajlm-1296	188	2	.	.	PUNCT
ajlm-1296	188	3	https://doi.org/10.1634/theoncologist.2009-0203	https://doi.org/10.1634/theoncologist.2009-0203	PROPN
ajlm-1296	188	4	durie	durie	PROPN
ajlm-1296	188	5	bg	bg	PROPN
ajlm-1296	188	6	,	,	PUNCT
ajlm-1296	188	7	salmon	salmon	NOUN
ajlm-1296	188	8	se	se	PROPN
ajlm-1296	188	9	.	.	PUNCT
ajlm-1296	189	1	the	the	DET
ajlm-1296	189	2	current	current	ADJ
ajlm-1296	189	3	status	status	NOUN
ajlm-1296	189	4	and	and	CCONJ
ajlm-1296	189	5	future	future	ADJ
ajlm-1296	189	6	prospects	prospect	NOUN
ajlm-1296	189	7	of	of	ADP
ajlm-1296	189	8	treatment	treatment	NOUN
ajlm-1296	189	9	for	for	ADP
ajlm-1296	189	10	multiple	multiple	ADJ
ajlm-1296	189	11	myeloma	myeloma	NOUN
ajlm-1296	189	12	.	.	PUNCT
ajlm-1296	190	1	clin	clin	PROPN
ajlm-1296	190	2	haematol	haematol	NOUN
ajlm-1296	190	3	.	.	PUNCT
ajlm-1296	191	1	1982;11(1):181–210	1982;11(1):181–210	X
ajlm-1296	191	2	.	.	PUNCT
ajlm-1296	192	1	alexanian	alexanian	PROPN
ajlm-1296	192	2	r	r	PROPN
ajlm-1296	192	3	,	,	PUNCT
ajlm-1296	192	4	barlogie	barlogie	NOUN
ajlm-1296	192	5	b	b	PROPN
ajlm-1296	192	6	,	,	PUNCT
ajlm-1296	192	7	dixon	dixon	PROPN
ajlm-1296	192	8	d.	d.	PROPN
ajlm-1296	192	9	renal	renal	PROPN
ajlm-1296	192	10	failure	failure	NOUN
ajlm-1296	192	11	in	in	ADP
ajlm-1296	192	12	multiple	multiple	ADJ
ajlm-1296	192	13	myeloma	myeloma	NOUN
ajlm-1296	192	14	.	.	PUNCT
ajlm-1296	193	1	pathogenesis	pathogenesis	NOUN
ajlm-1296	193	2	and	and	CCONJ
ajlm-1296	193	3	prognostic	prognostic	ADJ
ajlm-1296	193	4	implications	implication	NOUN
ajlm-1296	193	5	.	.	PUNCT
ajlm-1296	194	1	arch	arch	ADJ
ajlm-1296	194	2	intern	intern	NOUN
ajlm-1296	194	3	med	med	PROPN
ajlm-1296	194	4	.	.	PUNCT
ajlm-1296	195	1	1990;150(8):1693–1695	1990;150(8):1693–1695	NUM
ajlm-1296	195	2	.	.	PUNCT
ajlm-1296	196	1	https://doi.org/10.1001/archinte.1990.00040031693017	https://doi.org/10.1001/archinte.1990.00040031693017	PROPN
ajlm-1296	196	2	dimopoulos	dimopoulos	PROPN
ajlm-1296	196	3	ma	ma	PROPN
ajlm-1296	196	4	,	,	PUNCT
ajlm-1296	196	5	kastritis	kastritis	PROPN
ajlm-1296	196	6	e	e	PROPN
ajlm-1296	196	7	,	,	PUNCT
ajlm-1296	196	8	rosinol	rosinol	PROPN
ajlm-1296	196	9	l	l	NOUN
ajlm-1296	196	10	,	,	PUNCT
ajlm-1296	196	11	et	et	PROPN
ajlm-1296	196	12	al	al	PROPN
ajlm-1296	196	13	.	.	PUNCT
ajlm-1296	197	1	pathogenesis	pathogenesis	NOUN
ajlm-1296	197	2	and	and	CCONJ
ajlm-1296	197	3	treatment	treatment	NOUN
ajlm-1296	197	4	of	of	ADP
ajlm-1296	197	5	renal	renal	ADJ
ajlm-1296	197	6	failure	failure	NOUN
ajlm-1296	197	7	in	in	ADP
ajlm-1296	197	8	multiple	multiple	ADJ
ajlm-1296	197	9	myeloma	myeloma	NOUN
ajlm-1296	197	10	.	.	PUNCT
ajlm-1296	198	1	leukemia	leukemia	NOUN
ajlm-1296	198	2	.	.	PUNCT
ajlm-1296	199	1	2008;22(8):1485–1493	2008;22(8):1485–1493	NUM
ajlm-1296	199	2	.	.	PUNCT
ajlm-1296	200	1	https://doi.org/10.1038/leu.2008.131	https://doi.org/10.1038/leu.2008.131	PROPN
ajlm-1296	200	2	simonsson	simonsson	PROPN
ajlm-1296	200	3	b	b	PROPN
ajlm-1296	200	4	,	,	PUNCT
ajlm-1296	200	5	brenning	brenne	VERB
ajlm-1296	200	6	g	g	NOUN
ajlm-1296	200	7	,	,	PUNCT
ajlm-1296	200	8	kallander	kallander	NOUN
ajlm-1296	200	9	c	c	PROPN
ajlm-1296	200	10	,	,	PUNCT
ajlm-1296	200	11	et	et	PROPN
ajlm-1296	200	12	al	al	PROPN
ajlm-1296	200	13	.	.	PROPN
ajlm-1296	201	1	prognostic	prognostic	ADJ
ajlm-1296	201	2	value	value	NOUN
ajlm-1296	201	3	of	of	ADP
ajlm-1296	201	4	serum	serum	NOUN
ajlm-1296	201	5	lactic	lactic	ADJ
ajlm-1296	201	6	dehydrogenase	dehydrogenase	NOUN
ajlm-1296	201	7	(	(	PUNCT
ajlm-1296	201	8	s	s	NOUN
ajlm-1296	201	9	-	-	NOUN
ajlm-1296	201	10	ldh	ldh	NOUN
ajlm-1296	201	11	)	)	PUNCT
ajlm-1296	201	12	in	in	ADP
ajlm-1296	201	13	multiple	multiple	ADJ
ajlm-1296	201	14	myeloma	myeloma	NOUN
ajlm-1296	201	15	.	.	PUNCT
ajlm-1296	202	1	eur	eur	PROPN
ajlm-1296	202	2	j	j	PROPN
ajlm-1296	202	3	clin	clin	PROPN
ajlm-1296	202	4	invest	invest	PROPN
ajlm-1296	202	5	.	.	PUNCT
ajlm-1296	203	1	1987;17(4):336–339	1987;17(4):336–339	X
ajlm-1296	203	2	.	.	PUNCT
ajlm-1296	204	1	https://doi.org/10.1111/j.1365-2362.1987.tb02197.x	https://doi.org/10.1111/j.1365-2362.1987.tb02197.x	PROPN